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The focus of disease research often surrounds therapeutic pathway identification and the 
subsequent investigation of proteins or compounds that potentially interfere with disease 
mechanisms. However, finding targets and effective therapeutic domains often 
overshadows another important aspect of drug delivery and efficacy; the method of 
domain conjugation. Unfortunately the combination of good therapeutic components and 
good therapeutic design can often be amiss, with differing skills and groups needed to 
marry the two together. In recognition of this, there are new techniques emerging that 
aim to not only address old problems of stable conjugation, but incorporating new 
knowledge of drug design.  
This research takes a reverse approach to drug design in order to better comprehend 
requirements which are often an afterthought; first looking at conjugation technique and 
then how it can best be exploited. Thereby, exploring how different conjugation methods 
can be used to complement existing therapeutic and internalisation strategies.  
Here, two methods of conjugation were investigated through attachment of bacterial toxin 
domains derived from botulinum A and diphtheria, with the intention of targeting 
neuroblastoma cells using a variety of specific and non-specific pathways. Both conjugation 
techniques proved to be stable in vitro and capable of binding a variety of domains 
consistently. The data here also emphasized the importance of endosomal escape proteins 
to increase the translocation of catalytic domains into the cytosol. It was demonstrated 
that the conjugates formed were able to facilitate the binding between targeting and 
catalytic domains, enabling specific neuroblastoma internalisation. Moreover, that three 
domains were able to conjugate together using a linking method and could form a co-
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Chapter 1: Introduction 
1.1 Considering Conjugation 
Combining protein domains allows synthesis of novel drugs for treatment of various 
diseases (Sandvig & van Deurs 2005; Yeh et al. 2011). Such novel drugs may exploit proteins 
that bind cells specifically and catalytic domains which could exert a potent therapeutic 
effect within the cell. A number of factors need to be contemplated in drug construction; 
if the conjugation between different protein domains is unstable then the drug will fall 
apart in the bloodstream, not target the cells and cause side effects. On the other hand, if 
it is not cleavable then the domains will not break apart inside the lysosomes of cells and 
could interfere with the efficiency of the catalytic domain. There are also issues with 
making multidomain drugs, for instance if an optimal ratio of particular therapeutic 
domains is required then there is difficulty in ensuring that the particular ratio is 
synthesised without heterogeneity or the different domains interfering with each other.  
The consideration of conjugation technique between protein domains for the production 
of therapeutics is an important step in drug design, where the consequences can influence 
stability and efficiency of the therapeutic product (Stephanopoulos & Francis 2011). As 
technology and understanding of therapeutic construction evolves so does specifications 
for desirable protein linking; therefore, there is an ongoing need to investigate methods of 
conjugation in order to develop drugs, methods of probing or tagging. From this, it is 
important that many avenues of protein conjugation are investigated to allow the greatest 
efficiency in a designed therapeutic. 
 
1.1.1 Bioconjugation methods 
A suitable linker between drug components should be stable in the blood, but not interfere 
with the effects of the attached drug once it has reached the desired location, often the 
cytosol. There have been many reported methods of protein conjugation, but the 
appropriate modification strategy is influenced by the desired supramolecular properties. 
Broadly, conjugation types can be divided into non-cleavable and cleavable (Srinivasarao 
et al. 2015). Non-cleavable bonds, such as maleimide bonds or recombinant fusion, can be 
used to conjugate a variety of domains consisting of drug and probes (McCombs & Owen 
2015). For instance, antibody drug conjugates (ADCs) function through the conjugation of 
an antibody to various cytotoxic drugs; antibodies are a commonly used way to specifically 
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target receptors on cells in vivo and in vitro, therefore ADCs developed to exploit this 
through targeting and internalising specifically diseased cells and delivering their payload 
(Kitson et al. 2013; Huennekens 1994). Once the ADC enters the lysosomes its structure 
degrades leaving an amino acid chain attached to the drug; the drug can then exert its 
function (McCombs & Owen 2015). However, the conjugated amino acid chain can 
interfere with drug efficacy; therefore, there is a growing trend for cleavable linkers 
between drugs and carriers in order for drugs to function unimpeded (McCombs & Owen 
2015; Lee et al. 2013). Cleavable bonds are those where either chemical, photolytic or 
enzymatic activity can cause breakage, examples which have been investigated for this 
purpose include disulphide and hydrazone bonds (Leriche et al. 2012).  Hydrazone bonds 
are stable at neutral pHs, however have shown in some studies to readily hydrolyse and 
have a short biological half-life (Kovaříková et al. 2008; Hruskova et al. 2011).  
The uncleavable maleimide bonds is the most commonly used protein conjugation strategy 
owing to their ability to stably bind to lysine and cysteine residues in a single step process 
(Fontaine et al. 2015). Whilst there are maleimide-conjugated FDA approved drugs such as 
the ADCs Brentuximab vedotin and Trastuzumab emtansine, the long term stability of 
these drugs is poor (Fontaine et al. 2015; Ponte et al. 2016). Because of this, there is a 
demand for simple yet physiologically more stable alternatives.  
The maleimide reaction is shown in figure 1.1:A, where either the sulfhydryl (SH) or amino 
group (NH2) can bind to the maleimide group via Michael addition to conjugate the two 
proteins (Kalia & Raines 2007). However, at neutral pH the conjugate can undergo the 
retro-Michael reaction, causing the product to separate; there are also reports of 
favourable binding to albumin and glutathione in plasma, making this instability a 
particular issue in vivo (Tumey et al. 2014; Kitagishi et al. 2015; Wei et al. 2016). This 
unfavourable stability has been investigated, with reports of between 35-67% break down 
in mouse plasma over 3 days (Christie et al. 2015; Badescu et al. 2014). There have been 
many ways where maleimides have been altered to increase the stability, for instance 
hydrolysing the maleimide ring, hence preventing the retro-Michael reaction from 
occurring (fig 1.1:A). However, this then turns a one-step protocol into multi-step protocol, 
where increased temperatures or pHs are needed for efficient hydrolysis or catalysts are 
used which could disrupt the proteins conjugated (Lyon et al. 2014; Kalia & Raines 2007). 
Disulphide bonds have been shown to form and retain stability at neutral and acidic pH, 
but are reduced in the lysosomes via lysosomal enzymes (Lee et al. 2013; Arunachalam et 
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al. 2000). Disulphide bonds are usually formed when sulfhydryl (SH) groups on chemicals 
or on cysteine amino acids bind together. Their stability makes them favourable to use for 
conjugating proteins or chemicals, however they are often overlooked in favour of 
maleimide because cysteines are often less present than lysines within proteins and 
because of the uncontrolled homo and heterodimerisation between SH groups. 
Succinimidyl 3-(2-Pyridyldithio)Propionate (SPDP) is a chemical used to facilitate the 
introduction of a cysteine onto a protein, where an NH2 residue displaces the succinimidyl 
group at one end, leaving a pyridyldithio group at the other end in order to 'cap' the 
reactive sulfhydryl group. This 'cap' can then be removed by reducing the disulphide bridge 
through reagents such as DTT, and the released SH group can then conjugate to another 
protein, often via a maleimide group (Shi et al. 2009; Manjappa et al. 2011) (fig. 1.1:B). 
It has been shown in examples that the pyridyl-disulphide (pyridyldithio) group on SPDP 
can be bound directly to SH groups, forming a disulphide bond and a pyridyl thione, which 
does not interfere with the conjugated proteins and is small enough to be easily filtered 
(Carlsson et al. 1978; Stuchbury et al. 1975) (fig. 1.1C). Whilst this technique has been 
identified, the conjugation and stability of pyridyl-disulphide formed disulphide bonds 
have yet to be thoroughly explored from a biological perspective independent of SPDP, or 
as a way to potentially modify proteins and enzymes with peptides (Eby et al. 2012; Van 





Figure 1.1 – Diagrams of bioconjugation methods 
A) Shows the maleimide reaction with a sulfhydryl (SH) group forming a conjugation 
between the two proteins, via Michael addition, represented by R and R', joined by a 
succinimide ring. The retro-Michael reaction is a slow reaction which reverses the Michael 
addition. Hydrolysis can occur to the succinimide ring, where it breaks open and this 
stabilises the structure preventing the retro-Michael reaction. B) Succinimidyl 3-(2-
Pyridyldithio)Propionate (SPDP) structure. This is composed of a succinimidyl group one end 
which is displaced by NH2 residues. The pyridyldithio end can then be reduced by DTT to 
expose an SH group, which is often then bound to maleimide domain. C) SH groups on 
cysteine residues can be sufficient to displace the pyridyl disulphide, forming a disulphide 




1.1.2 Alternative linking strategies 
As well as using chemical covalent attachment between therapeutically relevant domains 
to synthesise drugs, there are numerous alternative conjugation strategies which could be 
appropriate to use depending on the requirements of the product. For instance, there are 
examples where proteins in nature bind extremely stably and specifically through either 
covalent or non-covalent means, some of these have then been hijacked to bring together 
drug domains, probes or targeting domains, using these stably binding proteins as ‘glue’ 
(Hartley 1989; Reddington & Howarth 2015). Examples of these protein-derived 
conjugation techniques include ‘SpyCatcher/SpyTag’. Derived from bacterial fibronectin 
binding proteins, there have been reports showing that by having either the ‘SpyCatcher’ 
or the ‘SpyTag’ attached to various domains in a library, the conjugation between select 
proteins could be done on demand, making a useful and flexible conjugation tool (Moon 
et al. 2016; Zakeri et al. 2012). Other proteins which have been similarly used include the 
barnase-barstar module and an adapter/docking-tag system based on mutated fragments 
of RNAse (Rossi et al. 2012). 
There are however examples where protein conjugation can be facilitated by enzymes; for 
instance, it has been demonstrated that the bacterial transpeptidase sortase A will cleave 
between the threonine and glycine in a LPCTG motif, generating an acyl-enzyme 
intermediate. This then reacts with N-terminal glycines to create an amide bond. 
Therefore, proteins can be expressed with the recognition motifs before sortase A is added 
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(Levary et al. 2011). Whilst the reaction is quick and efficient, because enzymes are 
required there are added reagents and conditions which need to be considered for this 
conjugation technique which are not required in spontaneous reactions. Therefore, for the 
purpose of this work, spontaneous reactions are preferable.  
Another example of protein-derived conjugation is SNARE stapling; this is a method which 
uses the self-assembling potential of the SNARE complex (Sudhof & Rothman 2009) (fig. 
1.2). Endogenously, the SNARE complex forms between the SNARE peptides on vesicles 
and docking membranes, where the complex formation overcomes the forces required to 
merge the two membranes together, forming pores between the two compartments; 
because of this function, SNARE complexes are extremely stable (Montecucco & Molgó 
2005; Zhang et al. 2016). The SNARE complex relies on the formation of the complex 
through three or more different helical proteins. This could be an advantage, because 
there are instances within drug design where more than two domains are needed to 
conjugate, for instance in dual targeting or where more than one drug needs to be used; a 
suitable method to design such a multidomain complex has yet to be thoroughly 
developed. Hypothetically, it should be possible to attach each of these SNARE proteins to 




Figure 1.2 – Diagram of the formation of the SNARE complex 
Diagram showing three SNARE proteins which come together and form the SNARE complex; 
a supercoiled quasi-irreversible structure. SNARE PDB ID: 5W5D (McNicholas et al. 2011; 




SNARE-stapled conjugation research has previously shown that catalytic domains derived 
from botulinum can be linked via the SNARE complex to growth factors and other receptor 
binding domains to target and internalise into specific cells (Arsenault et al. 2013; Darios 
et al. 2010). However, the data currently is limited to attaching botulinum domains and 
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there has only been utilisation of two out of the four available SNARE helices. Therefore, 
there is an interest in determining whether SNARE-stapling could be used to link numerous 
different targeting and catalytic proteins together; moreover, whether three or more 
separate proteins could be attached to the SNARE helices and successfully form a triple-





1.2 In Vitro cancer cell targeting 
Synthesised complexes were to be tested on cells to determine how well the constructs 
are able to internalise their attached catalytic proteins. For this, it was decided to utilise 
adherent cell lines which can be grown, incubated with samples and assayed easily in vitro. 
Owing to the nature of the botulinum neurotoxin research and neuronal cell models used 
previously in this laboratory, neuroblastoma cells were chosen as the main test model.  
 
1.2.1 Neuroblastoma pathology 
Neuroblastoma is a rare cancer of the brain, but the most common form of death from 
paediatric cancer of children between the ages of 1 and 5 (Louis & Shohet 2015). It is a 
neuroendocrine tumour arising from the neural ganglia of the peripheral nervous system 
which often exhibits extreme heterogeneity. Mostly, it originates in the adrenal glands but 
can arise from nerve tissues in the neck, abdomen, chest and pelvis; however, it can 
develop anywhere along the sympathetic nervous system, as it arises from the neuroblasts 
(Louis & Shohet 2015). The prognosis of the cancer is primarily dependant on the stage of 
differentiation; whilst low-risk tumours can have good outcomes simply from surgery or 
observation only, high risk tumours can be difficult to successfully treat even with the most 
intensive treatment (Pinto et al. 2015).  
Prognosis for developed cancer in children over 18 months remains poor, even if 
aggressive multimodal therapy is used, with high risk cancer prognosis rates remain at 30% 
with relapse being common (Hoy 2016). However, in 2015 the FDA approved the first 
antibody therapy for neuroblastoma. Dinutuximab (Unituxan) is a monoclonal antibody 
which targets the glycolipid GD2 on cancer cells and is used in a combined therapy with IL-
2, 13-cis-Retinioic acid and GM-CSF (Hoy 2016). Whilst there are side effects such as 
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neuropathy, there was significant increase in event-free survival in Phase III trials (Ploessl 
et al. 2016). That said, there is still plenty of potential for using neuroblastoma within this 
research, not just as a proof of concept for drug construct delivery, but to identify and 
investigate alternative receptors which can be exploited for therapeutic targeting 
(Megison et al. 2013).   
 
1.2.2 Neuroblastoma cell lines 
There are numerous cell lines which can be used as an in vitro model of neuroblastoma; it 
is a very heterogeneous cancer, therefore cells taken from a variety of sources each have 
their own behaviour and signalling pathways (Ngan 2015). For instance, Neuro2A are a 
fast-growing mouse derived neuroblastoma cell line which is commonly used for 
differentiation into neurite-like morphology (Ma’ayan et al. 2009). SH-SY5Y and LA-N-5 
cells on the other hand are slower growing human derived neuroblastoma that can be 
differentiated with a variety of adrenergic, cholinergic and dopaminergic features, with SH-
SY5Y being often used for Parkinson’s disease models (Biedler et al. 1978; Lopes et al. 2010; 
Hill & Robertson 1998). However, by keeping the cells undifferentiated they maintain their 
proliferative cancer-like phenotype in an adherent monolayer and are a suitable model for 
delivering conjugated complexes (Shastry et al. 2000).  
 
1.2.3 Alternative useful cell models 
The J774.2 mouse macrophage cell line has been found to have an increased sensitivity to 
numerous therapeutic toxins, most likely due to enhanced macropinocytosis (Rust et al. 
2015). This feature is useful for the initial identification of potential internalisation 
strategies through increased likelihood of observing effects which a less sensitive cell line, 
such as a neuroblastoma, would not measure. Thereby can be used as a foundation upon 
which internalising strategy amendments can be built upon.  
 
 
1.3 Enzymatic toxins for targeted therapy 
Enzymatic toxins, both derived from plants and bacteria, have emerged as strong 
candidates for cancer therapy owing to their high potency, their intracellular stability and 
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high turnover rate (Siegall 1994; Antignani & FitzGerald 2013). However, their size often 
makes them a challenge to deliver without their endogenous binding domains. 
Nonetheless, there is a drive to harness their unique catalytic properties, attaching them 
to targeting moieties to increase their efficiency of internalising into the cells (Liu et al. 
2014; Pastan et al. 1993). In addition, the proteinous nature of toxin-derived therapeutics 
makes it possible to manipulate them through reduction and plasmid engineering. 
Therefore, this project adopted toxin-derived enzymes to investigate their effects upon 
neuroblastoma cells and as a means of determining whether conjugated complexes can 
successfully deliver their payload.  
 
1.3.1 Botulinum Neurotoxins  
Botulinum neurotoxins (BotNT) are a product of Clostridium botulinum and other 
Clostridium bacteria. These toxins are proteases, and catalytically cleave SNARE peptides 
at specific locations. SNARE proteins endogenously are used to dock and fuse vesicles with 
intracellular compartments or the plasma membrane, cleaving these proteins is sufficient 
to inhibit exocytosis and can result in paralysis and death (Tighe & Schiavo 2013). Thereby, 
the botulinum toxin is usually used clinically for a variety of hypersecretory syndromes or 
hyperexcitibility disorders of peripheral nerve terminals (Luvisetto et al. 2015).  
Like many other bacterial toxins, Botulinum Neurotoxin serotype A (BotNT/A) is composed 
of 2 chains: A light chain which is the catalytic domain, and a heavy chain which contains 
the translocation domain and the receptor binding domain (Montal 2010) (fig. 1.3:A). 
Unlike other bacterial toxins, the full length toxin is often used in treatment, as opposed 
to utilising only certain domains of the toxin.  BotNT/A is the isoform most often used both 
at bench and clinic and it has been FDA approved since 1989 for numerous conditions such 
as strabismus and blepharospasm, with it later being also approved for chronic migraine, 
spasticity and cosmetic procedures (Chen 2012; Jost et al. 2015). At a cellular level, 
BotNT/A is not toxic to cells, instead it has been shown to cleave SNAP25 and inhibit 
exocytosis. There is potential that BotNT/A could also have therapeutic applications in 
cancer; because it inhibits exocytosis there are findings suggesting that this could alter 
signalling in the tumour microenvironment causing a decrease in cancer cell growth or 
even blood vessel dilation, potentially allowing enhancement of chemotherapy delivery 




Figure 1.3 – Schematics of the structures of various toxins 
A-D) Layout of the domains of Botulinum Neurotoxin A, Diphtheria toxin, Ricin and BLF1 
respectively. Red: Catalytic domain, Green: Translocation domain, Blue: Receptor binding 
domain (Greenfield et al. 1983; Thompson et al. 1990; Halling et al. 1985; Lee et al. 2007). 
 
 
1.3.2 Diphtheria Toxin 
Diphtheria toxin (DT) is endogenously produced by the bacteria Corynebacterium 
diphtheria and shares a similar structural layout to BotNT/A, with a light chain catalytic 
domain and a covalently attached heavy chain (fig. 1.3:B). Its catalytic domain has ADP-
ribosylation activity to inactivate eukaryotic elongation factor 2 (eEF-2), preventing the 
translocation of t-RNA through the ribosome thus inhibiting protein synthesis, eventually 
killing the cell (Bell & Eisenberg 1996). DT belongs to a family of proteins called Ribosomal 
inactivating proteins (RIPs), which target the specific pathways of protein synthesis and 
can be used to target cancer (Siegall 1994). DT is also particularly useful as within the 
cytosol it is estimated to inactivate up to 2000 eEF-2s/min; from this, a single diphtheria 
toxin molecule is able to kill a cancer cell (Yamaizumi et al. 1978; Moynihan & 
Pappenheimer 1981). 
Because of its toxic effects and extreme potency, DT has been extensively researched as 
an effective treatment for a variety of cancer types with there being many clinical trials of 
DT conjugated drug candidates (Y. M. Li et al. 2013; Frankel et al. 1995). To date, there is 
only one diphtheria-conjugated drug on the approved by the FDA: Denileukin diftitox 
(Ontak) is approved for treatment of human cutaneous T-cell lymphoma and is composed 
of the first 389 amino acids of DT recombinantly fused to IL-2 to bind to upregulated IL-2 
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receptors in T- cells, thus facilitating internalisation and resulting in cell death (Fuentes et 
al. 2015; Duvic & Tapur 2008). This construct contains the catalytic light chain and the 
translocation domain of DT, but not the endogenous binding domain so as to avoid 
undesired cell targeting, this technique is common with most toxin-derived therapeutics 
(Frankel et al. 1995).  
However there are limitations of using DT, for instance DT is commonly vaccinated against 
in the first world. Moreover, there have been reported side effects for DT-conjugated drugs 
such as flu-like symptoms or vasculitis (Cohen et al. 2005; Duvic & Tapur 2008). However, 
solutions are being explored to overcome the immunogenicity of the toxin by mutating  
with point mutations or wrapping in immunoliposomes (Schmohl et al. 2015; Vingerhoeds 
et al. 1996).  
 
1.3.3 Ricin  
Ricin is a cytotoxic protein isolated from castor bean seeds. Like DT and BotNT/A is exists 
in subunits, a catalytic A-chain and a targeting B-chain which are linked together via 
disulphide bond (Tyagi et al. 2015). Unlike DT and BotNT/A there is no translocation 
domain (fig. 1.3:C), nonetheless it is one of the most toxic proteins in nature (Halling et al. 
1985). Ricin is an N-glycosidase which removes an adenine residue from a highly conserved 
loop of rRNA. This prevents the subsequent binding of eukaryotic elongation factor 1 and 
2, halting protein synthesis resulting in cell death and making it part of the RIP family along 
with DT (Endo & Tsurugi 1987; Dever & Green 2012).  
There are numerous examples of ricin A-chain being attached to targeting domains as a 
candidate for cancer therapy, some of which have managed to progress to clinical trial 
phase, however there are currently no FDA approved drug based on ricin (Słomińska-
Wojewódzka & Sandvig 2013; Frankel et al. 1995). Part of this is because there have been 
problems with off target effects such as vascular leak syndrome due to inappropriate toxin 
entry into the endothelial cells, which can cause issues such as multiple organ failure and 
oedema (Baluna et al. 1999; Polito et al. 2016). Another issue with ricin and other RIPs is 
that they can be highly immunogenic, stimulating patients to produce antitoxin antibodies 
which decreases the half-life, and therefore efficacy, of the construct (Kreitman 1998; 
Antignani & FitzGerald 2013). Nonetheless, with modifications to reduce immunogenicity, 
ricin could still be a useful therapeutic protein for cancer research  (Li et al. 2009).  
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1.3.4 BLF and alternative toxins 
In addition to those listed above, there are other toxins that are also used for re-targeting 
to cancer cells such as pseudomonas exotoxin, produced by the bacteria Pseudomonas 
aeruginosa, which inhibits eEF-2 in a manner similar to DT (Shimamura et al. 2010; Weldon 
& Pastan 2012). Saporin on the other hand is more comparable to ricin; derived from the 
seeds of the Saporin officinalis, it is another RIP that depurinates adenine residues on 
ribosomal subunits which irreversibly inhibits protein synthesis (Polito et al. 2011; Quadros 
et al. 2013). 
RIPs remain some of the most toxin proteins in nature; they come in numerous structures, 
sizes and functions from both plant and bacterially derived sources and there has yet to be 
a completely uniform classification of them due to their variety (Schrot et al. 2015). 
Nonetheless, their protein synthesis inhibiting function and the consequent cell death 
resulting from their internalisation has enabled them to be attractive for targeting to 
cancer cells; however, drug candidates containing these toxins still have issues with side-
effects and unwanted toxicity. 
Interestingly, it has emerged that a newly identified RIP toxin inhibits protein synthesis 
potentially without killing cells. Burkholderia Lethal Factor1 (BLF1) is a toxin derived from 
the bacteria Burkholderia pseudomallei. Whilst the bacteria has been associated with 
melioidosis and infection often resulting in death, BLF1 is an inhibitor of the eukaryotic 
initiation factor 4A (eIF-4A) which has been identified as an oncogene and as a potential 
druggable target (Cruz-Migoni et al. 2011; Chu & Pelletier 2014). Significantly, BLF1 has 
been shown to prevent growth of cells in vitro without activation of the caspase pathway 
(Rust et al. 2015). It had been previously identified as a new tool for targeted delivery 
(Walsh et al. 2013), however the findings that BLF1 may inhibit growth of cells without 
killing could offer new drug candidates with reduced toxicity and side effects.  
 
 
1.4 Internalisation techniques 
Most therapeutic agents target proteins and mechanisms within the cell cytosol, this 
requires them to be internalised into cells efficiently and be able to reach the location 
within the cell needed to induce catalytic effect. This process often involves delivery 
strategies to first internalise the drug and then allow it to escape cellular compartments to 
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reach the therapeutic target. There have been numerous diverse methods developed to 
internalise drugs into cells; their efficiency can depend on a variety of pathways, both 
specific and non-specific to particular cell types depending on their external receptors or 
protein signature (Böhme & Beck-Sickinger 2015). Because of the size of therapeutic 
protein drugs it is difficult for them to pass through the cell membrane, hence 
internalisation strategies are needed to overcome biological barriers and improve both the 
efficiency and specificity of drug targeting (Sandvig & van Deurs 2005). Most often, the 
strategy for efficient internalisation is to conjugate internalisation proteins or peptides to 
the therapeutic domain, so that as the targeting domain binds to cell receptors and is 
endocytosed, so too is the therapeutic domain (fig. 1.4). There are a large variety of 
internalisation domains which have been investigated for this purpose.  
 
 
Figure 1.4 – Schematic showing basic drug internalisation pathway 
Diagram showing the strategy most adopted by researchers for drug construction and 
internalisation: A therapeutic domain is conjugated to an internalisation domain to 
facilitate uptake into cells. This method can be used through proteins using non-specific 
pathways internalisation pathways such as CPPs (Reissmann 2014) or receptor mediated 
endocytosis where receptors are either recycled back to the cell surface (e.g. transferrin 
receptor) (Tortorella & Karagiannis 2014) or degraded in the lysosomes to prevent further 
signalling (e.g. EGF receptor) (Seshacharyulu et al. 2013). 
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1.4.1 Cell penetrating peptides 
Cells are known for their ability to prevent non-specific entry of proteins and 
macromolecules, and only employs specific pathways for the transport of desired proteins. 
About 30 years ago there was the discovery of small sequences which were able to pass 
through the membranes of cells unhindered via non-specific delivery, these were referred 
to as cell penetrating peptides (CPPs) (Reissmann 2014) These short sequences are 
traditionally composed of either numerous positively charged amino acids such as lysine 
or arginine (polycationic CPPs) or have an alternating structure of polar and non-polar 
amino acids (amphipathic CPPs), however many different varieties of CPPs have been 
developed over recent years (Bechara & Sagan 2013) (Table 1.1). These were developed as 
a new drug delivery method and several have been established as ways of efficiently 
translocating a variety of cargo into cells, such as small molecule drugs, proteins and 
fluorescent labels (Koren & Torchilin 2012; Young Kim et al. 2015).  
Initially CPPs were derived from proteins such as HIV and drosophila antennapedia, 
resulting in Penetratin and TAT, however since then there have been numerous forms 
artificially synthesised (Nischan et al. 2015; Ma et al. 2012). As well as being shown to bind 
and deliver small proteins and nucleic acids, some CPPs have also been shown to deliver 
larger proteins into cells in vitro, such as BotNT/A (1-448) and β-galactosidase  (Farkhani et 
al. 2014; Montrose et al. 2013; Saffarian et al. 2016).  
There is a lot of dispute regarding the mechanisms of cell entry, enabling them to 
internalise and deliver cargo before being broken down by lysosomes or recycled. There 
are reports showing that chlorpromazine or other macropinocytosis inhibitors will inhibit 
CPP uptake at low concentrations (< 5 µM), but at higher concentrations it appears that 
they internalise via non-endocytic mechanisms (Fischer et al. 2004; Chao & Raines 2011). 
There is further evidence that CPPs interact with the cell membrane and can form pores 
suggesting that fatty acids on the surface of the cell interact with arginine residues (R), 
common in CPPs. This then leads to the formation of channels, where on the cytosolic side 
the pH decreases and the fatty acids are protonated, releasing the peptides and resealing 
the channel (Herce et al. 2009; Herce et al. 2014). There is also a proposed ‘inverted-
micelle’ mechanism which suggests that electrostatic interactions between the lipid bilayer 
and CPPs trigger conformational changes in the peptide, causing it to bind to the bilayer 
and changing its properties causing encapsulation (Alves et al. 2008; Cardoso et al. 2012). 
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In reality, uptake is probably a mixture of many cell entry pathways depending on 





Type Origin Charge Sequence Reference 







TAT peptide  Protein  HIV (48-60)  Cationic  GRKKRRQ
RRRPPQ  
 (Vives et 
al. 1997)  
TAT peptide Protein HIV (47-57) Cationic YGRKKRR
QRRR 
(Ignatovich 







et al. 2001) 






(Lin et al. 
1995) 




Synthetic N/A Cationic RRWWRR
WRR 
(Delaroche 
et al. 2007) 









Table 1.1 – Table of Cell penetrating peptides (CPPs) and their sequences 
 
Whilst these peptides were designed to enter into cells efficiently and indiscriminately, this 
has been a double-edged sword as specific delivery into diseased cells is most often 
preferable. There are reports of attempts to develop tissue specific CPPs through using in 
vivo or in vitro phage display; for example, motifs have been identified in peptides for 
targeting tumour vasculature in particular cancers (Zahid & Robbins 2015; Arap et al. 2012; 
Lim et al. 2013). However this supports a more receptor-based method of entry, as 
opposed to a non-specific, therefore questioning the definition of a CPP. Whilst there have 
been positive results in various disease models which in some cases have prompted clinical 
trials, there are currently no CPP drugs approved by the FDA (Guidotti et al. 2017) 
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Nonetheless, their ability to be taken up in a variety of cell lines makes them particularly 
useful for investigation into proof of concept delivery. 
 
1.4.2 Ligand-receptor interaction and internalisation 
In order to give targeted toxins more specificity in selecting cancer tissue over healthy 
tissue there is an established method where ligands or ligand-like peptides are conjugated 
to therapeutic domains and bind to receptors specific to disease (Allen 2002; Toporkiewicz 
et al. 2015). It is known that many varieties of cancer have particular upregulated receptors 
on the surface of the cells, these receptors can be exploited by using endogenous or 
synthetic proteins to target the upregulated receptors and attaching drugs (Srinivasarao et 
al. 2015). Once the ligand is bound to the overexpressed receptors, the conjugate can be 
endocytosed into endosomes where it is then either recycled, processed or directed to the 
lysosomes to be degraded. However, via endosomal escape the internalised toxin is able 
to translocate into the cytosol where it can exert its function.  
There have been many successful examples of ligand directed toxins, the most successful 
of which have made it to clinical trials and even FDA approval (Duvic & Tapur 2008; Böhme 
& Beck-Sickinger 2015). As previously mentioned, Ontak is a drug which has IL-2 
conjugated to a portion of DT, but there have been other examples of interleukins used to 
target toxins owing to their overexpression in numerous cancer cell types (Cohen et al. 
2005; Kunwar et al. 2010). Additionally, there have been a variety of examples where other 
ligands have been utilised for cancer targeting, such as EGF or transferrin, and have been 
able to deliver toxin domains to neuroblastoma cells and others (Raso & Basala 1984; 
Yotsumoto et al. 2009). Table 1.2 list some of the ligands which have been previously 
identified for neuroblastoma targeting, and others which have been shown to target other 
cancers but may have potential to target neuroblastoma.   
Sometimes however, it is undesirable when developing drugs to use endogenous ligands. 
Despite the fact that they can have high specificity and potentially efficient internalisation 
they can activate undesired pathways, for instance increased cell growth; these receptors 
are of course upregulated in cancer for a reason. Therefore, once the target receptors have 
been identified through endogenous ligands or otherwise, peptides or proteins can be 
engineered which bind to the receptor and still internalise without the unwanted increase 
in pathway activation (Nicklin et al. 2000; Li & Mao 2014). Like CPPs, peptide ligands are 
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selected from phage-display libraries or chemical synthesis. This technique has resulted in 
peptide ligands being identified which specifically bind to receptors (Guardiola et al. 2015). 
It should be noted that this method can have a lot of overlap with CPPs, as there are 
peptides which have been identified which share similar sequences to CPPs but with more 
receptor-dependent internalisation (Arap et al. 2012). 
Targeting of cancer tissue increases intratumoural accumulation of drug, increasing the 
toxicity; it is also aided partially by the dense, leaky vascular system which accompanies 
most solid tumours. However, it does rely on the external signature of the cell remaining 
unchanged throughout, as if it does change then it could lead to tumour resistance 
(Toporkiewicz et al. 2015). Unfortunately, many cancers in later stages are highly unstable 
and therefore can repeatedly mutate to alter their receptor make-up over time, meaning 
that populations of cancer cells remain resistant to chemotherapy (Kuczynski et al. 2015). 
Alternatively, heterogeneity is a problem in many types of cancer and is especially known 
in neuroblastoma, where a population of cancer cells will have numerous clusters of cells 
each expressing different receptors making targeting the whole population a significant 
challenge (Ngan 2015).  
To address this, most courses of cancer treatment employ more than one individual 
therapy, although there are strategies emerging to incorporate more than one targeting 
method into a single therapy. Whilst antibody based dual-targeting is now being 
established as an important strategy to combat the resistance of cancer, ligand based dual-
targeting has not been explored to the same extent because the means of conjugating two 
ligands together with one therapeutic domain remains a complex process (Kontermann 
2012; Chester et al. 2015). Bulk delivery carriers such as liposomes and nanoparticles have 
touched upon coating the surfaces with numerous ligands, however these are often 
heterogeneous and bulk delivery is not always desired (Rangger et al. 2013; Gao et al. 
2014). The need remains therefore to develop a conjugation method which is able to bring 
together two targeting domains together with a therapeutic domain to produce a 
homogenous, ratio-controlled product, where all components of the complex retain their 













µ opioid receptor 
-- Neuroblastoma (Glaser et al. 1981; 
Arttamangkul et al. 
2000) 
Substance P –  






(Mustafa et al. 2008; 
Muñoz et al. 2005) 
Corticotrophin-releasing 
hormone (CRH) – 





Neuroblastoma (Arsenault et al. 
2013) 
Vasoactive intestinal 
peptide (VIP) –  
VIP receptors 1 and 2 
Micelles Neuroblastoma, 
Breast Cancer 
(Ding et al. 2013; 
Pence & Shorter 
1992) 
Neuropeptide Y  (NPY) – 
NPY receptors 1-5 
Nanoparticles Neuroblastoma, 
Breast cancer 




polypeptide (PACAP) and 
PACAP 2 – 
PACAP receptor, VIP 
receptors 1 and 2 
-- Neuroblastoma (De Boisvilliers et al. 
2016; Falktoft et al. 
2009) 
Ciliary neurotrophic 
factor (CNTF) –  





Neuroblastoma (Kuroda et al. 2001; 
Arsenault et al. 2013) 












(Seshacharyulu et al. 
2013; Master & 
Gupta 2012; 
Herschman 1984) 
Tumour necrosis factor 
alpha (TNFα) – 










(Oshima et al. 2014; 
Bigatto et al. 2015; 
Arsenault et al. 2013) 
Adrenomedullin – 
calcitonin receptor  like 
receptor (CLR), Receptor 
activity-modifying 




(Wang et al. 2014; 
Wu et al. 2015) 
 





1.4.3 Antibody directed cell internalisation 
Antibodies possess numerous attributes which make them desirable to be used for cancer 
targeting. For instance they can be selectively developed for high binding affinity whilst 
being molecularly homogenous, they can also be humanised or chimeric to decrease 
immunogenic reactions and can be engineered in very versatile ways (Becker & Benhar 
2012; Smaglo et al. 2014). From these, antibody-drug conjugates (ADCs) have developed, 
where, instead of ligands, antibodies are conjugated to toxins in order to target and deliver 
to specific cells; these are referred to as immunotoxins (Kreitman 1998; Antignani & 
FitzGerald 2013).  
Antibody therapy often uses ligand internalisation studies as a foundation in order to 
design and develop an immunotoxin with specific binding characteristics in mind. Antibody 
production is expensive, and this limits its usefulness at early stages of drug target 
research. Nonetheless, in recent years there has been a boom in antibody therapy 
production because of their specificity to receptors, even those without endogenous 
ligands, without the unwanted receptor-pathway activation. This has led to numerous 
antibody based drugs being FDA approved through targeting receptors such as EGF, TNFα 
and others (Scott et al. 2012; X.-X. Li et al. 2015; Deeks 2016). Whilst antibodies have been 
used to target cells, often instead of drug attachment they retain the endogenous 
sequence in the antibody to activate the immune system to kill the cell; out of over 65 
monoclonal antibody drugs which have been approved, only two of them currently 
available are conjugated to a drug (Beck & Reichert 2014).  
On the other hand, there is no shortage of research or demand for antibody-drug 
conjugates; unstable and inefficient conjugation has been named as one of the reasons for 
their current lack of success (Perez et al. 2014; Thomas et al. 2016). There have been many 
examples where antibody drug conjugates have been developed to meet different cancer 
varieties, however there has yet been a method developed to consistently synthesise 
stable ADCs which optimise disease targeting and drug action (Bornstein 2015; Ducry & 
Stump 2017; Beck & Reichert 2014). As antibodies and antibody derived domains have 
emerged as the targeting method of choice, it is clear that solutions are needed to address 





1.5 Endosomal escape and cytosolic delivery 
All of the approved ADCs until now have only used small molecule drugs as their payload, 
this is because once antibodies internalise and the payload released it is more likely to 
translocate to the cytosol if it is a small molecule than if it is a large protein. Because of 
this, endosomal escape is not a current consideration in ADC design (Perez et al. 2014; 
Bornstein 2015). However, there new methods being explored to aid the cytosolic delivery 
of large proteins, allowing immunotoxins to fully develop as a successful avenue of drug 
research (Fuchs et al. 2016; Becker & Benhar 2012).  
Most therapeutic enzymes target proteins in the cytosol, so after cell internalisation there 
needs to be a way for the toxin to escape endosomes and reach its target for there to be a 
catalytic effect. As previously mentioned, the endocytic pathway takes up proteins and 
other components from the surrounding environment, often into endosomes, and then 
does one of three things: (i) it can degrade the internalised proteins through passage to 
the lysosomes where proteins undergo enzymatic degradation, or (ii) it can be recycled 
and transported out of the cell via exocytosis. The third option, is that the internalised 
proteins undergo endosomal escape, where the proteins pass into the cytosol (Varkouhi 
et al. 2011). Endosomal escape is an important and currently an intensively researched 
area, it is critical to the pharmaceutical efficiency of many drugs, as most targeted proteins 
and pathways of pharmaceutical relevance are within the cytosol. However, a ubiquitous 
method of cytosolic translocation has yet to be identified. As is, endosomal escape is often 
a limiting factor in drug delivery, hence there is a shift in focus from only targeting cells to 
also focusing on efficient cytosolic delivery (Fuchs et al. 2016; Bostad et al. 2015; Shete et 
al. 2014) 
There are several researched methods of endosomal escape, for instance, viruses and 
bacteria have evolved ways of efficiently translocating inside of cells. In enveloped viruses 
there can be fusion directly between the envelope and cell membrane which encourages 
endocytosis and there is subsequent cell lysis, whereas viruses without an envelope have 
been known to create pores (Medina-Kauwe 2003; Hogle 2002). Pore formation is also a 
common way which bacteria get from the endosomes or phagosomes to the cytosol, using 
proteins which are activated by reducing agents or low the pH found in vesicles to allow 
cytosolic escape without compromising the endosomal membrane (Mandal & Lee 2002). 
Another endosomal escape method triggered by low pH is the proton sponge effect, this 
is facilitated by agents with a high buffering capacity. For instance, histidine-rich molecules 
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can show a buffering effect upon protonation of their imidazole ring; it induces ion and 
water intake into the endosomes, which swell then ruptures the endosomal membrane 
(Pack et al. 2000). A similar example exists where tertiary amine groups containing a 
hydrophobic chain can accumulate in endosomes and become detergents upon 
protonation caused by the low pH, resulting in a disruption of the endosomal membrane 
(Miller et al. 1983). However, it is worth noting that some of these endosomal escape 
methods which involve the lysis or disruption of the membrane may result in cell death, 
which can be undesirable (Lönn et al. 2016). 
 
1.5.1 Utilising toxin cytosolic translocation proteins 
By researching the translocation domains which are already present in toxins such as 
botulinum and diphtheria, an understanding has developed on their mechanism of 
function and how they can be exploited to enhance drug delivery. It has been suggested 
that the change in pH when the botulinum translocation domain is internalised into early 
endosomes causes it to interact with the membrane and allows pores to form (Nagahama 
et al. 2014) (fig. 1.5). This pore allows the catalytic light chain domain of botulinum to get 
into the cytosol whilst chaperoned by the translocation domain to retain its stability 
(Fischer et al. 2012; Araye et al. 2016; Koriazova & Montal 2009). It is proposed that this is 
the same mechanism used for the diphtheria translocation domain (Murphy 2011; 
Chassaing et al. 2011); although, there is additional data supporting that the translocation 
domain of diphtheria also inhibits the early endosome maturation, hence increasing the 
time available for escape before lysosomal degradation (Antignani & Youle 2008). It has 
also been reported that within the translocation domains of botulinum A, C and D and 
diphtheria there is a 10 amino acid loosely conserved sequence, which is also seen in 
anthrax and could account for the similarity in translocation mechanisms  (Trujillo et al. 
2006; Jiang et al. 2015). The fact remains that some of the most toxic known proteins in 
negligible amounts are being still efficiently translocated into cells through their 
translocation domains; it was even noted that without the receptor binding domain, the 
light chain and the translocation domain of BotNT/A were able to enter particular cells 
independent of any targeting domain (Fischer et al. 2008).  
The research into how bacterial and plant agents escape into the cytosol has given way to 
the translocation domain being used as a way to increase drug translocation. For instance, 
Ontak is composed of the first 391 amino acids of diphtheria, which is both the catalytic 
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and translocation domain, attached to IL-2 (Fuentes et al. 2015). There are also examples 
of research and patents where the translocation domains of these toxins are harnessed; 
the translocation domain of diphtheria has been attached to alternative catalytic domains, 
including botulinum, to increase translocation (Sutton & Shone 2004; Shone et al. 2003). 
Moreover, it has even been shown that the conjugation of the translocation domain of 
diphtheria to plasmids increases gene transfection (Kakimoto et al. 2009). This strongly 
indicates that particular translocation domains on toxic proteins can assist in cytosolic 
delivery, and therefore would be a useful avenue to explore through conjugation to 
targeting and therapeutic domains.  
 
 
Figure 1.5 – Endosomal escape of toxins and peptides 
Schematic showing the endosomal escape of toxins and peptides. Both botulinum and 
diphtheria have endosomal escape facilitated by their translocation domains which insert 
into the endosomal membranes in response to the pH of the early endosome and form 
channels (Koriazova & Montal 2009; Antignani & Youle 2008). Ricin has not got a 
translocation domain, but its A chain facilitates protein folding which leads it through the 
ERAD pathway to the endoplasmic reticulum where it then escapes (Sun et al. 2004). 
Peptides can escape the endosomes through a variety of mechanisms depending on its 
amino acid composition, however GALA and HA2 fuse with the membrane in response to 
low pH (Varkouhi et al. 2011). 
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1.5.2 Utilising peptides for endosomal escape  
Additionally, there are several peptides which have been reported to increase the presence 
of attached proteins into cytosol. For instance, GALA is a short anionic synthetic 
amphipathic peptide sequence which, when in the endosome, is protonated due to the 
low pH causing a conformational change which allows it to fuse with the lipid bilayer. The 
proposed mechanism is that the inserted GALA peptides then aggregate together and form 
pores, allowing endosomal proteins to cross into the cytosol (Nicol et al. 2000; Lewis 2014; 
Parente et al. 1988). The attachment of GALA has also been shown to increase the cytosolic 
location of nanocapsules and increase transfection efficiency (Futaki et al. 2005; Nishimura 
et al. 2014). 
Influenza virus hemagglutinin (HA) is a glycoprotein which fuses the influenza virus capsid 
with cell membranes for internalisation. A 20 amino acid peptide within the subunit HA2 
was identified as a sequence which under acidic conditions will bind and disrupt endosomal 
membranes leading to endosomal escape (Wiley & Skehel 1987; Neundorf et al. 2009). 
There are also reports that CPPs with histidine rich domains are able to successfully 
translocate into the cytosol and can be used as a transfection peptides (Järver et al. 2007). 
It has been demonstrated that when cationic CPPs are exposed to acidic environments 
within endosomes they are able to bind to the endosome bi-layer and leak through the 
membrane following a pH gradient (Yang et al. 2010; Madani et al. 2013). However, this 
method of endosomal escape is limited in that it may not facilitate the cytosolic 
translocation of attached proteins, therefore, CPPs are being used in combination with 
other endosomal escape peptides such as HA2 (Neundorf et al. 2009; Liou et al. 2012; 
Tünnemann et al. 2006). This sort of combination of internalisation domains, endosomal 
escape domains and therapeutic domains is becoming more popular because it addresses 
the bottleneck of cytosolic translocation. Through new conjugation methods, it is hoped 
that these processes can be explored more efficiently.  
 
 
1.6 Aims of Thesis 
This introduction has laid out four main themes: conjugation, toxins, cell internalisation 
methods and endosomal escape. This thesis aims to use pyridyl disulphide conjugation and 
SNARE linking to be able to further understand the nature of particular therapeutic toxins, 
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identify cell internalisation peptides or proteins for neuroblastoma targeting, and 
investigate how to enhance conjugate cytosolic translocation through endosomal escape. 
In doing so, it is hoped that new findings will be made in these areas, but also that it will 
identify the limitations and potential of particular conjugation methods for drug 
construction. Furthermore, it is the ambition of this project that these findings will aid the 
development of other conjugation methods in wider research, that it may contribute to 
strategies for the optimisation of antibody-drug conjugate development and future 






















2-YT powder Invitrogen - Thermo Fisher Scientific 
Acetic acid (Glacial) Thermo Fisher Scientific 
Agar Scientific Lab Supplies 
Agarose Biogene 
Ammonium persulphate (APS) Thermo Fisher Scientific 
Ampicillin Panreac 
Benzonase Nuclease  Sigma-Aldrich 
Bovine Serum Albumin (BSA) Thermo Fisher Scientific 
Bromophenol Blue BDH Chemical 
Calcium Chloride (CaCl ) Sigma-Aldrich 
Coomassie Brilliant Blue BDH Chemical 
Chloramphenicol Panreac 
Desipramine Sigma-Aldrich 
Deoxyribonuclease I from bovine pancreas Sigma-Aldrich 
DMSO Sigma-Aldrich 
EDTA Thermo Fisher Scientific 
Ethanol Thermo Fisher Scientific 
Fish skin gelatine Sigma-Aldrich 
D-Glucose Sigma-Aldrich 
Glycerol Thermo Fisher Scientific 
HEPES Thermo Fisher Scientific 
Hydrochloric acid (HCl) Thermo Fisher Scientific 
IPTG Melford 
Lipofectamine 3000 Invitrogen 
Magnesium Chloride (MgCl ) Acros Organics 
Magnesium Sulphate (MgSO ) Merck 
MES running buffer (x20) Life Technologies - Thermo Fisher 
Scientific 
Methanol Thermo Fisher Scientific 




Octyl β-D-glucopyranoside (OG) Thermo Fisher Scientific 
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Pargyline hydrochloride Sigma-Aldrich 
Paraformaldehyde (PFA) Sigma-Aldrich 
Phosphate Buffered Saline (PBS) (x10) Thermo Fisher Scientific 
Protogel National Diagnostics 
Resolving gel buffer Bio-Rad Laboratories 
Sodium Chloride (NaCl) Thermo Fisher Scientific 
Sodium Dodecyl Sulphate (SDS) Thermo Fisher Scientific 
Sodium Hydrocarbonate (NaHCO ) Sigma-Aldrich 
Sodium Hydroxide NaOH Sigma-Aldrich 
Stacking gel buffer Bio-Rad Laboratories 
TCEP Sigma-Aldrich 
TEMED Sigma-Aldrich 
Transfer Buffer (x10)/ Tris-glycine buffer Fluka 
Triton-X-100 Thermo Fisher Scientific 
Tween-20 Thermo Fisher Scientific 
Xylene cyanol Sigma-Aldrich 
 




All made at Room Temperature (RT) unless otherwise stated. RT was measured at 20˚C. 
Buffer A:  Made with 10 mL 1 M HEPES pH 7.3 (20 mM – final concentration), 10 mL 5 M 
NaCl (100 mM), made up to 500 mL with deionised water (dH O). 
Lysis Buffer (Protein purification): Made with 10 mL 1 M HEPES pH 7.3 (20 mM), 50 mL       
5 M NaCl (500 mM), 1 mL 0.5 M EDTA (1 mM), made up to 500 mL with dH O. 
Low Salt Buffer: Made with 10 mL 1 M HEPES pH 7.3 (20 mM), 10 mL 5 M NaCl (100 mM), 
2.5 mL 20 % Triton-X-100 (0.1 %), 1 mL 0.5 M EDTA (1 mM), made up to 500 mL with dH O. 
High Salt Buffer: Made with 10 mL 1 M HEPES pH 7.3 (20 mM), 100 mL 5 M NaCl (1 M),    
2.5 mL 20 % Triton-X-100 (0.1 %), 1 mL 0.5 M EDTA (1 mM), made up to 500 mL with dH O. 
4x loading Buffer (SDS-PAGE gel): Made with 3.2g SDS (approx. 12 %), 20 mL 0.5 M Tris-
HCl pH6.8 (approx. 0.25 M), 640 µL 0.5 M EDTA, 16 mL 50 % Glycerol (approx. 20 %),              
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2.5 mL dH O, 1.5 tips Bromophenol Blue. This is then diluted in water to make x1 and x2 
loading buffers. 
SDS-PAGE staining solution: Made in the following order- 200 mL Methanol, 1 tip 
Coomassie Brilliant Blue, 700 mL dH O, 100 mL Glacial Acetic acid. 
4x Sample Lysis Buffer (Westerns): 4g SDS (8 %), 25 mL 0.5 M Tris-HCl pH6.8, 800 µL 0.5 
M EDTA (8 mM), 10 mL 50 % Glycerol (10 %), 1.5 tips Bromophenol Blue, up to 50 mL dH O. 
Membrane Transfer Buffer: Made with 700 mL dH O, 100 mL 10x Transfer buffer, 200 mL 
Methanol. 
PBS-T: Made with 100 mL 10x PBS, 900 mL dH O, 0.5 mL Tween (0.05 %). 
Membrane blocking solution: 5 mL (vol) Milk powder, made up to 50 mL PBS-T. 
MES running buffer: Made with 950 mL dH O, 50 mL MES running buffer (x20). 
Tris-Glycine Running buffer (x10): 500 mL 10x transfer buffer, 5g SDS. Diluted to x1 in 
deionised water when running gels. 
SDS-PAGE 12 % resolving gel: made with 1.33 mL dH O, 2.0 mL 50 % Glycerol (sterilised), 
2.5 mL Resolving Gel buffer (1.5 M Tris pH 8.8), 4 mL Protogel (30 % (w/v) Acrylamide,       
0.8 % (w/v) Bis-Acrylamide), 100 µL 10 % SDS (in water) To be added just before pouring 
gel:      80 µL 10 % (w/v) Ammonium persulphate (APS), 8 µL TEMED. 
SDS-PAGE stacking gel: made with 3.8 mL dH O, 1.5 mL Stacking gel buffer (0.5 M Tris pH 
6.8), 600 µL Protogel (30 % (w/v) Acrylamide, 0.8 % (w/v) Bis-Acrylamide), 60 µL 10 % SDS 
(in water). To be added just before pouring gel: 80 µL 10 % (w/v) Ammonium persulphate 
(APS), 8 µL TEMED. 
TAE buffer (x50): 242 g Tris base is dissolved in dH O, 57.1 mL glacial acetic acid is then 
added and 100 mL EDTA 500 mM (pH 8.0) solution. The final volume is then bought up to 
1 L. Diluted in dH O before use. 
Basal Buffer (Radiation experiments): 132 mM NaCl, 5 mM KCl, 0.6 mM MgSO .7H O,       
5 mM NaHO , 2 mM CaCl , 10 mM D-glucose, 20 mM HEPES, pH 7.4.  
Release Buffer (Radiation experiments): 67 mM NaCl, 70 mM KCl, 0.6 mM MgSO .7H O, 
5 mM NaHO  , 2 mM CaCl ,  10 mM D-glucose, 20 mM HEPES, pH 7.4. 
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4% PFA (1L) – made by Rebecca Bresnahan (Davletov Lab) - Heat 0.7 L of 1xPBS to 55-       
57 ̊ C (do not allow to go over 60 ̊ C). Add 40 g of PFA powder, then add 2 M NaOH dropwise 
until all PFA has dissolved (~1-1.5 mL). Cool on ice to RT, then add 1xPBS to make up to 1 
L. Add HCl (5 M) dropwise to return pH to 7.4. Filter through 0.45 µm filter. Aliquot into 10 
mL falcons and freeze -20C. 
Blocking solution – made by Rebecca Bresnahan (Davletov Lab) – The following reagents 
are added before being made up to 400 mL in water, the solution is stirred for a few hours 
until all reagents are dissolved before being aliquoted into 10 mL stocks and stored at              
-20 ˚C: 8 g BSA (2 %), 8 mL fish skin gelatine (2 %), 0.4 mL Tween-20 (0.1 %), 40 mL 10x PBS 
(x1). 
 
2.1.3 Broths and antibiotic stocks 
2-YT Media: Made with 16 g 2-YT powder, 500 mL dH O (2-YT used at 32 g/L). Autoclaved. 
2-YT Agar: Made with 6.4 g 2-YT powder, 200 mL dH O, 3 g Bacto-Agar. Autoclaved, the 
antibiotics were added when cooling, or carefully microwave until melted and add the 
antibiotics and pour into dishes after 30 minutes cooling.  
Ampicillin 100mg/mL: 1 g Ampicillin in 10 mL dH O. 
Chloramphenicol 50mg/mL: 0.5 g Chloramphenicol in 10 mL 100% Ethanol. 
IPTG 100mM: 238.3 mg IPTG in 10mL dH O. 
 
2.1.4 Enzymes and Proteins 
Unless otherwise stated, all proteins listed here were expressed and purified in-house by 
myself from existing plasmids (see section 2.2 for protein synthesis and purification). All 
plasmids were pGEX based.  For those which are marked with (*) the plasmid sequences 
can be found in Appendix 1. Molarity is calculated through protein size: If protein size is 
XDa, then 1 M = X g/L, so 1 µM= X µg/L.  
The concentration (mg/ml) of pure stocks was measured through Nanodrop (Thermo 
Fisher Scientific). The concentration of mixed samples and formed complexes was 
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measured relative to BSA standards on SDS-PAGE via ChemiDoc XRS (Bio-Rad) (see section 
2.3.4).  
Protein Approx. 
protein Size  
Supplier of Plasmid Additional Notes 




Gift from Professor 





Diphtheria Light Chain (aa. 
1-193) 
23 kDa Generated by Dhevahi 
Niranjan (Davletov lab) 
 
Diphtheria Light Chain 
Translocation Domain (aa. 1-
388)* 
48 kDa Generated by Dhevahi 
Niranjan (Davletov lab) 
 
Diphtheria Light Chain 
Translocation Domain (aa. 1-
388) – SNAP25B* 
68 kDa Ordered from Dundee 
Cell products 
 
Diphtheria Light Chain 
Translocation Domain (aa. 1-
388) - Diphtheria Light Chain 
(aa. 1-196)* 
67 kDa Ordered from Dundee 
Cell products 
 
Diphtheria Light Chain 
Translocation Domain (aa. 1-
388) – Diphtheria (aa. 179-
190) – Cysteine rich domain 
* 








Ricin Light Chain  (aa. 1-267) 29.6 kDa Generated by Dhevahi 
Niranjan (Davletov lab) 
 
Botulinum/A Light Chain (aa. 
1-438) 





Botulinum/A Light Chain 
Translocation Domain (aa. 1-
852)* 
100 kDa Generated by Dhevahi 




Botulinum/A Light Chain 
Translocation Domain (1-
852) – SNAP25B * 
120 kDa Generated by Dhevahi 
Niranjan (Davletov lab) 
 
Botulinum/A Light Chain 
Translocation Domain (1-
852)-S25CRD 
123 kDa Generated by Rose 





SNAP25B- Cysteine rich 
domain (S25-CRD)* 
2.7 kDa Generated by Dhevahi 




Synaptobrevin (aa.2-94)* 10.5 kDa Generated by Dhevahi 
Niranjan (Davletov lab) 
 
SNAP25 trunc (aa.2-204)* 20 kDa Generated by Dhevahi 






SNAP25 wildtype 25 kDa Generated by Dhevahi 
Niranjan (Davletov lab) 
 
mCherry 24 kDa Generated by Dhevahi 




mCherry-4cys 27 kDa Generated by Rose 





Synaptobrevin (25-84) – 
Ciliary neurotrophic factor 
(Brevin-CNTF)* 




Syntaxin 3 (195-253) -Ciliary 
neurotrophic factor (Syx-
CNTF)* 





Epidermal Growth Factor 
(Brevin-EGF)  
 




Botulinum/A Light Chain 
Translocation Domain (aa. 1-
852)- Ciliary neurotrophic 
factor 
 




Botulinum/A Light Chain 
Translocation Domain (aa. 1-
852)- Epidermal Growth 
Factor 
 




Botulinum/A Light Chain 
Translocation Domain (aa. 1-
852)-NPY 





stocks at -80˚C 
Botulinum/A Light Chain 
Translocation Domain (aa. 1-
852)-PACAP 





stocks at -80˚C 
Botulinum/A Light Chain 
Translocation Domain (aa. 1-
852)-PACAP2 





stocks at -80˚C 
Botulinum/A Light Chain 









stocks at -80˚C 
Botulinum/A Light Chain 
Translocation Domain (aa. 1-
852)-VIP 





stocks at -80˚C 
Botulinum/A Light Chain 
Translocation Domain (aa. 1-
852)-TNFα 
Predicted: 
117 kDa  
 





stocks at -80˚C 
 





All peptides were synthesised to order by PeptideSynthetics. 6-aminohexanoic acid (Ahx) 
is composed of six inert linear carbon atoms which are used to insert space between the 
peptide and attachments. All stocks arrive lyophilised and are diluted to 10 mg/ml stocks 
in 100 % DMSO and stored at -20 ̊ C. Peptides are further diluted to working concentrations 














CPBrevinMM-Ahx-Thio Ac-AAKLKRKYWWKNLKMM-Ahx-C(pyridyldithio)-NH2  
Thio-Ahx-CPBrevinMM Ac-(pyridyldithio)C-Ahx- AAKLKRKYWWKNLKMM -NH2 
CPBrevinMM Ac-AAKLKRKYWWKNLKMM-NH2 
CPPenetratin-Ahx-Thio Ac-RQIKIWFQNRRMKWKK-Ahx-C(pyridyldithio)-NH2  
Thio-Ahx-CPPenetratin Ac-(pyridyldithio)C-Ahx-RQIKIWFQNRRMKWKK-NH2 









Table 2.35– Sequences of Peptides used 
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2.1.6 Cell lines 
All cell lines used for experiments are listed below: 
Cell line Species Disease derived 
from 
Cell type Supplier Pass. number 
received 
J774.2 Mouse Reticulum cell 
sarcoma 





Neuro2a Mouse Neuroblastoma Neuroblast ATCC pass.3 
SH-SY5Y Human Neuroblastoma Neuroblast Sigma pass.21 










Antibodies were used either with western blot (WB) or Immunocytochemistry (ICC) 
Primary Antibody Species Dilutions Supplier 
SNAP25 Rabbit 1:4000 (WB), 1:500 (ICC)  In-house 
SNAP25 Mouse 1:4000 (WB), 1:500 (ICC) Biolegend – SMI81 
Cleaved SNAP25 
(cSNAP25) 
Rabbit 1:5000 (WB), 1:1000 
(ICC) 
In-house – further 
purified by Charlotte 
Leese 
Syntaxin 1  Rabbit 1:1000 (WB) In-house 
β-III-tubulin Mouse 1:2000 (WB), 1:1000 
(ICC) 
R&D Systems – 
MAB1195 
CNTFR Mouse 1:1000 (WB), 1:200 (ICC) R&D Systems – MAB303 
EGFR Rabbit 1:1000 (WB), 1:200 (ICC) Gift from Liz Smythe  
Cell Signalling – 2232S 





Secondary Antibody Dilutions Supplier 
Sheep anti-mouse (HRP tag) 1:24000 (WB) Amersham 
Donkey anti-rabbit (HRP tag) 1:24000 (WB) Amersham 
Goat anti-mouse (Alexa Fluor 488 tag) 1:2000 (ICC) Life Technologies 
Goat anti-rabbit (Alexa Fluor 488 tag) 1:2000 (ICC) Life Technologies 
Goat anti-mouse (Alexa Fluor 594 tag) 1:2000 (ICC) Life Technologies 
Goat anti-rabbit (Alexa Fluor 594 tag) 1:2000 (ICC) Life Technologies 
 







2.2 Recombinant protein generation 
To set up the restriction digests for recombinant plasmid formation, 4 µL of each of the 
donor and recipient plasmid DNA was mixed with 1 µL of each required restriction enzyme, 
1 µL of each required 10x enzyme buffer and made up to 10 µL in DNase free water 
(Thermo Fisher Scientific) (table 2.7). All plasmids used in these experiments were pGEX-
KG (fig. 2.1). The sample was then incubated for 1 hour at the required incubation 
temperature. After incubation finished, 5 µL FastAP (Thermo Fisher Scientific) was added 
to the recipient DNA only and is then left to incubate at 37 ˚C for a further 10 minutes. 
To make the 1 % agarose gel, 0.5 g of electrophoresis grade agarose was added to 50 mL 
of 1x TAE buffer, then microwaved until the agarose had dissolved. After leaving to stand 
for 20 minutes, 1 µL sybrsafe DNA gel stain (Thermo Fisher Scientific) was added and 
agarose was poured into casing and the comb was inserted. The gel was then inserted into 
the tank (Bio-Rad) and is filled up with 1X TAE buffer as running buffer.  
Once restriction reactions were ready, 2.5 µL of 5X agarose loading buffer (Bioline) was 
added to reactions. Samples were run on 1 % agarose gel at 70 mV for 45 minutes with 
DNA ladder (Hyperladder 1 kb – Bioline). An image was taken by gel imaging with blue light 
as opposed to UV (U:Genius3 - Syngene). The relevant bands were then cut from the gel 






time and temp. 
Buffer Notes 
SmaI NEB 25 ˚C, 1 hour CutSmart 
(NEB) 
Used in double Digest with XbaI 
for BotLcTd/A restriction, SmaI 
was added first then after 1 
hour at 25 ˚C XbaI was added 
and incubated for a further hour 
at 37 ˚C 
XbaI Promega 37 ˚C, 1 hour CutSmart 
(NEB) 
See above 
EcoRI NEB 37 ˚C, 1 hour NEBuffer 
2.1 (NEB) 
Used for mCherry restriction 
SalI NEB 37 ˚C, 1 hour NEBuffer 
3.1 (NEB) 
Used for the removal of the 
cysteine rich domain from 
Diphtheria Light Chain 
Translocation Domain (aa. 1-
388) – Diphtheria (aa. 179-190) 
– Cysteine rich domain * 
 
Table 2.79– Restriction enzymes and their conditions of use.  
 
After DNA purification, the DNA concentrations were measured by Nanodrop and a ligation 
reaction set up using 100 ng Donor plasmid DNA, 3x molar ratio of Insert DNA (calculated 
through NEBioCalculator – NEB), DNase free H2O up to 9 µL, 10 µL T4 DNA ligase buffer 
(NEB) and 1 µL T4 DNA ligase (NEB). Reactions were left at room temperature for 30 
minutes then 5 µL was used to transform 30 µL of DH5α cells. DH5α cells (Thermo Fisher 
Scientific) were grown and made competent in house by Charlotte Leese through Rubidium 
Chloride incubation, they are not resistant to any antibiotics. Transformation of DNA into 
DH5α cells was done in the same way as detailed in section 2.2.1, however 
chloramphenicol is not added.  
After colonies grew, 4 from each plate were used to inoculate 5 mL 2-YT culture broth with 
ampicillin and grown overnight at 37 ˚C with shaking. The bacteria was then harvested and 
mini-prepped using a kit (Qiagen). The DNA extracted from the mini-prep was then be run 
agarose gel with and without restriction digestion to ensure that the plasmid has the 
desired inserts. Once the desired plasmids were identified they were then transformed 
into BL21-gold (DE3) pLysS bacteria competent cells and the protein synthesised as 





Figure 2.16 – Map of pGEX-KG plasmid with restriction sites 
A) Overall map of pGEX-KG plasmid, showing the location of the Lac1 initiator, the 
Glutathione S-Transferase site (GST), the Multiple Cloning Site (MCS) and the Ampicillin 







2.3 Expression and purification of recombinant proteins cloned in pGEX-
KG vector 
2.3.1 Transformation of BL21-gold (DE3) pLysS competent cells 
BL21-gold (DE3) pLysS (Agilent) were made competent for transformation by Charlotte 
Leese (Davletov lab) through Rubidium Chloride incubation. The cells are resistant to 
chloramphenicol, whilst the pGEX plasmid is resistant to Ampicillin. 
Agar plates were first made by mixing 2-YT Agar before autoclaving and storing. Agar was 
then melted in microwave before mixing 1:1000 with ampicillin 100 mg/mL and 
chloramphenicol 50 mg/ml and approximately 15 mL placed in each 100 mm x 15 mm plate 




To transform pGEX-KG vectors into competent cells for expression of proteins, an aliquot 
was first defrosted on ice before 25-30 µL was put in one tube for each vector sample. 1 
µL DNA was added to each competent cell sample and gently mixed, then incubated for 30 
minutes on ice and mixed twice meanwhile. The samples are then heat shocked for 30 
seconds at 42 ˚C and returned to the ice for a further 5 minutes. 300 µL of 2-YT media, pre-
warmed at 37 ˚C, was added to samples then incubated in a shaker at 37 ˚C for 1 hour. The 
media and cells are then spread on ampicillin and chloramphenicol agar plates and 
incubated overnight at 37 ˚C.  
After colonies had grown, some were harvested and grown overnight in 5 mL 2-YT media 
with antibiotics at 37 ˚C shaking. In order to store the bacteria without need for re-
transformation, stocks could then be made by mixing 600 µL 50 % glycerol (sterilised) with 
400 µL bacteria overnight culture.  
 
2.3.2 Low temperature expression and purification of proteins 
All pGEX-KG plasmids which were expressed contained not just the protein of interest but 
also GST with a thrombin cleavage site. To grow and express the GST-proteins whose 
vectors had been transformed into competent cells, firstly a colony from a plate or a 
glycerol stock pinch was placed in 5 mL 2-YT media and 5 µL of both ampicillin 50 mg/mL 
and chloramphenicol 50 mg/mL and incubated overnight with shaking at 37 ˚C. The 
following day the overnight culture was poured into a 2 L flask with 500 mL sterile 2-YT 
media with 500 µL of both ampicillin 50 mg/mL and chloramphenicol 50 mg/mL, and grown 
for a further 3 hours (approximately) at 37 ˚C until the OD600 reached between 0.5 and 0.7 
as measured by Colorimeter (WPA Biowave). 0.5 mL IPTG (Melford) 100 mM was then 
added and the flask was incubated overnight shaking at between 18-20 ˚C. 
The bacteria was then pelleted using a centrifuge at approximately 5000 rcf for 15 minutes, 
and supernatant was discarded into empty flasks and Virkon added to sterilise any 
remaining bacteria. The pellet was re-suspended in 5 mL lysis buffer and cOmplete EDTA-
free protease inhibitor cocktail (Roche) through shaking (50 mL Lysis buffer has 1 Protease 
inhibitor tablet dissolved into it before use to make 1x stock), keeping the samples on ice 
when not on the shaker. Re-suspended pellet was then converted into a 50 mL falcon tube 
while another 5 mL lysis buffer + PI was used to re-suspend any pellet remaining in the 
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centrifuge container. The cell suspension was then snap frozen either in dry ice with 
ethanol or in -80 °C freezer for 15 minutes and then put it in RT water for 20-30 min. 
12 µL of 1 M MgCl  stock and ~ 2 mg of deoxyribonuclease I from bovine pancreas was 
then added once thawed and the samples then rotate at room temperature for 10 min. 
Triton X-100 is then added for a final concentration of 2 % (approx. 1.5 mL of 20 %) and 
rotated for 20 minutes at 4 ˚C.  
Meanwhile 0.5mL of Glutathione Sepharose beads (GE Healthcare) was pipetted into two 
15 mL falcon tubes, these were washed twice in low salt buffer by centrifuging at 2000 rcf 
for 1 min. The cell sample was then centrifuged for 20 minutes at 7000 rcf at 4˚C, 3 µL of 
supernatant was saved for gel analysis and the rest poured on the beads and incubated for 
at least 1 hour rotating at 4˚C. The sample was then centrifuged at 2000 rcf for 1 minute 
and 3 µL of the flow through saved for gel analysis. The beads were then washed twice in 
high salt buffer and twice in low salt buffer before re-suspending in 7.5 mL low salt buffer, 
with 10 µL saved for gel analysis. The beads then had a further 7.5 mL glycerol added, 
which was mixed well at 4 ˚C before storing at -20 ˚C.  
Loading buffer was then added to the gel analysis samples and run on an in-house SDS-
PAGE gel as described in section 2.5. 
 
2.3.3 Thrombin cleavage of GST 
To separate the protein from the glutathione beads, GST was cleaved by thrombin (Sigma-
Aldrich). The beads were first washed twice with buffer A to remove the glycerol, then 
transferred to a 2 mL tube where the beads were further washed once with buffer A and 
made up to 2 mL, 5 µL was kept for gel analysis. 20 µL thrombin (diluted 250 units into 1 
mL dH2O) was then added and incubated for 30 minutes at 37 ˚C shaking. It should be 
noted that proteins containing a translocation domain have a thrombin cleavage site 
between the light chain and the translocation domain in addition to the one between the 
GST and protein N-terminus. Because of this, after thrombin incubation both of these sites 
are cleaved and these proteins exist as two subunits held together by a disulphide bond 




Figure 2.27– Diphtheria Light Chain Translocation FPLC purification example 
A) UV trace showing relative protein detected in each filtrate fraction, with the expressed 
protein leaving the FPLC column between fractions 9-28, and the xylene cyanol tracer in 
fractions 34-36.  B) SDS-PAGE showing fractions taken from FPLC and their protein content: 
the band near 50 kDa is likely to correspond to diphtheria Light Chain Translocation domain 
(DipLcTd), which has a molecular weight of around 48 kDa, and so for this example fraction 
14 is the purest. The band near 25 kDa is likely to be a breakdown product of the 




Beads were then transferred to Spin Columns (Generon) and spun down multiple times 
(maximum volume is 700 µL) to separate beads from protein sample for 1 minute at 13,000 
rpm. 5 µL of both the beads and elute was saved for gel analysis. Some proteins such as 
those with free cysteines, require the addition of tris(2-carboxyethyl)phosphine (TCEP) at 
4 mM for 30 minutes at room temperature to reduce binding. The elute was then 
concentrated with a concentration column (Vivaspin 10,000 MWCO) to 0.5 mL using 
centrifugation at 5000 rcf (progress checked every 5 minutes). The concentrated sample 
was then transferred to a spin column for 1 minute to remove bubbles and foam for Fluid 
Phase Liquid Chromatography (FPLC). FPLC was used on most of the proteins to ensure 
purity, but especially on those where there are excessive undesirable protein fragments in 
which have been expressed, for instance diphtheria Light Chain Translocation Domain 
(DipLcTd) (fig. 2.2). 
Xylene cyanol was sometimes added to the concentrated eluate in order to see protein 
sample whilst loading onto the FPLC (AKTA UPC-900) to be filtered through the column (GE 
Healthcare: Superdex 200 Increase 10/300 GL). The FPLC makes a UV trace and the relevant 
fractionations were taken and 5 µL from each taken for gel analysis. The 5 µL gel analysis 
samples were then run on an in-house SDS-PAGE gel. Figure 2.2 uses dipLcTd as an example 
of the FPLC trace and fractionations on lab-made SDS-PAGE gel. These are done individually 




2.4 Protein conjugation 
2.4.1 Pyridyl disulphide binding 
In order to allow conjugation to form between pyridyl disulphide containing peptides and 
proteins with unbound cysteine residues, the proteins which were believed to contain free 
cysteine groups were incubated with the pyridyldithio-peptide in an equivalent or excess 
molar ratio for 1 hour at room temperature (20 ˚C) diluted in buffer A. The incubation time 
and particular incubation reagents varied between experiments, but unless otherwise 




2.4.2 SNARE formation 
SNARE complexes were formed by combining an equal molar ratio of syntaxin, 
synaptobrevin and SNAP25, or proteins containing these sequences. The method was 
optimised to 1 hour incubation in buffer A containing 0.4 % OG (See Chapter 3), however 








Figure 2.38– Example of calculating protein concentrations using BSA standards. 
A) Progression of SDS-PAGE with samples and BSA standards through band analysis on 
ChemiDoc XRS (Bio-Rad). The botLcTd/A put into the linked sample was measured at 600 
nM as diluted from Nanodrop (Thermo) reading. B) Table of band intensities of subfigure A 
rows 3-6 measured by band analysis software. C) Graph of BSA standard concentrations 
against band intensity with linear trendline and trendline equation. D) Table of band 
intensities of the boiled CNTFx1-BotLcTd/A linked sample, taking the botLcTd/A-S25 band, 
and the formed CNTFx1-BotLcTd/A linked sample (unboiled) (rows 1 and 2 from subfigure 
A). Using the trendline equation, the amount of protein in µg could be calculated. From this 
and the size (kDa) of the protein the concentration in nM of the samples can be calculated. 
Note that the botLcTd/A-S25 concentration has been measured as close to the predicted 
600 nM.  
 
 
2.4.3 Reduction through TCEP 
All TCEP reactions were done through incubating proteins up to 0.2 mg/ml in 4 mM TCEP 
for half an hour at RT unless stated otherwise. TCEP was filtered out of sample through 
FPLC 
 
2.4.4 Measuring protein concentration 
Pure protein stock concentrations were measured through Nanodrop (Thermo Fisher 
Scientific). When there is a mix of proteins in a sample, for instance in linked samples, 
samples were run on SDS-PAGE with BSA standards 0.1-0.4 µg (fig. 2.3). The bands were 
then analysed on the ChemiDoc XRS which were then used to make a standard curve to 
measure the approximate concentration of the protein band. The size of the protein (kDa) 
was then used to determine the molarity. Figure 2.3 gives an example of CNTFx1-





2.5 Cell culture 
2.5.1 Cell line cultures 
All cell lines were cultured in a 37 °C, 5 % CO₂ humidified incubator (Panasonic – Incusafe) 
and passaged twice a week. J774.2, SH-SY5Y and Neuro2A cell lines were cultured in 
Dulbecco’s modified Eagle medium + GlutaMax (DMEM) (Life Technologies) supplemented 
with 10 % foetal bovine serum (FBS) (Life Technologies). LA-N-5 cell line was cultured in 
RPMI 1640 + GlutaMax (Life Technologies) with 10 % FBS.  The cell stocks were not grown 
in any antibiotics. Cell stocks were maintained in T25 flasks (Thermo Fisher Scientific) 
All cell lines were passaged using Trypsin-EDTA 0.25 % (Sigma), apart from the J774.2 cell 
line which was passaged by cell scraping. For viable cell counting, cells were diluted 1:1 in 
trypan blue dye (Bio-Rad) and counted in duplicate using an automated cell counter (Bio-
Rad). 
Cells were kept for either 10 weeks or 20 passages (whichever is shorter) before disposing 
and defrosting new batch of cells. 
Incubators and culture hoods (Esco – Airstream) were cleaned monthly to prevent 
infection. All cells were spot-checked for mycoplasma annually by Jackie Price using PCR 
detection kit (Sigma-Aldrich); there was no significant mycoplasma infection detected in 
any of the cell cultures over the project.  
 
2.5.2 Cell line freezing and defrosting 
Cells were removed from liquid nitrogen and incubated for 1 minute in a 37 ˚C water bath 
before defrosting and diluting in 5 mL pre-warmed media. The cells were then centrifuged 
for 5 minutes at 3000 rpm before aspirating the media and replacing with fresh media and 
placing in culture flasks for incubation. Cells were passaged at least twice to recover from 
liquid nitrogen before use.  
Cells were frozen by growing to confluency in a T75 flask before trypsinising and cell 
counting. Cells were centrifuged and re-diluted in FBS + 10 % DMSO before placing 1.5 mL 
in cryo-tubes (Thermo Fisher Scientific) each containing 2x10  cells. The cryo-tubes were 
then put in a freezing container (Nalgene) and frozen overnight at -80 ˚C and then placed 




2.5.3 Cell plating and sample addition 
Unless otherwise indicated, Neuro2A and J774.2 were seeded at a density of 5x10³ cells 
per well in 96-well plates, 1.5x10⁴ cells per well in 48-well plates and 5x104 cells per well 
in 6 well plates (All plates were purchased from Corning). SH-SY5Y were seeded at a density 
of 1x10⁴ cells per well in 96-well plates, 3x10⁴ cells per well in 48-well plates,  2.5x104 in 24 
well plate and 8x104 cells per well in 6 well plates. LA-N-5 cells were seeded at 2x10⁴ cells 
per well in 96-well plates, 6x10⁴ cells per well in 48-well plates and 1.5x105 in 6 well plate. 
In 96 and 24 well plates the wells around the edge were not used and were instead filled 
with sterile PBS. All cells seeded for incubating with samples were dosed with Penicillin-
Streptomycin cocktail (PenStrep) (Sigma-Aldrich) diluted 1:100. All plates after seeding 
remained at RT for around 10 minutes to allow to settle before putting into 37 ̊ C incubator 
to prevent cells clustering into the centre of wells (Lundholt et al. 2003).  
Cells seeded into 96 well plates had a volume of 90 µL, 48 well plates had a volume of          
270 µL, 24 well plates had a volume of 900 µL and 6 well plates were seeded with a 
minimum volume of 2 mL. All cells were incubated for a minimum of 4 hours after plating 
before samples were added, unless stated otherwise, all plates had sample added on the 
same day as seeding. Samples which had been previously diluted in either cell media or 
PBS were then further diluted x10 into plate wells. Standard incubation time before 
assaying or harvesting was 3 days unless stated otherwise. All 96 well plates had the 
samples added in triplicate, whereas other plates were always incubated singularly with 
each sample. 
Samples containing OG at either 0.4 % or 0.2 %, depending on cell type and sample 
concentration, were further diluted in OG at a constant concentration before diluting 1 in 
10 in cell media + PenStrep and vortexing. Half of the media was then removed from all 
wells to be dosed before sample taken from the top and diluted into plate well media 1 in 
2. It was important that the samples were made with more than 50 % excess. The reason 
for this was to allow any OG which has not fully solubilised to sink to the bottom of the 
sample, so the sample to be added into the wells could be taken off the top without there 
being excess insoluble OG, which was toxic to cells.  
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Where there were samples containing Lipofectamine3000 (LF3000), samples to be added 
had LF3000 added to make an overall concentration of 5 % before incubating for 15 
minutes. The samples were then added into wells, diluting the sample 1 in 10.  
 
 
2.6 SDS-PAGE and Western blotting 
2.6.1 Cell harvesting and lysis 
To lyse cells for Western blot samples, 1X western lysis buffer was made by mixing 250 µL 
4X lysis buffer with 750µL dH20, 10 µL 1 M MgCl2 and 1 µL ≥250 units / μL Benzonase 
Nuclease (added just before use). The cells (seeded in 48 well plate) were aspirated and 60 
µL 1X Western lysis buffer added to each well. The plate was then shaken for 10 minutes 
shaker 850 rpm on Grant Bio PMS-1000i plate shaker before mixing and each sample 
placed into a 1.5 mL tube. Tubes were then boiled at 95-100 ˚C for 3 minutes before 
centrifuging at 13,000 rpm for 1 minute. The samples could then be used for western blot, 
or frozen at -20 ˚C until use. 
 
2.6.2 Making SDS-PAGE gels 
Gel plates were assembled into cassettes, ensuring bottom of plates were level and had 
formed a seal with the rubber in holder. 5 mL resolving gel buffer was then put between 
the glass plates, and small volume of water layered on top of setting gel using 1 mL syringe 
before the gel was left to set for 20 minutes. The excess water was later removed once set 
by tipping and drying with tissue paper. 
2 mL stacking gel was then placed on top of the resolving gel and a 15 lane comb 
immediately inserted in the stacking gel, inserting diagonally to avoid bubbles. Gel was 
then left to set for 20 minutes. The combs were removed after setting and the wells are 
washed with dH O. The gels could be used immediately or wrapped in wet towel and 




2.6.3 SDS-PAGE and protein staining 
Samples of approx. between 0.1 and 0.5 µg protein were loaded onto a gel with a 
maximum sample size of 10 µL. 3 µL 4x Sample buffer was then added to each sample and 
vortexed before loading into pre-cast gel (Novex NuPage 12 % Bis-Tris gel – Invitrogen) or 
lab-made gel with a ladder (5 µl for SDS-PAGE and 15 µl for western blot – Bio-Rad Precision 
Plus Dual colour protein standard). Pre-cast gels were run using MES x1 buffer and lab-
made gels were run using Tris-Glycine x1 running buffer, both were prepared by diluting 
the concentrated stocks with appropriate amounts of dH2O. 
Standard gels or Western blots were typically run at 180 mV for 50 minutes until the 
bromophenol blue reached the bottom. Western blots and gels requiring the separation 
of cleaved SNAP25 band from whole SNAP25 were run at 180 mV for 110 minutes. 
Gels containing SNAREs required them to be run with cold (+4 ̊ C) 1x MES buffer in a bucket 
of ice for 110 minutes at 180 mV to prevent breakage. SNAREs were pipetted into two 
Eppendorf tubes before adding loading buffer, one was boiled at 95 ̊ C for 3 minutes before 
centrifuging, cooling and loading, whereas the other was loaded as normal; together these 
samples gave the ‘before’ and ‘after’ samples for SNARE formation.  
Lab-made gels as shown in section 2.3.2 were used for protein analysis after running 
through the FPLC. These gels were run at 200 mV for 40 minutes. 
After gel running had completed the gel was removed from the cassette and submerged 
in SDS-PAGE staining solution, it was then microwaved for 30 seconds and then placed on 
a rocker at RT for 20 minutes. The gel was then removed from the stain and then de-stained 
in water overnight. Images of the gels were taken on the ChemiDoc imager for record 
keeping and any band analysis required. 
  
2.6.4 Western Blotting 
8-15 µL of each sample was loaded onto pre-cast gel and run at 180 mV for appropriate 
amount of time (as described in section 2.3.3). Transfer membrane (Immobilon-P – Merck) 
was activated by soaking with methanol then placing with 2 sheets of whatman paper (GE 
Healthcare) into transfer tank (Bio-Rad) containing cold membrane transfer buffer. After 
gel had run, the following were then layered onto the Black side of transfer cassette: 
Sponge, 1 whatman paper, Gel (flipped so ladder was on the right), membrane, whatman 
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paper, sponge. The cassette was closed and placed in transfer tank along with a freezer 
block and 4 ˚C membrane transfer running at constant 250 mA for 1 hour. The membrane 
was removed and washed with water, then placed in blocking solution rocking for 30 
minutes. Primary antibody was added, then rocked overnight in cold room. The following 
morning the membrane was washed with PBS-T for 5 minutes three times before fresh 
blocking solution containing secondary antibody was added. Membrane was then rocked 
at room temperature for 30 minutes. The membrane was then further washed with PBS-T 
for 5 minutes three times before SuperSignal West (Dura Extended Duration substrate- 
Thermo Fisher Scientific) was prepared (600 µL per membrane). The membranes were 
placed on visualisation tray, then SuperSignal West solution was added and distributed 
evenly by tipping the tray. Cling film was placed over membranes, which were then 
processed in a dark room using exposure to photofilm (Amersham Hyperfilm – GE 
Healthcare) before placing through X-ray film processor (Optimax 2010). Images were then 
taken by ChemiDoc for digital storage and band quantification.  
 
Figure 2.49– Demonstration of Band analysis for Western blot 
A) Images of band detection software drawing around protein bands. B) Quantification of 
the band intensities and subsequent calculation of the % cleaved SNAP25 band based off 
the total band intensity detected.  
 
 
2.6.5 Western blot band quantification 
To measure band intensity or % SNAP25 cleavage in Western Blots, images taken of the 
blot on the Bio-Rad were quantified by band analysis software. A densitometric analysis 
was performed on the band, setting the background intensity to 100 before, then creating 
a report which gave a value for the relative band intensities. The % was taken by taking the 
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value for the cleaved band and then dividing it by the value for the combined bands added 




2.7 Cell count and viability assays 
2.7.1 Automated cell counts 
Cell concentration and % viability was measured before plating by automated cell counter. 
10 µL cells was mixed with 10 µL trypan blue solution (Sigma-Aldrich) and 10 µL of the mix 
was inserted into cassettes (Bio-Rad) which was then inserted into an automated cell 
counter (TC20 – Bio-Rad). This was done in duplicate and the average taken. The machine 
calculated the values for the total cell concentration, the alive cell concentration and the 
% alive cells. 
 
2.7.2 MTT assay 
A 12 mM MTT stock solution was prepared by adding 1 mL of sterile PBS to 5 mg of MTT 
and mixed through vortexing, often overnight incubation at 4 ˚C would fully dissolve the 
solution however occasionally it would need to be centrifuged to remove any particulate 
material that did not dissolve. An SDS-HCl solution was made by adding 10 mL of 0.01 M 
HCl to 1 g of SDS which was gently shaken until fully dissolved.   
Cell media was removed through careful aspiration from the cells to be analysed (in 96 well 
plate) and it replaced with 100 µL of phenol red free DMEM (Gibco – Thermo Fisher 
Scientific) + 10 % FBS. 10 µL of the 12 mM MTT stock solution was then added to each well, 
including a medium only negative control well.  . The plate was then incubated at 37 ˚C 5 
% CO2 for 4 hours. 100 µL of the SDS-HCl solution was added to each well and mixed 
thoroughly using the pipette, the plate was then further incubated for 37 °C for 4 hours. 
Each sample was then mixed again using a pipette and end point absorbance read using a 
microplate reader at 560 nm (iMark – Bio-Rad). Plates were analysed by removing the 





10 µL DeepBlue Cell Viability solution (Biolegend) was added to each well to be analysed, 
including 3 background wells, and the plate was placed at 37 ˚C, 5 % CO  for 4 hours. After, 
plate was removed and analysed for fluorescence, measuring the absorbance at 560 nm 
and the emission at 590 nm (Fluoroskan Ascent – Labsystems). Plates were analysed by 
removing the background values and the % reading was based off the wells containing 
untreated cells. All error bars on alamarBlue assay graphs represent standard deviation.  
 
2.7.4 Hoescht/PI viability assay 
Cells which were intended for fluorescence were seeded in 96 well glass bottomed imaging 
plates (Greiner). At appropriate time points, the cells were then washed with phenol-red 
free DMEM media before adding Hoechst 33342 (Life Technologies) (1:2000) and 
propidium iodide (PI) (Life Technologies) (1:2000) stains to investigate cell viability. 
Hoechst dye is cell permeable and stains the DNA of all cells, whereas PI is cell impermeable 
and only stains the DNA of dead cells. Cells were incubated at 37 °C for 15 minutes before 
imaging using an epifluorescence microscope (DMIRB, Leica). 3 images were taken per well 
using 20x objective and both total cells and PI stained cells were counted using image J. 




2.8.1 Live cell imaging 
Cells were seeded in 96 well glass bottomed imaging plates (Greiner) and left overnight. 
Samples were then incubated with fluorescent proteins for the time stated. In the case of 
live cell microscopy, the cells were then washed twice with PBS, before incubating a further 
10 minutes in phenol red-free media with Hoechst 33342 (Life Technologies) (1:2000). The 
cells were then imaged at x20 or x40 on epifluorescence microscope (DMIRB, Leica) for 




2.8.2 Fixing cells on plates or glass coverslips 
Glass cover slips (radius 25 mm, Marienfeld, Germany) were sterilised by plating in 6 well 
plates and rocking for 1 hour in 100 % ethanol, before washing three times in sterile PBS. 
The coverslips were then aspirated and left to dry in the sterile hood under ultraviolet light 
for 1 hour. The plates could then be sealed and stored at 4 ˚C until needed.  
Wells and coverslips for cell seeding were laminin coated at 10 µg/mL (Sigma-Aldrich) for 
over 1 hour at 37 ˚C incubation. 40 µL laminin in PBS was used to coat in 96 well glass 
bottomed imaging plate, 1 mL in 6 well plate with glass cover slips. Unless stated 
otherwise, cells were seeded as described in section 2.4.3.  
After cell growth and sample addition (if required), cells were then washed twice with PBS 
before fixing for 10 minutes at room temperature with PFA 4 %. The PFA was then removed 
and the samples permeabilised for 15 minutes with PBS-0.3 % Triton X-100. The cells were 
then washed twice with PBS before being saturated with blocking solution for at least 1 
hour at RT, if coverslips were being used then pieces of parafilm were used as ‘coverslips’ 
to avoid dehydration. The primary antibody was then incubated for 1 hour at room 
temperature. The samples were washed twice with PBS before the secondary antibody 
was added at a concentration of 1:2000 along with DAPI (Sigma-Aldrich) if needed at 
1:1000 for 45 minutes whilst protected from light. Samples were then washed twice with 
PBS. The 96 well glass bottomed imaging plates were left in the third wash of PBS, wrapped 
in foil and stored at 4 ˚C  
Glass coverslips were mounted by removing excess PBS with tissue paper after washing, 
before placing face down on glass slides (Menzel Glaser 76 x 26 mm) with 20 µL mounting 
media (DAPI Fluoromount-G-SouthernBiotech). The slides were left to dry for over 24 
hours before imaging. The slides were protected from light and stored at 4 ˚C.  
 
2.8.3 Microscopes 
The two microscopes used throughout this project were an inverted epifluorescence 
microscope (DMIRB, Leica) and a confocal microscope (Nikon A1 TIRF).  
The most often used microscope was the Leica, which used a mercury vapour lamp to pass 
light through an R4 filter cube for fluorescent images. In addition to this, all brightfield 
images were taken on this microscope. This microscope could be used with both slides and 
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96 well imaging plates. Image J was used to analyse the images. The scaling was set by 
Rebecca Bresnahan (Davletov lab) using a micro-ruler, the following scaling was applied 
manually to all images.  
 
Objective Size Units 
5x 468.7114 Pixels / mm 
10x 0.928 Pixels / µm 
20x 1.88 Pixels / µm 
40x 3.7667 Pixels / µm 
Table 2.810– Scaling for epifluorescent microscope 
 
The confocal microscope was only used to image the slides, this employed a hyper selector 
to select laser wavelengths based on the specific secondary antibody used. Laser intensity, 
offset and HV were conserved between experiments.  Scaling was automatically inputted 
onto images using the NDi6d plug-in on image J.  
 
2.8.4 Image J analysis 
Image J was used to draw around cells and have the average cell intensity calculated, this 
was done freehand on all cells which had visible boundaries within a defined random area. 
The cells were drawn around on the brightfield image, and the overlay was then compared 
to the DAPI image before finally placing it over the image to be analysed (either FITC or 
mCherry) (fig. 2.5:A). The software would produce a value of the average pixel intensity 
across the cells drawn around, for these images no adjustment tool was used and all 
images were taken in the same session with the same exposure. Image J was used to count 
cells manually using the counting tool (fig. 2.5:B). It should be noted that it was sometimes 
difficult to judge where the boundaries of the cell lay so this method is not 100 % accurate, 
especially taking into account that some cells clumped together when confluent or during 
apoptosis. Nonetheless the images were analysed consistently. The values were then 





Figure 2.510– Figure demonstrating the techniques used in ImageJ 
A) Images showing hand-drawn traces around brightfield images, before comparing the 
overlay to the DAPI images and then placing the overlay over the image to be measured for 




2.9 Radioactivity assay 
Radiation measurements were completed by samples being placed in 6 mL scintillation 
tubes (Sarstedt). All samples were made up to 1 mL in basal buffer before placing in tubes 
and topped up with 4 mL scintillation fluid per tube (Emulsifier-Safe – PerkinElmer). The 
tubes were then put in racks and placed in a scintillation counter (WinSpectral 1414 α/β – 
PerkinElmer). Scintillation counter was calibrated using provided [H3] and [C14] sources. 
Every experiment used controls containing either no radiation or known concentrations of 
radiation. Wipe tests were done after every experiment using lint-free paper soaked in 
ethanol, wiping areas, and then placing in scintillation vials with scintillation fluid. Quench 
curves were done manually to compare between the predicted Disintegrations per Minute 
67 
 
(DPM) and the received Counts per minute (CPM). All buffers and experimental protocols 
were based off previous experiments: (Shone & Melling 1992; Géraldine et al. 2010; 
Atcheson et al. 1994; Davletov et al. 1998; Biedler et al. 1978) 
All buffers used had their pHs measured at between 7.3-7.4. Quench curves were made by 
titrating known concentrations of [3H]-NA (Noradrenaline, levo-[ring-2,5,6-3H] – Perkin 
Elmer) into 1 mL basal buffer before scintillation analysis. Alternatively, known 
concentrations of cell lysates were mixed with known concentrations of [3H]-NA before 
scintillation analysis. There was no measured difference between the quench of release 
buffer and basal buffer. When basal buffer was incubated for 45 minutes with cells there 
was no measured difference in the quench between the incubated and non-incubated 
basal buffer, therefore the same quench values could be used. The quench value for cell 
lysates was taken with 3 or more known values of [3H]-NA at each experiment attempt 
owing to the variety of the values, this was done by seeding and harvesting excess 
untreated wells. In addition, other wells not to be tested with [3H]-NA were incubated with 
equivalent botulinum domain containing samples to get approximate representative 
cleavage of the radiation added wells. 
Unless stated otherwise, cells were seeded at 2.5x104 cells in culture media in laminin 
coated 24 well plates, after 4 hours any samples to be added were diluted 1 in 10 into the 
wells. Wells were added in triplicate: one well to measure basal release, one to measure 
stimulated release, and one to be lysed and the SNAP25 cleavage measured on western 
blot. Cells were incubated for 72 hours at 37 ˚C 5 % CO2. After 72 hours the incubation 
media was removed and replaced with basal buffer with 20 mM pargyline, 0.2 mM ascorbic 
acid and 1.25 µCi [3H]-NA (46.25 kBq) for 45 minutes at 37 ˚C. There was always at least 1 
well without [3H]-NA added as a control. After 45 minutes, a control well had the [3H]-NA 
containing incubation buffer removed and placed in a scintillation vial. The well was then 
washed 3x 1 minutes with basal buffer before incubating for 5 minutes with Trypsin-EDTA, 
then a further 5 minutes with 0.4 % triton X-100 + 0.2 % Benzonase nuclease in PBS added 
1 in 2. The cell homogenate was then extracted and placed in a scintillation vial for analysis. 
Once the CPM readings have been converted to DPM through factoring quench, the % cell 
uptake was determined.  
For wells to be analysed for [3H]-NA release, all incubation media was removed and placed 
in scintillation vials before the wells were washed 3 x 2 minutes with basal buffer. Release 
was then measured by incubating the cells for 5 minutes with either basal buffer or release 
68 
 
buffer. The buffer was then removed and kept for scintillation radioisotope counting. The 
well was then washed 3 x 1 minute with basal buffer before incubating for 5 minutes with 
Trypsin-EDTA, then a further 5 minutes with 0.4 % triton X-100 + 0.2 % Benzonase nuclease 
in PBS added 1 in 2. The cell homogenate was then extracted and placed in a scintillation 
vial for analysis. Through using quench and converting CPM to DPM, the % release of the 
samples was determined. 
 
 
2.10 Rat blood harvesting 
The harvesting of rat blood was done by Rebecca Bresnahan on a deceased 3-4 week old 





N refers to the number of completely independent experiments, n is the number of repeats 
within the experiments.  
The null hypothesis is that there is no significant difference between specific populations 
of data; this was tested throughout the project through two different statistical tests: 
Student’s T-Test were done through GraphPad Prism to determine whether the null 
hypothesis was correct when there were two data sets. On the other hand, one-way 
ANOVA tests were also done through GraphPad Prism was used to determine whether the 
null hypothesis was correct when there were 3 or more data sets. Sometimes, if the null 
hypothesis was indicated to be false then additional Student’s T-Tests would be done to 
further determine relationships.  
These are both used to determine the p-value of the relationship, which in turn denotes 
the level of significance, or put another way, the chance that the null hypothesis is correct. 
A p-value of 0.05 (or 5 % chance that the null hypothesis is correct) was used as the 
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threshold for significance, with further levels of significance also noted, denoted at the 
following: P>0.05 = NS P<0.05 = * P<0.01 = **  P<0.001=***, where NS = Not significant. 
The statistical test used and the levels of significance are stated in the figure legends of 
each appropriate figure.  
Anomalies were rare but did occur, most often due to human error or mis-dosing of cells. 
Anomalies were judged to be outside ± 3.5 standard deviations of the mean assuming that 
all data points were normally distributed (99.7 % of data points are within 3 standard 
deviations if data is normally distributed). Anomalies were removed from data sets.  
All error bars shown in this project represent 1 standard deviation of the mean, assuming 




Good Laboratory practise was employed at all times throughout this project. Lab coat and 
gloves were worn at all times at the bench. Masks and goggles were worn when working 
with PFA. Control of Substances Hazardous to Health (COSHH) forms were kept up to date 
and new ones written when needed (e.g. Radioactive substances). Proteins or complexes 
which contained toxins were first deactivated with 0.5 M HCl + 2 % SDS before disposing 
of. Experiments involving radioactive substances adhered to the University of Sheffield 
Policy and Procedures and the Work Certificate obtained for unsealed sources; full training 
was provided. Wipe tests were completed after every experiment and radioactive waste 









Chapter 3: Establishing protein modification and binding 
techniques for controlled protein conjugation.  
 
3.1 Introduction 
As previously discussed, conjugation is an important yet often overlooked factor within 
drug design. There is prevailing preference for cleavable linkers over fused linkers as there 
is the advantage that the targeting domain can be cleaved away and will not therefore 
interfere with the therapeutic domain (Böhme & Beck-Sickinger 2015; Chen et al. 2014). 
Whilst conjugation via pyridyl disulphide has already been established as a method of 
conjugation, there is very little focus on the biological aspects of it: its limitations and how 
it influences proteins, its stability and conjugation efficiency. However there are drawbacks 
to pyridyl disulphide binding, such as that only two components can be brought together, 
whereas there is a demand for a protein platform which can assemble multiple domains. 
In this regard, SNARE complexes could offer an avenue of research to address this need 
(Arsenault et al. 2013). 
Therefore, both pyridyl disulphide modification and SNARE linking will be individually 
investigated as techniques for conjugation, each having the potential to meet different 
demands for drug construction. Here, both methods are explored, optimised and 




3.2.1 Enzymatic domains of therapeutic enzymes can have unbound sulfhydryl 
groups on cysteine residues.  
Many toxins such as diphtheria and ricin are formed from a Light Chain (LC) enzymatic 
subunit attached via disulphide bridges to a targeting heavy chain, sometimes with the 
addition of a translocation domain (fig. 3.1:A-C) (Bell & Eisenberg 1996). The enzymatic 
domains of ricin, diphtheria, burkholderia lethal factor 1 (BLF1) and botulinum have shown 
potential as therapeutics for cancer treatment, with botulinum also being investigated for 
the alleviation of chronic pain and migraine (Tyagi et al. 2015; Dressler & Benecke 2007; 





Figure 3.11- Numerous therapeutic enzymes contain cysteine residues for potential 
modification 
 A-D) Schematics showing the structure of toxins and the amino acid sequences of their 
catalytic (enzymatic) Light Chain (LC) domains with the cysteine residues highlighted 
(Greenfield et al. 1983; Thompson et al. 1990; Halling et al. 1985; Lee et al. 2007). E) SDS-
PAGE of Catalytic domains of toxins shown in A-D after 3 hours at 22˚C (Bot = Botulinum). 
F) SDS-PAGE showing dimerisation of light chains (LCs) after 1 month at -20˚C and the 





By preparing plasmids with the light chain domain of these toxins, it is possible to express 
the enzyme with the cysteines unbound by the heavy chain, leaving them potentially free 
to conjugate to other proteins. This could also theoretically happen by expressing the full 
length toxin and incubating with a reducing agent such as TCEP, however the heavy chain 
would then need to be separated from the rest of the sample and also there is the added 
risk of exposure to the full length toxin. The enzyme alone, without the heavy chain, has 
lost the ability to efficiently translocate inside cells, thereby decreasing the toxic risk to the 
user. 
Figures 3.1:A-D shows the subunit layout of the toxins botulinum A, ricin, diphtheria and 
BLF1 and the amino acid sequences for the enzymatic domains, highlighting the cysteine 
residues with potentially unbound SH groups. Because of the unbound cysteines on the 
enzymes there is a risk of aggregation; figure 3.1:E shows the toxin LCs after 3 hours at 
room temperature, with minimal aggregation, indicating relative stability of LC samples. 
However, it was noted that prolonged storage above -80 ˚C resulted in dimerisation, whilst 
this was avoided, the aggregated protein could be reduced back to its monomeric state 
through incubation at RT for 30 minutes with 4 mM TCEP (fig. 3.1:F). The protein would 
then need to undergo filtering through Fast Protein Liquid Chromatography (FPLC) in order 
to separate the TCEP from the protein before further use.  
 
3.2.2 Selection of Cell-Penetrating peptides for pyridyl disulphide attachment 
Cell Penetrating Peptides (CPPs) are short amphipathic peptides which are used for the 
non-specific delivery of drugs and proteins via conjugation (Koren & Torchilin 2012; 
Farkhani et al. 2014) Previously established CPPs Penetratin and TAT were attached to the 
fluorophore FITC as well as endosomal escape sequence HA2, and a 25 amino acid 
cytoplasmic portion of the SNARE protein cellulobrevin (VAMP3) (aa.12-37) as a control 
(fig. 3.2:B) (Ramsey & Flynn 2015; Dunican & Doherty 2001). CP-BrevinMM was previously 
investigated by Violeta Ruipérez of Bazbek Davletov’s lab as a potential CPP due to its 
numerous cationic residues over a portion of the synaptobrevin sequence; this short 
sequence was isolated and shown in vitro to increase the internalisation of siRNA through 
non-covalent complex formation (Appendix 2). It was hypothesised that that CP-BrevinMM 
would be better at internalising into cells than CP-Brevin due to the hydrophobic 
methionine residues at the C-terminus, which are part of the transmembrane domain of 
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synaptobrevin and potentially encourages interaction with plasma membranes; therefore 
both CP-BrevinMM and CP-Brevin were labelled with FITC to compare.   
 
 
Figure 3.22- Identification of usable Cell Penetrating Peptides    
A) Showing J774.2 cells stained with and without Hoechst, image taken at x40 objective.. 
B) Amino acid structures of the peptides which were attached to FITC. Green=cationic 
amino acid, blue=polar/hydrophilic amino acid, pink=non-polar/hydrophobic amino acid. 
C) Live cell imaging after 2 hours in 500 nM FITC-peptide samples green=FITC-peptide (400 
ms), blue= Hoechst (20 ms). Scale bars represent 100 µM, image taken at x40 objective. D) 







J774.2 macrophage cells were incubated with the 500 nM (approx. 1µg/ml) FITC-peptides 
for 2 hours to allow internalisation before the cells were washed, incubated with Hoechst 
for 10 minutes then immediately imaged.  Images of each well were taken and the cells 
were drawn around the raw images in Image J to acquire the average pixel intensity for 
quantification. Figure 3.2:C-D shows that CP-Penetratin and CP-BrevinMM were the most 
efficient at internalising into J774.2 cells. It also showed that CP-BrevinMM was taken up 
more than CP-Brevin, indicating that the hydrophobic C-terminus influenced uptake. 
Figure 3.1:B shows that both CP-Penetratin and CP-BrevinMM had around 40% of their 
amino acids as positive (green) mixed with numerous hydrophobic (purple) and other 
hydrophilic (blue) residues. This combination of cationic and amphipathic sequencing may 
be the reason for their successful internalisation. Because there appeared to be the most 
FITC present in the cells, it was decided that CP-Penetratin and CP-BrevinMM were to be 
synthesised with a pyridyl disulphide domain at either the N or C terminus. 
 
3.2.3 Pyridyldithio-peptides conjugate to the cysteine residues on enzymes. 
The two selected CPPs were synthesised externally with pyridyl disulphide domains on 
either the N or C terminus to establish whether they could bind to the free cysteines on 
proteins (fig. 3.3:A). When ricinLC was incubated with excess pyridyldithio-CPPenetratin 
(thio-CPPenetratin) and loaded with SDS into an SDS-PAGE gel there was complete shift in 
the protein band, even at only 15 minutes incubation (fig 3.3:B). This strongly indicates 
that all of the ricinLC managed to successfully conjugate to the thio-CPPenetratin, and was 
shown to be the case in 10% DMSO in water, buffer A and buffer A with 0.4% Octyl β-D-
glucopyranoside (OG), a non-ionic surfactant (fig. 3.3:C). It should be noted that as well as 
a large primary band where ricinLC conjugated to thio-CPPenetratin, a small secondary 
band formed above the main band. This is because the ricinLC has 2 free cysteines (fig. 
3.1:C), therefore a small proportion of the protein has managed to bind thio-CPPenetratin 
to both the free SH groups. The formation of the second band does not noticeably increase 
on further incubation (fig. 3.3:B). It is likely that one of the cysteines is more internal than 
the other in the ricinLC structure, hence decreasing the chance that thio-CPPenetratin will 
bind. On the other hand, figure 3.3C shows when the enzyme BLF1 was incubated with 
thio-CPPenetratin in the same environments, there was no conjugation noted despite the 
1 cysteine residue in the amino acid chain. It was hypothesised that this was because the 
cysteine was within the internal structure, therefore BLF1 was boiled for 3 minutes at 95˚C 
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with SDS to disrupt the structure before incubating with thio-CPPenetratin. Figure 3.3:D 
shows that after boiling, there is approximately 50% conjugation between BLF and thio-
CPPenetratin, indicating that the hypothesis was correct; this makes sense as BLF1 is the 






Figure 3.33- Cysteine groups are needed for pyridyldithio binding 
A) The amino acid sequence of CP-Penetratin and CP-BrevinMM with pyridyldithio domains. 
B) SDS-PAGE looking at the how incubation time influences disulphide bond formation; 
ricinLC was incubated with thio-CPPenetratin at a variety of time points. C) SDS-PAGE 
comparing the pyridyldithio conjugation between ricinLC and BLF. This was done at 2 hours 
incubation at room temperature where the peptide had been diluted in a variety of buffers 
before incubation. Buffers: A- 10% DMSO in water. B- Buffer A. C- Buffer A + OG 0.4%. D) 
SDS-PAGE showing BLF boiled at 95 ˚C incubated with thio-peptide enabling it to form 50% 
conjugation. E) SDS-PAGE showing that both the cysteine and the pyridyldithio group are 
needed to form an efficient bond, however small amounts of non-specific binding occur. 
F,G and H) SDS-PAGE showing ricinLC, diphtheriaLC and botulinumLC/A incubated with 
thio-peptides and peptide-thios to determine whether the orientation of the pyridyldithio 
domain influenced binding, these samples were incubated at 95 ˚C for 3 minutes prior to 
gel loading. I) Schematic summarising findings of the figure: The light chains of ricin, 
diphtheria and botulinum A from figure 3.1 were able to have all their cysteine residue 
bound to thio-peptides with varying efficiency. BLF however did not find to any thio-peptide 
conjugation unless it was first boiled to denature the protein structure. Red: protein LCs. 
Blue: thio-peptides.  
 
 
DiphtheriaLC is shown in figure 3.3:E to also conjugate to thio-CPPenetratin, forming 1 
band on the SDS-PAGE gel owing to its 1 free cysteine. When CP-Penetratin with no 
pyridyldithio group was incubated with diphtheriaLC there was a small amount of non-
specific binding, which is unsurprising given the reactive nature of cysteines; however, 
there is a clear difference between conjugations of diphtheriaLC to the -thio and non-thio 
peptides.  
Figures 3.3:F-H show that there was no difference in conjugation when the pyridyldithio 
domain was attached to the N or C terminus of either CP-Penetratin or CP-BrevinMM with 
ricinLC, diphtheriaLC or botulinumLC/A. BotulinumLC/A was also able to form multiple 
bands, with up to 3 bands forming where the 3 free cysteine residues; however, like ricinLC, 
only one of the cysteine residues was able to efficiently conjugate. The size of the protein 
did not appear to influence the efficiency of conjugation. It should be noted that some 
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dimerisation of the enzymes was visible over time due to the reactivity of the SH groups, 
however when stored at -80°C and with minimisation of freeze-thaw cycles, a monomeric 
stock was sustained. There was no dimerisation within the pyridyldithio-attached stocks. 
Together, the data here clearly shows that cysteines can bind efficiently to pyridyldithio-
peptides (fig. 3.3:I); moreover, that the cysteines on the proteins will bind to the 
pyridyldithio-peptides preferentially rather than homodimerising. 
 
3.2.4 The length of peptide-thio potentially influences binding efficiency 
A variety of peptide-thio samples of different sizes were accumulated to determine 
whether the length of the peptide influences the binding efficiency. Because of the nature 
of the synthesis, 45 amino acids was the maximum number of peptides used as each amino 
acid was added in separate reactions, therefore increased amino acid size lead to increased 
cost and potential decrease in quality. Figure 3.4:A shows the amino acid sequence of the 
CPPs, ligands and peptides which had pyridyl disulphide bound to them.  
The results in figure 3.4:B shows that after 1 hour incubation there was full binding of the 
smaller peptides, however syntaxin45-thio did not bind as efficiently. Then the same 
samples spent 24 hours at 4 ˚C and there was an increase in the amount of syntaxin45-thio 
conjugated to ricinLC. It is unclear whether this is because of the increased length of the 
peptide or because of the quality of the peptide sample, which may have been hindered 
due to the size of the peptide. Alternatively, the reason for differences in binding may have 
been due to the different amino acid composition of the peptides, each with different 
charges and isoelectric points, meaning that the interactions between ricinLC and each 
peptide would have been different and could potentially influence the efficiency of 
conjugation. Whilst inconclusive, length or peptide charge may be factors which need to 
be considered when attempting to conjugate peptides. It is noted that there is a difference 
of only 4 amino acids between the length of CRH and syntaxin45, suggesting that 
potentially protein charge or quality of stock may be the more influential factor than 




Figure 3.44- Peptide length potentially influences binding efficiency    
A) Peptides of different amino acid lengths were synthesised with the pyridyl disulphide 
group attached (-thio). B) SDS-PAGEs showing conjugation of differing length thio-peptides 
at 1 hour and 24 hours, showing increase of binding at 24 hours of the largest peptide 
syntaxin45-Ahx-Thio (N=2).  
 
 
3.2.5 The disulphide conjugation between peptide-thio and protein is stable at all 
tested physiological pHs, and does not influence the catalytic activity of 
botulinumLC/A  
The stability of the disulphide bond formed through pyridyl disulphide binding to cysteines 
was measured through monitoring breakdown of the conjugation at a variety of 
physiological pHs for 3 hours shaking at 37 ˚C. Through SDS-PAGE it was shown that at 
none of the conditions tested was there any observable breakdown of conjugation 
throughout the time interval (fig. 3.5:A).  
Additionally, it was important to establish whether the conjugation of small peptides to 
proteins influenced the function of the enzymes themselves. Botulinum A endogenously 
cleaves SNAP25 and this can be mimicked by botulinumLC/A in vitro through incubation 
with SNAP25 (Vaidyanathan et al. 1999). Because only 9 amino acids are cleaved off 
SNAP25 by botulinumLC/A there is little size difference between the full length protein and 
the cleaved version, however this cleavage can be seen by running on SDS-PAGE for longer 
to sufficiently separate the cleaved band from the uncleaved band. BotulinumLC/A either 
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on its own or previously incubated with CPPenetratin-thio was added at particular 
concentrations to 0.5 mg native SNAP25 and the relative proportion of SNAP25 cleavage 
was observed. Figure 3.5:B shows that there was no difference in the amount of SNAP25 
cleavage at any of the concentrations tested, indicating that the binding of small peptides 
to the enzyme via the cysteine has no influence on enzyme efficiency. 
 
 
Figure 3.55- The disulphide bond formed between cysteines and pyridyl disulphide group 
is stable at physiological pHs and does not influence catalytic activity  
A) SDS-PAGE gel showing that there was no breakdown of the disulphide bond at a variety 
of physiological pHs over 3 hours at 37˚C (N=2). B) The catalytic function of bound vs 
unbound botulinumLC/A was tested through incubating with SNAP25 for 1 hour at RT 
(N=2). 
 
3.2.6 A cysteine-rich domain can be recombinantly fused to proteins without 
endogenous cysteine groups to conjugate pyridyldithio-peptides 
There are numerous proteins which potentially have useful therapeutic or experimental 
benefit that do not have cysteines. For instance, in order to further determine stability of 
peptide-protein conjugations, such as in rat plasma or cell lysates, a fluorescent protein or 
sequence that could be picked up by western blot would have to be used. MCherry protein 
is similar in size to both ricinLC and diphtheriaLC, it is fluorescent on SDS-PAGE gels as well 
as can be used as a protein for imaging in cells, so would be useful to be able to attach 
small peptides to in order to see the effects particular peptides have on delivery. However, 
mCherry does not have any cysteines in its amino acid structure. It was therefore 
hypothesised that a mCherry could me made with cysteines by cloning a cysteine rich 
sequence into the mCherry plasmid and expressing it to form a mCherry that would be able 
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to bind to pyridyldithio-peptides. Wild type (WT) SNAP25B has a cysteine rich domain 
between amino acids 84 and 92 (Oyler et al. 1989). Through restriction digest, the 
sequence for mCherry was inserted into a pGEX plasmid containing the SNAP25 cysteine 
rich domain (S25-CRD) (fig. 3.6:A). This was then transformed into bacteria, mini-prepped 
and expressed as mCherry-S25CRD (fig. 3.6:B-C). It was shown in figure 3.6:D that the 
expressed mCherry-S25CRD was able to conjugate to CPPenetratin-thio whereas the 
mCherry without the free cysteines was not; thereby creating a useful tool for further 
investigating modification of proteins and how peptide binding influences their behaviour.  
 
3.2.7 Disulphide bridges formed between pyridyl disulphide groups and cysteine 
residues are stable in rat plasma, but break apart in cell lysates.  
As previously mentioned, drugs need to remain stable in a variety of physiological 
environments such as the blood stream. The disulphide bond has been reported to remain 
stable in the blood, but it is reduced intracellularly by reducing proteins such as Gamma-
interferon-inducible lysosomal thiol reductase and glutathione reductase (Arunachalam et 
al. 2000; Patil et al. 2015). Therefore, it is important to determine the stability of the 
constructs synthesised both in rat plasma and in the cell lysates, now possible using the 
previously constructed mCherry-S25CRD.   
To determine whether the pyridyldithio bond was stable in physiological conditions such 
as plasma or cell lysates it was first important to acquire the cell lysates. Cells are often 
lysed through a combination of triton x-100 and benzonase nuclease, however it is 
important to also check that the disulphide conjugation is stable in a sample containing 
both these reagents. Harvested Neuro2A neuroblastoma cells (2x10 ) were incubated for 
half an hour at room temperature with 1mL either buffer A or buffer A containing 0.2% 
triton x-100 + 0.1% benzonase nuclease (Merck 2017), the samples were then centrifuged 
for 5 minutes at 5000 rpm and the supernatant removed and run on a western blot with 
β-III Tubulin antibody. The Western blot shows that β-III Tubulin was released when 
incubated with triton x-100 and benzonase nuclease, therefore concluding that this was a 
sufficient method of cell lysis (fig. 3.7:A). To ensure that the pyridyldithio conjugation is 
stable in lysis buffer, ricinLC-thio-CPPenetratin was incubated in either 0.2% triton x-100, 
0.1% benzonase nuclease or both for two hours before running on SDS-PAGE gel. Figure 






Figure 3.66- A cysteine rich domain from SNAP25 can be attached to non-cysteine 
containing proteins so they can be further modified with thio-peptides  
A) Schematic showing the insertion of mCherry into a pGEX plasmid containing the 
sequence for the cysteine rich domain of SNAP25. B) Diagram showing S25-CRD sequence 
recombinant fusion to the C-terminus of mCherry, forming mCherry-S25CRD. C) UV 
luminescent image of DNA plasmid after mini-prep and further digestion by EcoR1 showing 
successful insertion of mCherry insert. D) SDS-PAGE showing the binding of CPPenetratin-
thio to mCherry and mCherry-S25CRD after 1 hour incubation (N=2). PDB ID: 2H5Q. S25-
CRD was hand drawn (McNicholas et al. 2011; Berman et al. 2000) 
  
 
Rat blood was taken immediately after the culling of untreated male rats (see methods) 
and immediately centrifuged for 5 minutes at 5000 rpm. The supernatant was then diluted 
1:5 in buffer A before running on a SDS-PAGE gel with the extracted lysates to determine 
relative protein concentrations (fig. 3.7:C) 
MCherry-S25CRD was incubated either with or without CPPenetratin-thio in buffer A, rat 
plasma or Neuro2A cell line lysates (fig 3.7:D). Whilst the unconjugated mCherry-S25CRD 
at 0 hours could be seen at approximately 25 kDa, after 3 days at 37 ˚C in buffer A it had 
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completely dimerised to around 50 kDa. On the other hand, the conjugated mCherry-
S25CRD after 3 days at 37 ˚C in buffer A remained at around 25 kDa, this shows therefore 
that it is only when the disulphide bond between the pyridyldithio peptide and the protein 
is reduced that the protein is free to dimerise. In rat plasma, the CPPenetratin-thio 
attached mCherry-S25CRD remained at approximately 25kDa with only little increase in 
the 50kDa band, indicating that the majority of CPPenetratin-thio was still bound, 
preventing it from dimerising. However, when combined with the cell lysates for 3 days, 
there was complete dimerisation, suggesting that the disulphide linker had been cleaved 
allowing the mCherry-S25CRD to dimerise. Together, this shows that the conjugation is 







Figure 3.77- Pyridyl disulphide conjugation is stable for 3 days in rat plasma but is broken 
down in cell lysates  
A) Western blot showing 0.4% Triton + 0.1% Benzonase nuclease is sufficient for breaking 
open cells to release cell lysate. B) SDS-PAGE showing ricinLC binding to CPPenetratin-thio 
and being stable after 3 hours incubation at RT with triton x-100 0.2% and benzonase 
nuclease 0.1%. C) SDS-PAGE showing lysates on from cells and rat plasma as a 
representation of the relative concentration of samples. D) UV trace of mCherry-S25CRD 
and the attachment of CPPenetratin-thio showing that stability of the pyridyldithio formed 
disulphide bond in rat plasma, cell line lysates and buffer A at 37 ˚C (N=2) E) UV trace 
showing mCherry-CRD conjugation; excess mCherry-S25CRD was bound to CPPenetratin-
thio over 3 hours so only 50% was bound, when ricinLC was added and incubated for a 
further 3 hours there was no difference to the % mCherry-S25CRD which was conjugated. 
Additionally, mCherry-S25CRD for was added to CPPenetratin-thio-ricinLC and incubated 
for 3 hours; there was no noted conjugation of mCherry-S25CRD, indicating that existing 
bonds are not disrupted by excess SH groups (N=2).  
 
 
It is also possible to look at the nature of the bond through using mCherry-S25CRD. For 
instance, whether it falls apart and reforms or if it is constantly stable. In order to observe, 
this mCherry-S25CRD was incubated with enough CPPenetratin-thio to conjugate half; 
after 3 hours ricinLC was added yet there was no decrease in the amount of mCherry-
S25CRD bound. Likewise, excess ricinLC was incubated with CPPenetratin-thio and after 3 
hours mCherry-S25CRD was added; yet after another 3 hours there was no observable 
mCherry-S25CRD conjugation (fig. 3.7:E). This supports previous evidence that the 
disulphide bond formed between pyridyl disulphide groups and cysteines is stable.  
 
3.2.8 Octyl β-D-glucopyranoside (OG) can expose unbound cysteines in within 
protein structures 
As previously discussed, botulinum A exists in three subunits, the catalytic light chain, the 
translocation domain and the binding domain. Until this point only the catalytic ability and 
modification of the LC has been investigated; however, there have been studies which 
suggest that the translocation domain could potentially increase the cytosolic 
translocation of the light chain, so may improve cytosolic effect (Araye et al. 2016; Fischer 
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et al. 2008). Along with being a much larger protein at 100 kDa, the botulinum A light chain 
translocation domain (botLcTd/A) (amino acids: 1-872) has 5 cysteines, although two of 
them are conjugated to form the disulphide bridge which endogenously exists between 
the two subunits (fig. 3.8:A). Therefore, there are three cysteines remaining for potential 
thio-conjugation. Figure 3.8:B shows that when CRH-thio peptide was incubated with 
botLcTd/A there was little conjugation, however when Octyl β-D-glucopyranoside (OG) 
was introduced at a variety of concentrations there appeared to be an increase in 
conjugation, with 100% conjugation to at least 1 cysteine at 1.2% OG after 1 hour at RT.  
Octyl β-D-glucopyranoside (OG) is a mild non-ionic surfactant which disrupts the hydrogen 
binding within the secondary protein structure without denaturing the proteins or 
affecting protein catalytic activity (Koley & Bard 2010; Morandat & El Kirat 2007); these 
disruptions decreases the integrity of the protein structure, potentially allowing thio-
peptides to bind to the newly exposed cysteines. Thio-CRH was used as it is the largest 
quick binding thio-peptide in possession and would therefore give a greater difference in 
size if it conjugated. Conclusively, there were three bands for the three free cysteines. 
There was increased conjugation as the OG concentration increased, suggesting that OG 
influences the exposure of the cysteines in a concentration dependant manner. The most 
likely reason that botLC/A was able to conjugate without the assistance of the OG whereas 
botLcTd/A required OG could be because botLC/A endogenously binds to its heavy chain 
and therefore needs to have the cysteines available on the edge of the protein after post-
translational modification. On the other hand, botLcTd/A does not endogenously 
conjugate to other domains via cysteines, and the reactive nature of cysteines means that 
it is far more stable to keep the unconjugated cysteines inside the post-translational 
structure. This is then altered by OG ‘loosening’ the structure of the proteins through 
disruption of hydrogen bonds to give access to the cysteines. Using OG to expose some of 
the internal structure is far more preferable to the boiling which was used in figure 3.3:D 
because through this method there is still the potential to have the same catalytic activity.  
To further investigate the potential for S25-CRD to be attached to proteins, and whether 
botLcTd/A could bind to cysteines without the need for OG, botLcTd/A-S25CRD was made 
in the same way as mCherry-S25CRD was in figure 3.5 (fig. 3.8:C). Gel analysis of the 
restriction enzyme digested plasmid purified after mini-prep strongly indicates that 
botLcTd/A-S25CRD was successfully made (fig. 3.8:D). Additionally, after expression, both 
botLcTd/A and botLcTd/A-S25CRD were reduced with TCEP then run on SDS-PAGE gel, 
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which showed that the botLcTd/A-S25CRD had a larger translocation domain subunit than 
botLcTd/A (fig. 3.8:E). When incubated with thio-CRH only for 24 hours at 4 ˚C, 
approximately 50% of the botLcTd/A-CRD was conjugated (fig. 3.8:F). When the thio-CRH 
was incubated with botLcTd/A-S25CRD in the presence of OG there was a similar increase 







Figure 3.88- Octyl β-D-glucopyranoside (OG) can expose cysteines within protein 
structures 
A) Amino acid sequence of botulinum A light chain and translocation domain (botLcTd/A) 
with the cysteine residues highlighted. B) SDS-PAGE showing no conjugation between thio-
CRH and botLcTd/A without OG but 100% botLcTd/A was conjugated to at least 1 thio-CRH 
peptide at 1.2% OG at 24 hours at 4˚C N=2. C) Schematic of the botLcTd/A with S25-CRD 
added which was made in the same way as mCherry-S25CRD, showing all 5 of the cysteines 
in the botLcTd/A structure (yellow) excluding those in the S25-CRD. Circled are the two 
cysteines which form a disulphide bridge between the LC and Td domains. D) UV 
illumination of plasmid samples run after mini-prep and digestion with SmaI and XbaI. E) 
Both botLcTd/A and botLcTd/A-S25CRD run on SDS-PAGE after reducing by TCEP, showing 
the different sizes of the reduced subunits. F) SDS-PAGE showing approximately 50% of 
botLcTd/A-S25CRD was conjugated to thio-CRH after 24 hours at 4 ˚C, whilst almost 100% 
of the botLcTd/A-S25CRD was conjugated to at least one thio-CRH at 0.8% OG (N=2). 





It can therefore be concluded that S25-CRD attachment is possible and can be used for the 
conjugation to thio-peptides, however in neither mCherry-S25CRD nor botLcTd/A-S25CRD 
was there 100% attachment, with botLcTd/A being around 50% and mCherry at about 75%. 
This difference in conjugation is probably due to a variety between the two proteins in how 
the added domain folded or reacted with the existing structure, but the S25-CRD is 
receptive to OG addition. 
 
 
3.2.9 Proteins attached to SNARE helices could potentially be used to form 
multifunctioning complexes 
Whilst cysteine rich domains can be fused to proteins to allow thio-peptide modification, 
it would be difficult to get the pyridyl disulphide group on proteins, as opposed to 
chemically synthesised peptides, for a protein-protein conjugation. This is because they 
are too big to be made reliably synthetically. Additionally there is the limitation with pyridyl 
disulphide conjugation where only two components can be brought together, but there is 
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a demand for methods which will allow more proteins to be brought together in a 
controlled ratio to form multidomain complexes. This requires a system where particular 
components can be used and react to form a homogenous sample of multidomain drug. 
SNARE proteins are a family of proteins which are involved in the endogenous mechanisms 
surrounding vesicular transport. Four helices come together to form a supercoiled 
complex; There is 1 helix in synaptobrevin, 1 in syntaxin and 2 in SNAP25 (Sudhof & 
Rothman 2009). Because of the spontaneous and quasi-irreversible binding, it is possible 
to attach therapeutically relevant proteins to different SNARE proteins and then as the 
SNARE complex forms the individual proteins will be bought together in a controlled ratio, 
forming a multifunctioning complex (Darios et al. 2010; Arsenault et al. 2013). For example, 
figure 3.9:A shows how a SNARE forms normally, but then in figure 3.9:B botLcTd/A is 
recombinantly fused to SNAP25 and the ligand EGF is recombinantly attached to 
synaptobrevin. When incubated together with syntaxin45 they could theoretically form a 
complex which would combine the therapeutic potential of botLcTd/A with the receptors 
and cell internalisation potential of EGF.  
Initially, it was vital to investigate the conditions needed for efficient SNARE complex 
formation. An alternative SNAP25 was used, SNAP25trunc, due to better protein 
expression than the wild-type version; all the cysteine domains in this version were 
substituted to remove potential unwanted thio-conjugation. In figure 3.9:C the helix 
domains of all three SNARE proteins, SNAP25trunc (aa.2-204), syntaxin45 (aa.1-45) and 
synaptobrevin2 (aa.2-94) were incubated together for 2 hours at RT with  different 
concentrations of OG. Half of the sample was then boiled to break apart any SNARE 
complex that may have formed and this was then compared to the unboiled sample. It was 
found that in the absence of OG, SNARE components on their own formed little SNARE 
complex after 2 hours, however with increased OG% there was increased SNARE 
formation. At 0.4% OG all of the synaptobrevin was used up, whereas at lower 
concentrations there was still a proportion of protein left over from all of the visible 
components, indicating that there was still potential for further complex formation. It 
should be noted that syntaxin45 is small and was often run off the end of the gel in these 
experiments. It was also highlighted in this figure the importance of using correct ratios of 
individual proteins for SNARE complex formation, otherwise there is a lot of excess of any 
one particular protein. The ratio for adding protein had to be in mM rather than mg protein 
because of the different sizes of proteins, and in this instance 1 mM of one component 
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reacts with 1 mM of the other components independent of size. Figure 3.9:D showed that 
the SNARE complex formation reaction was fully complete after 1 hour at RT, as indicated 
by the absence of synaptobrevin at this time. From this data, unless specified all SNARE 
complexes will be made with the syntaxin45 (syx45), synaptobrevin (brevin) and 







Figure 3.99– Investigating SNARE complex formation 
A) Schematic of SNARE complex being formed from individual SNARE proteins. B) Schematic 
of SNARE complex being formed from SNARE proteins which have been recombinantly 
fused to therapeutic proteins and targeting proteins. C) SDS-PAGE showing SNARE 
formation after 2 hours with various concentration of OG, showing complete SNARE 
formation at 0.4% OG (n=2). D) SDS-PAGE showing SNARE formation with 0.4% OG at a 
variety of timepoints, showing complete SNARE formation even at 1 hour at room 
temperature (N=2). E) SNAP25 after being incubated with botLC/A and LcTd/A for 30 
minutes. F) SNAP25 after being incubated for 1hr at RT with botLC/A and botLC/A which 
had been pre-incubated with OG 0.4% for one hour, showing no observable difference in 
the cleavage (N=2). EGF PDB ID: 1JL9. BotLcTd/A PDB ID: 3BTA. PDB ID: 5W5D (McNicholas 
et al. 2011; Berman et al. 2000). 
 
 
Because it was found that OG 0.4% was necessary for the efficient formation of SNARE 
complexes it was important to determine whether this OG addition would have any 
influence on the catalytic function of enzymes. Initially, this was to be investigated 
botLcTd/A, but it was shown that botLcTd/A did not have any catalytic effect on SNAP25 
within 30 minutes of incubation, unlike botLC/A (fig. 3.9:E). This is either because the 
botLcTd/A which has been expressed is not functional, or more likely because the LC 
domain is unable to function if the Td is attached; this is also seen in diphtheria (Ariansen 
et al. 1993). Like when previously determining whether thio-conjugation influenced 
catalytic activity (fig. 3.5:B), a naked SNAP25 assay was used to investigate OG effects on 
catalytic activity. It was found that there was no noticeable difference between the 
cleavage of full length SNAP25 when incubated with botLC/A on its own or botLC/A which 
had been pre-incubated for 1 hour with 0.4% OG (fig. 3.9:F). This data is in agreement with 
previous studies showing that OG addition does not denature proteins, however direct 




3.2.10 SNARE complexes are stable at a variety of physiological pHs, rat plasma 
and cell lysates. 
It is important to determine whether SNAREs are stable at a range of physiological pHs to 
investigate their suitability as a drug platform. SNAREs were formed in buffer A for 1 hour 
before incubating at 37 ˚C in a variety of physiological pHs for 3 hours. There was no 
noticeable breakdown of the SNARE complex in any of the conditions tested (fig. 3.10:A). 
In order to further determine the stability of the SNAREs in physiological conditions, they 
were subjected to 3 day stability tests in rat plasma and lysates. Instead of using mCherry, 
this was done using full length SNAP25 and measuring breakdown through western blot 
with a SNAP25 antibody (αSNAP25). The SNAP25 containing proteins that were 
successfully expressed are shown in figure 3.10:B. Figure 3.10:C shows that αSNAP25 will 
bind to SNAP25 cleanly in Neuro2A and SH-SY5Y and cell lysates, but not J774.2 lysates 
owing to the lack thereof. Also, that the αSNAP25 will only bind to the full length SNAP25 
and not the truncated version. Additionally, botulinumLcTd/A-SNAP25 (botLcTd/A-
SNAP25) was able to be detected by αSNAP25 because it contains the full length sequence. 
When botLcTd/A-SNAP25 is reduced by TCEP it forms two bands, the botLC/A (50 kDa) and 
the remaining Td-SNAP25 (75 kDa); as expected, the western blot shows that the αSNAP25 
antibody only binds to the Td-SNAP25 portion. Together, this shows that αSNAP25 is clean 
and does not exhibit non-specific binding.  
Like figure 3.7:A, figure 3.10:D shows that SNARE complex stability is not influenced by the 
presence of 0.2% triton x-100 and 0.1% benzoase nuclease. Figure 3.10:E shows that after 
3 days in buffer A there was no observable breakdown of the SNARE complex. In rat 
plasma, there was comparable amounts of SNARE to the buffer A samples at day 1, with 
minimal SNARE degradation between day 1 and 3. Additionally, there was no significant 
SNARE breakdown between 1 and 3 days in J774.2 cell lysate. This was expected as the 
breaking of SNARE complexes is done by the specialised ATPase NSF, which endogenously 
unfolds the SNARE complex in an ATP dependant reaction to their initial form; as there was 
no added ATP in the system there was no breakdown. Interestingly there appeared to be 
a decrease in the amount of SNAP25 after 3 days in rat plasma which was repeatable. This 
only happened in the rat plasma, so it could be possible that SNAP25 is binding to an 
alternative protein, or was denatured; nonetheless, there was no influence on the amount 
of formed SNARE. This data therefore shows that there is good stability of SNAREs, 
however this data may not be representative of what happens inside cells due to the 




Figure 3.1010- SNARE complexes are stable at a variety of physiological pHs, rat plasma 
and cell lysates 
A) SNARE complexes were formed over 1 hour before incubating for a further 3 hours in a 
variety of biological pHs; there was no noticeable breakdown of the SNARE complex within 
this time (N=2). B) Schematic of the 3 SNAP25 containing proteins expressed, and the 
reduction of botLcTd/A-SNAP25 after incubation with TCEP. C) SDS-PAGE gel and an 
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accompanying western blot of the same gel with αSNAP25 antibody, showing that the 
antibody is specific, also that J774.2 cell lysate does not have SNAP25. D) Control SDS-PAGE 
gel showing SNARE stability in buffers containing 0.2% triton x-100 and benzonase nuclease 
0.1%. E) Western blot showing SNARE stability in buffer A, rat plasma and J774.2 cell lysates 
over 3 days at 37˚C (N=2). 
 
 
3.2.11 Proteins can be attached to SNARE complexes through pyridyldithio or 
recombinant conjugation.  
The purpose of these investigations into the formation and stability of the SNARE complex 
has been to determine the suitability of the SNARE complex for a potential multidomain 
drug platform. Thus far it appears that there is adequate efficiency in the assembly and 
that they are stable enough in various pHs and rat plasma for SNARE stapling to be utilised 
as a conjugation method. Therefore, it now can be determined whether proteins or 




Figure 3.1111 – Proteins can be attached to the SNARE complex through recombinant and 
pyridyldithio mediated conjugation 
A) Schematic of protein components needed to form ricinLC-thio-SNARE and ricinLC-SNARE. 
B) SDS-PAGE showing formation of ricinLC-SNAREs where ricinLC is attached either via 




RicinLC-thio-syntaxin45 was formed by adding syntaxin45-thio in excess to ricinLC then 
filtering excess thio-syntaxin45. The resulting sample was then incubated with 
synaptobrevin (brevin) and SNAP25 and OG 0.4% for 1 hour to form ricinLC-thio-SNARE. 
This was then compared with ricinLC-SNAP25 (recombinantly fused), syntaxin45 and 
brevin formed complex, ricinLC-SNARE (fig. 3.11:A). The SDS-PAGE shows that both ricinLC-
thio-SNARE and ricinLC-SNARE formed well. One of the issues however with the ricinLC-
thio-SNARE was that a small band can be seen under the ricinLC-thio-syntaxin45 band 
which disappears when boiled; this indicates that not all of the syntaxin45-thio was filtered 
properly and that it is forming complexes without the ricinLC attached.  Also, in the ricinLC-
thio-SNARE one can see that after 1 hour there are still remaining components of all three 
of the SNARE proteins, whereas for ricinLC-SNARE the ricinLC-SNAP25 was completely used 
up, indicating that the reaction had finished (fig. 3.11:B). This indicates that the ricinLC 
could be bound to syntaxin45-thio in a way which potentially obscures the reaction site, 
giving either a slower reaction or making a proportion of the protein no longer functional.  
Additionally, there appears to be issues with filtering the ricinLC-thio-syntaxin45 from 
excess syntaxin45-thio which could be problematic if there is competition in formation. 
Either way it can be seen that attaching proteins to SNAREs recombinantly is more efficient 
process than doing it through thio-reactions because there are fewer components to be 
added. This demonstrates that proteins can be conjugated to SNARE proteins and the 
complex is still able to link together. Further investigations will determine whether more 






Conjugation between therapeutic and targeting domains is an important consideration 
within drug design; however, problems have arisen when conjugation methods are not 
adequate for long term stability in plasma, leading to drug degradation and an increase in 
side effects. This chapter has identified two usable methods for either the modification of 
proteins through peptides or attaching multiple proteins into large complexes. The data 
here has investigated the optimum conjugation conditions and the stability in a variety of 
conditions. Both pyridyl disulphide and SNARE formation methods were successfully 
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formed and shown to be stable in the conditions tested, however have yet to be introduced 
to cells to determine their effectiveness at delivering therapeutic enzymes to targeted 
cells. 
Disulphide bonds have long been recognised as a stable method of conjugation as it is one 
of the main ways which various endogenous proteins stabilise their structure (Braakman 
& Hebert 2013; Srinivasarao et al. 2015). It has been shown in these experiments, as well 
as wider literature, that the bond is stable in plasma, but that there are enzymes in the 
cytosol which are able to reduce them after endosomal escape such as glutathione 
reductase (Koriazova & Montal 2009; Patil et al. 2015). These properties make disulphide 
bonds ideal for drug construction, where the targeting domain of the therapeutic can be 
cleaved from the drug domain in order for it to function efficiently, but without it breaking 
apart in the plasma leading to side effects. Endogenously, synthesised proteins form the 
disulphide bonds within their structure before the proteins are cleaved into separate 
subunits, therefore there is control in how they are formed (Patil et al. 2015). However, 
controlled disulphide binding between two separate proteins is difficult as the chances of 
homodimerisation is equal to that of heterodimerisation, making the reaction inefficient. 
Therefore, it has been proposed in this chapter that pyridyl disulphide group is an efficient 
yet underutilised method to ensure efficient heterodimerisation in conjugated protein 
samples as the reaction between pyridyldithio and cysteine residues appeared to be 
preferential to cysteine-cysteine reactions whilst there was no dimerisation in between 
pyridyldithio groups. 
Provided that there is an available cysteine, up to 100% binding efficiency was detected 
from 15 minutes between proteins and pyridyldithio-peptides. The attachment of a 
recombinant cysteine rich domain to proteins was successful through plasmid 
manipulation, but unfortunately, neither of the S25-CRD attached proteins were able to 
bind more than 75% over 1 hour. This could be because of interactions between the S25-
CRD domain and the protein or that the tertiary structure of the overall protein meant that 
the S25-CRD was internally folded. Although there are 4 cysteines on the S25-CRD, there 
was only 1 band showing conjugation in both examples; this is most likely to be because 
the cysteines are within close proximity to each other and therefore there was not space 
for more than one to bind. However, another reason may be that they have internally 
conjugated or the protein folding does not allow binding to other cysteines. Significantly, 
when OG was added there was still only an addition of 1 band which does suggest that the 
95 
 
lack of more bands is not because of protein folding. It may be that smaller peptides or 
chemicals would be able to conjugate to more than one of the 4 cysteines. Both the 
BotulinumLcTd-S25CRD and mCherry-S25CRD showed that cysteines can be added to 
proteins and that they can be used to bind, however it may be worth considering using 
alternative cysteine rich domains in the hope that a better binding efficiency can be 
achieved. 
It has also been investigated here whether existing cysteines in a protein which are buried 
within the structure can be accessed through OG. The data shows there is increased 
binding in the presence of OG in most proteins tested and that when OG is added there is 
no influence on the function. However, only botulinumLC/A was tested and it could be that 
OG may influence function of other enzymes at particular concentrations, but this has not 
been investigated. It should be noted that OG mediated binding was not always successful, 
as when BLF was tested with OG there was no conjugation of thio-peptides despite the 
internal cysteine being bound through boiling in figure 3.3:D. Another significant matter 
with using OG is its toxicity in cells; therefore, to test OG containing complexes in cells it 
will be necessary to highly dilute the samples and test the cell threshold for OG tolerance. 
Whilst it was possible to modify existing cysteines of some proteins using OG, whether the 
modifications are functional have not yet been tested. There is the hypothesis that after 
the peptide has bound and the OG been diluted for adding onto cells, the tertiary structure 
recovers and this may mean that the modification is internalised and therefore would not 
be functional as a targeting peptide. This is something which has yet to be determined and 
will be addressed in future chapters.  
Once the disulphide bridge has formed, the data showed that addition of alternative SH 
groups does not interfere with the existing binding, therefore purification to a 
homogeneous product would result from the addition of beads or other large proteins to 
mop up excess pyridyldithio-peptides. Encouragingly, there was no degradation of the 
disulphide bridge at pHs between 4.5 and 7.5 and little noticeable cleavage after 3 days at 
37˚C in rat plasma, yet the bond was cleaved in cell lysates. Taken together, this strongly 
indicates that they would be stable in the blood stream and only break down once inside 
the cell, most likely through lysosomal enzymes. This finding however does bring into 
question why the protein dimerised in cell lysates if the disulphide bonds were reduced, as 
the dimerisation would have been because of cysteine residues forming homodimers 
though disulphide bonds. This should not have been possible if intracellular enzymes were 
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reducing all disulphide bonds. Reasons for this could be because over the three days the 
disulphide bond was cleaved but then the reducing enzyme responsible for this then 
denatured, allowing disulphide bridges to re-form. It is also possible that the thio-peptides 
were broken down or denatured so in these conditions there was preferable binding of the 
homodimer. Had an analysis been taken after 1 day in cell lysates this speculation would 
be more conclusive.   
Pyridyl disulphide conjugation is most often used only in reactions with SPDP. Because of 
the succinimidyl group on the SPDP, this linker is attached non-uniformly to the numerous 
and sporadic lysine residues which are often present in proteins and peptides. It is 
therefore important to consider the use of peptides which have been synthesised and 
fused with pyridyl disulphide groups without the rest of the SPDP linker. It should be noted 
that there are numerous publications which utilise the pyridyl disulphide group as a 
method of conjugation, however the method is not a focus and the techniques vary 
(Stuchbury et al. 1975; Van Der Vlies et al. 2010). Therefore, this section aimed to solely 
focus on the efficiency of pyridyldithio conjugation, its potential applications and stability. 
An unfortunate consequence of using pyridyl disulphide without SPDP is that it can be only 
attached to specially manufactured peptides whereas the point of SPDP is that it can utilise 
the readily available lysines on proteins. Therefore, whilst a protein that needs to be 
conjugated can be modified with cysteines if required, the modification with the pyridyl 
disulphide needs to be a short peptide, polymer or chemical.  
The other conjugation method in this chapter which was investigated was SNARE stapling. 
Like pyridyldithio conjugation, OG was needed to efficiently assemble the helices together 
into the complex; therefore, for these samples there also needs to be concerns addressed 
about potential OG-related toxicity. Endogenously formed SNARE complexes are regulated 
and assisted by a variety of proteins, such as SM proteins, which direct their fusogenic 
action and ensure specificity when docking (Sudhof & Rothman 2009). This however was 
unsuitable for the system here, but OG removes the regulation and specificity allowing the 
SNARE complexes to form completely and efficiently.  
As previously discussed, SNARE complexes are quasi-irreversible because of the high 
energy input required to disassemble them. It is facilitated mostly by N-ethylmaleimide-
sensitive factor (NSF), which is an ATPase and dissociates the SNARE complex through the 
energy released by ATP hydrolysis (Sollner et al. 1993).  It was therefore unsurprising to 
find that the SNARE complex is stable for 3 days in rat plasma. It was shown that unlike the 
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thio-binding there was no observable breakdown of the SNARE complex in lysates, 
however the reaction for breaking down the complex is ATP dependant, so without the 
addition of ATP it would not be expected. The fact that SNARE complexes require particular 
enzymes to dissociate them is potentially interesting because NSF only exists in the cytosol. 
So where the thio-constructs will break down in endosomes, there is the possibility for the 
complex to be stable in the endosomes and only break down in the cytosol, which could 
be a useful feature. It should be mentioned however that just because the SNARE complex 
itself is stable does not mean that attached therapeutic domains are definitely stable. In 
vivo the domains will be exposed to plasma and potential immunogenic reaction and 
therefore may be subjected to various protein eroding forces which the SNARE complex is 
more resistant to.  
It has been demonstrated here that as yet only ricinLC has been attached to the SNARE 
complex and there as only been the attachment of one domain. Before attaching other 
domains it is useful to determine which targeting proteins could be best utilised for 
internalising into neuroblastoma, which will be addressed in another chapter. It has yet to 
be seen whether there will be success in adding more than one component to the SNARE 
complex, however there are published examples of two domains being successfully added 
(Ferrari et al. 2011; Arsenault et al. 2013). Within this project it is eventually hoped that all 
three SNARE proteins can be conjugated to different domains and still link together into a 
complex. There is a concern regarding the method of domain attachment to the SNARE 
complex; whilst ricinLC was conjugated to the SNARE both recombinantly and through 
pyridyldithio binding, the syntaxin45-thio-ricinLC did not fully react with the other SNARE 
peptides, whereas this was not the case with the recombinant sample. It is not known how 
recombinant attachment to the toxins may influence the effects of the protein function. 
For instance, it has been shown that diphtheriaLC is only functional once cleaved from its 
heavy chain (Ariansen et al. 1993), and similar results were seen here where 
botulinumLcTd/A was not able to cleave SNAP25 but botulinumLC/A was in a 30 minute 
reaction. Therefore if there is a possibility that with the recombinant addition of a SNARE 
protein the diphtheriaLC would no longer function. On the other hand, it should be noted 
that the use of ricinLC-SNAP25 means that only one reaction needs to take place, as 
syntaxin45-thio-ricinLC needs to be formed separately.  
Lack of purity of the SNARE complexes is a potential issue as it is difficult to purify the 
SNARE-linked sample in the small quantities which are being made. Whilst not an issue at 
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this stage, un-stapled proteins later on may interfere with the fully linked product when 
incubated with cells. This reiterates the importance of forming the complexes through the 
correct molar ratio of each individual component, something which needs to be improved 
before cell dosing. Whilst having three components coming together opens up a new 
dimension of potential for protein conjugation, it adds another degree of complexity in the 
synthesis of the linked complexes. However, this complexity will hopefully prove to be 
overshadowed by the benefits of a unique system where numerous proteins can be linked 
together in a mix-and-match system using complementary SNARE proteins.  
Moving forward, this chapter has explored and established two methods of protein 
conjugation and modification. From this, they can be investigated separately in vitro with 
alternative targeting domains and toxins to identify which targeting domains best 
internalise into neuroblastoma, the effects of toxins in different cell lines, and the 
















Chapter 4: Investigating peptide-based cell delivery of enzymes 
through pyridyldithio group conjugation  
 
4.1 Introduction 
There is a universal demand for there to be more efficient methods of delivering large 
proteins, such as enzymes, into the cell cytosol in vivo without disrupting the cell behaviour 
or function. The plasma membrane is a barrier which separates the controlled internal 
environment of cells from the outside environment; because of this, the methods of 
internalisation into cells is highly regulated, making drug delivery a primary issue. 
Membranes normally are only permeable to small hydrophobic compounds, anything large 
or alternatively charged needs to use alternative means (Garnacho 2016). Therefore, there 
have been several methods developed to enhance the delivery of drugs, enzymes and 
other proteins or probes into cells. As explored previously in Section 1.4 the simplest of 
these methods is conjugation between a targeting domain and a therapeutic domain. Here, 
the pyridyl disulphide conjugation method established in Chapter 3 is further explored to 
determine whether it can be used to target therapeutic enzymes into cells via attached 
internalisation peptides. It is hypothesised that both CPPs and peptide ligands which have 
been pyridyldithio-conjugated to enzymes are able to direct them into the cytosol of cells 
in vitro in a concentration dependant way, where the enzymatic activity can be measured 




4.2.1 Cell growth and assay controls 
Cells to be used to investigate the hypothesis were first established through a series of 
controls to observe their growth and behaviour and how they responded to cell death 
assays. The murine and human neuroblast cells lines Neuro2A and SH-SY5Y derived from 
neuroblastoma were investigated as the main cell models to be used in these future 
experiments.  J774.2 cells are a macrophage cell line derived from mouse lymphoma that 
have been previously shown to have enhanced protein uptake and would therefore be 
more sensitive to any changes in the amount of toxin given (Rust et al. 2015). Whilst not a 
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neuroblastoma cell, J774.2 is a useful tool to gauge potentially more subtle catalytic effects 
of delivered drugs that may not be measured in neuroblastoma cells, and is therefore more 




Figure 4.112– Controls for cell line growth and growth assays 
A) Graph showing cell growth of two neuroblast cell lines, Neuro2A and SH-SY5Y and the 
macrophage cell line J774.2 measuring at 24 hour time points through Bio-Rad automated 
cell counter (n=2, N=3). B) Overall % of live cells recorded at each time point for each cell 
type. C) Images taken at each 24 hour time point of the three cell lines investigated (n=3, 
N=3) (x40 objective, all scale bars 100 µm). D) Graph showing the doubling times measured 





Cells were seeded into 6 well plates at 1x10  alive cells per well. Over the following three 
days one well each day was harvested and the overall cell count measured by Bio-Rad 
automated cell counter in duplicate (n=2), this experiment was then repeated in triplicate 
(N=3). The media was not changed over the 3 days. All cells formed an adherent monolayer 
over the bottom of the well. The data shows that the initial rate of cell growth was similar 
in all three cell lines, but that after this the rate of growth in SH-SY5Y cells was slower than 
J774.2 and Neuro2A (fig. 4.1:A). The cell count also showed that there was no significant 
increase in cell death over the time intervals measured (fig. 4.1:B). Images were taken of 
all wells before harvesting, showing the relative confluency, morphology and overall health 
of the cell samples (fig. 4.1:C). Figure 4.1:D was derived from the data in figure 4.1:A, which 
measured the doubling time through using the following formula to get an approximation 
in hours (Roth 2006): 
𝐷𝑜𝑢𝑏𝑙𝑖𝑛𝑔𝑇𝑖𝑚𝑒 =
𝐷𝑢𝑟𝑎𝑡𝑖𝑜𝑛 ∗ log (2)
log(𝑓𝑖𝑛𝑎𝑙 𝑐𝑜𝑛𝑐𝑒𝑛𝑡𝑟𝑎𝑡𝑖𝑜𝑛) − log (𝑖𝑛𝑖𝑡𝑖𝑎𝑙 𝑐𝑜𝑛𝑐𝑒𝑛𝑡𝑟𝑎𝑡𝑖𝑜𝑛)
 
Figure 4.1:D shows that initially all of the cells had doubling time of about 10 hours, but as 
confluency increased and media nutrients decreased the doubling time increased, which 
is to be expected. J774.2 and Neuro2A were less sensitive to the changes than SH-SY5Y, 
which massively increased its doubling time over three days. These growth behaviours are 
factors which need to be considered when plating and passaging, that more SH-SY5Y cells 
will be needed in a plate to reach full confluency in a desired interval than either J774.2 or 
Neuro2A. However, it is understood that this data is not the full picture, as higher or lower 
seeding density will most likely alter the growth rate. Through trial and error, it was 
calculated the cell concentrations needed for seeding each cell type which would result in 
approximately 80-100% confluency after 72 hours (see methods). 
 
 
4.2.2 Suitability of alamarBlue and MTT assays for measuring cell death in 
selected cell lines 
In order to determine the effects of catalytic domains of diphtheria and ricin, assays such 
as MTT and alamarBlue were be used. MTT is a yellow tetrazole which is reduced in living 
cells to a purple formazan through cellular oxidoreductase enzymes present in living cells. 
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AlamarBlue also uses reduction as a live cell indicator, with the blue dye resazurin being 
reduced to the highly fluorescent resorufin (Hayon et al. 2003; Rampersad 2012). Both 
assays use this metabolic activity to determine the relative number of live cells in a sample 






Figure 4.213– Establishing MTT and alamarBlue assays 
A) MTT assays showing cells grown in 96 well plate for 72 hours to confluency between 80-
100% and measured with a background reading. % values are the proportion of the MTT 
assay reading which consisted of the background reading (n=3, N=3). B) AlamarBlue assay 
showing cells grown in 96 well plate for 72 hours to confluency between 80-100% and 
measured with a background reading. % values are the proportion of the alamarBlue assay 
reading which consisted of the background reading (n=3, N=3). C) Graph showing the 
relationship between MTT AU and the number of J774.2 cells counted in images at x20 (n=2, 
N=9). D-F) Graph showing the relationship between alamarBlue AU and the number of 
J774.2, Neuro2A and SH-SY5Y cells respectively counted in images at x20 (n=2, N=9).  
 
 
Different individual cell lines have individual metabolic rates, and therefore cannot be 
directly compared against one another. But to ensure that assays were suitable for a 
particular cell line the cells were each seeded in 96 well plate in triplicate along with a 
background which contained media without any cells. After 72 hours, each plate was 
subjected to either MTT or alamarBlue assay where the absorbance or fluorescence of 
each of the cell types and the background was measured. The raw data was placed into 
graphs as shown in figures 4.2:A-B and the % of the value which was background was stated 
above each of the bar. Whilst MTT assays are widespread there was a low MTT AU value 
relative to background in the wells containing SH-SY5Y. This would mean that MTT assay 
would be unsuitable for measuring SH cells because there would be less precision in the 
data and higher error. A background reading of less than 10% was deemed suitable for use, 
therefore J774.2 and Neuro2A cells could be used with MTT, but not SH-SY5Y. All of the 
cell types could be used with an alamarBlue assay.  
It is generally assumed that metabolic rate is directly proportional to live cell count. 
However this is not always the case as factors such as cell confluency or media condition 
could influence metabolism. Figure 4.2:C-F show that for both MTT and alamarBlue assays 
in J774.2, Neuro2A and SH-SY5Y cells the cell number counted manually through well 
imaging was directly proportional to the AU recorded. It is understood however that 
different toxins may affect the metabolic rates of cells as well as the number, so for good 
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practise imaging of wells are taken alongside MTT and alamarBlue assays to ensure assay 
results are representative.  
 
4.2.3 Diphtheria light chain conjugated to CPPs via pyridyldithio groups can 
increase uptake of toxin in J774.2 cell line. 
The J774.2 macrophage cell line has been shown to internalise toxic enzymes more 
efficiently than neuroblastoma cells (Rust et al. 2015); because of this, J774.2 cells were 
initially incubated with either diphtheriaLC (dipLC) or thio-CPP conjugated dipLC to 
determine whether there was a difference in cytotoxicity. It was shown through MTT assay 
that none of the CPPs alone altered J774.2 % MTT AU either with or without pyridyldithio 
attachment (fig. 4.3:A). However, when dipLC was added at 100nM there was a decrease 
in MTT AU to about 40% of control levels, not dissimilar to that which had been previously 
reported (Rust et al. 2015). Figure 4.3:B shows that the MTT AU% decreases significantly 
between dipLC and dipLC-thio-CPPs, with both CP-Penetratin and CP-BrevinMM yielding 
similar results. This strongly indicates that both CPPs are enhancing the translocation of 
dipLC into the cell, where it remains functional and is therefore increasing the rate of cell 
death due to its enhanced internalisation. There was a small yet significant decrease in the 
MTT AU % when CPPs were added without the pyridyldithio group, showing that the non-
specific binding demonstrated in figure 3.3:E is capable of enhancing internalisation. 
However, the CPPs needed to be completely conjugated to the dipLC for there to be a large 
increase in internalisation. 
The effect of decreased MTT AU % between dipLC-thio-CPPs and dipLC was seen across 
numerous concentrations in figure 4.3:C, with the EC50 in these conditions being 50nM for 
dipLC and approximately 7nM for both dipLC-thio-CPPs when incubated for 72 hours. 
Further results showed that there was no difference in toxicity of the construct when the 
orientation of the pyridyldithio domain was moved between the N and the C termini of the 
CP-Penetratin. On the other hand, this was not the case with CP-BrevinMM (fig. 4.3:D). 
This is most likely because of the MM amino acids on the C-terminus of the peptide which 
caused the increase in FITC-peptide uptake in figure 3.2. Therefore, further experiments 
need to take into consideration the nature and function of the peptides involved, for 
instance the location of receptor binding domains or hydrophobic sequences, to consider 








Figure 4.314 – Investigating the effect of thio-CPP conjugation to diphtheriaLC in J774.2 
cells 
 A) Control showing that the CPPs and thio-CPP are not toxic in J774.2 macrophages when 
measured by MTT assay. B) MTT assay showing metabolic activity when 100nM samples 
are added, significance is shown compared between dipLC with unconjugated CPPs and 
dipLC with CPPs conjugated via pyridyl disulfide using Student’s T-test. C) Graph showing 
sample titrations measured against MTT assay readings after 72 hours incubation. 
Significance measured by one-way ANOVA for each concentration. D) Comparison of the 
activity of CPPs when thio-conjugated to either the N or C terminus. Significance measured 
by one-way ANOVA for each concentration. E) Images showing propidium iodide (PI) 
staining after 24 hours incubated with dipLC samples (x40 objective). F) Graph showing 
ratio of Hoescht stained and PI stained cells. Significance was measured compared to dipLC 
alone at the same concentration. Significance measured by Student’s T-test comparing 
against dipLC at the same concentration. Significance for statistical analysis: P>0.05 = NS 
P<0.05 = * P<0.01 = **  P<0.001=***. 
 
 
In order to further support the proposal that thio-CPP conjugation could efficiently deliver 
dipLC, dipLC  and dipLC-thio-CPPs were incubated with cells for 24 hours at either 10 nM 
or 100 nM before they were stained with propidium iodide (PI) (fig. 4.3:E). PI is a 
fluorescent DNA and RNA stain which cannot permeate through living cell membranes, 
therefore is a useful stain to detect cells which are apoptotic or necrotic. The PI staining 
was quantified as ratio, dividing the number of PI stained cells by the overall cells which 
were stained with hoescht. This showed that there was an increase in the cell death when 
thio-CPPs were conjugated to the dipLC at 10 nM but not at 1nM, supporting the previous 
MTT assay results (fig. 4.3:F). Whilst there was an increase in the cell death between dipLC 
and dipLC-thio-CPP, overall there was very little PI staining. The reason for this most is most 
likely that whilst the dipLC may have been delivered into the cell and inhibiting translation, 
most of the cells have not yet apoptosed.  
An important consideration however, is that there are references showing that one single 
dipLC enzyme is sufficient to kill cells (Yamaizumi et al. 1978). Therefore, it should be asked 
why there is not an even bigger increase in cell toxicity with the conjugation of CPPs than 
has been shown in this data, especially taking into account the enhanced uptake behaviour 
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of J774.2. There could be numerous explanations for this; for one, whilst CPPs can 
internalise normally themselves, they are unable to efficiently internalise as one would 
hope when conjugated to dipLC. Alternatively, conjugated dipLC-thio-CPPs are entering 
into cells but that either the dipLC or the CPP or both are trapped in the endosomes or 
other vesicles and are not entering into the cytosol efficiently. In this case, the CPP may 
not be able to escape the endosomes whilst attached to dipLC, or the CPP can escape the 
endosomes but is unable to facilitate the translocation of dipLC. On the other hand, it is 
possible that the dipLC that is being used here is not fully functional due to errors in protein 




4.2.4 Lipofectamine 3000 drastically enhances diphtheriaLC internalisation 
compared to diphtheriaLC-thio-CPP 
Lipofectamine 3000 (LF3000) is a transfection reagent which has been reported to 
efficiently deliver proteins and DNA into cells (Rust et al. 2015; Yu et al. 2016). In order to 
determine the functionality of the dipLC used, LF3000 was incubated with dipLC before 
adding onto J774.2 cells for 72 hours. LF3000 added at 0.5% dilution was shown not to be 
significantly toxic to J774.2 cells (fig. 4.4:A). When the same amount was added to various 
concentrations of dipLC with or without thio-CPbrevinMM conjugation there was complete 
toxicity at all concentrations tested (fig. 4.4:B). These data strongly indicate that the dipLC 
being used is fully functional even when conjugated to thio-peptides.  
Similarly as with dipLC, ricinLC was conjugated to thio-CPBrevinMM and thio-CPPenetratin 
and incubated at a variety of concentrations with J774.2 cells for 72 hours in order to 
compare toxicity and enzyme internalisation. Interestingly, unlike dipLC, there was no 
significant alteration in the cells when measured by MTT assay (fig. 4.4:C). However, when 
ricinLC was incubated with 0.5% concentration of LF3000 there was a massive shift in EC50 
compared to ricinLC alone. Together this strongly suggests that it is not the enzymes 
lacking function, but that either the CPPs are unable to transport the enzymes into the cells 
efficiently, or that the enzymes are transported into the cells yet cannot escape into the 





Figure 4.415- Lipofectamine 3000 enhances diphtheriaLC internalisation compared to 
diphtheriaLC-thio-CPP 
A) MTT assay of J774.2 cells incubated for 72 hours in 0.5% LF3000 and measured by MTT 
assay (n=3, N=3). B) J774.2 cells incubated with concentrations of diphtheriaLC with or 
without thio-CPBrevinMM conjugation and 0.5% LF3000 after 72 hours incubation (n=3, 
N=2). C) Titrations of ricinLC with or without CPPs conjugated, measured by MTT assay. 
Significance measured by one-way ANOVA for each concentration (n=3, N=3). D) J774.2 
cells incubated with concentrations of ricinLC with or without thio-CPBrevinMM 
conjugation and 0.5% LF3000 after 72 hours incubation (n=3, N=2). Significance for 
statistical analysis: P>0.05 = NS P<0.05 = * P<0.01 = ** P<0.001=***. 
 
 
4.2.5 Both thio-CPPenetratin and thio-CPBrevinMM increase the uptake of 
mCherry-S25CRD in J774.2 cells 
MCherry-S25CRD, first synthesised in chapter 3, was conjugated to thio-CPBrevinMM and 
thio-CPPenetratin similar to that in figure 3.6 before being incubated at 500 nM in J774.2 
cells and subsequently washed, hoescht stained and live imaged. Figure 4.5:A showed that 
there was a large increase in the amount of intracellular mCherry-S25CRD detected after 
2 hours when CPPs were conjugated. The result was quantified by analysing the average 
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pixel intensity over the cells in the raw images (fig. 4.5:B). Interestingly, when imaged at a 
higher magnification it was observed that the mCherry-S25CRD appeared vesicular inside 
the cell, as opposed to having a consistent presence throughout the cytosol (fig. 4.5:C).  
The images clearly show that the CPPs are enhancing the delivery of conjugated mCherry-
S25CRD into the cells, whereas the vesicular localising of the peptide seems to suggest that 
the protein is remaining in the endosomes and phagosomes instead of being delivered into 
the cytosol. This is in agreement with previous figures and would account for the lack of 
major increase in catalytic activity within the cytosol. Whilst it is true that there was a 
significant difference in the EC50 between dipLC and dipLC-thio-CPP constructs, as there 
would be more dipaLC entering into the intracellular compartments of the cell it could be 
assumed that the difference is because of small amounts of leakage from the endosomes. 
Whatever the particulars of the mechanisms, it can be concluded that whilst CP-Penetratin 
and CP-BrevinMM conjugation both do increase uptake of conjugated protein into 




4.2.6 CP-Penetratin and CP-BrevinMM are internalised significantly less in 
neuroblastoma cell lines SH-SY5Y and Neuro2A than J774.2 cells 
To determine whether the previously observed effects of the CPPs and their transportation 
properties could be applied to other cells, it was decided to investigate FITC-CPP and dipLC-
thio-CPP effects in neuroblastoma cell lines Neuro2A and SH-SY5Y. Figure 4.6:A shows that 
there is limited entry of FITC-CPP peptides after 2 hours incubation and subsequent 
washing, hoescht staining and live cell imaging. It should be noted that the images taken 
here had a higher exposure than in figure 3.2. It is unsurprising that there is less thio-CPP 
in the neuroblastoma cells compared to J774.2 given the phagocytic nature of 
macrophages and previous data relating to their increased internalisation rates (Lunov et 
al. 2011; Rust et al. 2015). For these following experiments, alamarBlue assay was used 
owing to the lack of sensitivity of the MTT assay with these cell lines. It was necessary to 
determine whether either cell line had resistance to dipLC; it was found in figure 4.6:B that 






Figure 4.516- Both CPPenetratin-thio and CPBrevinMM-thio increase the uptake of 
mCherry-S25CRD in J774.2 cells 
A) Objective 40x images showing mCherry-S25CRD internalisation into J774.2 with and 
without attachment of thio-CPPenetratin and thio-CPBrevinMM (n=2, N=2). B) Graph 
showing average pixel intensity within the cells, using the raw images, which were taken 
live cell at 300 ms exposure after 2 hours incubation inside the cells. Significance measured 
by Student’s T-test comparing against mCherry-S25CRD. C) 60x images of mCherry-S25CRD 
when attached to CPPs, showing punctated appearance of mCherry-S25CRD within the cells 









Figure 4.617- Fluorescent CPPenetratin and CPBrevinMM are internalised less in 
neuroblastoma cell lines than in J774.2 
A) Live cell imaging of Neuro2A and SH-SY5Y after 2 hours in 500nM FITC-peptide samples 
green=FITC-peptide (1200 ms), blue= Hoechst (20 ms) (x40 obj.) (n=3, N=2). B) Neuro2A and 
SH-SY5Y cells with LF3000 (0.5%), diphtheriaLC, or diphtheriaLC+LF3000 after 72 hours. 
Significance measured by Student’s T-test against diphtheriaLC in each cell (n=3, N=3). C 
and D) Neuro2A and SH-SY5Y cells with diphtheriaLC and diphtheriaLC-thio-CPP conjugates 
after 72 hours incubation. Significance measured by one-way ANOVA for each 
concentration (n=3, N=3). Significance for statistical analysis: P>0.05 = NS P<0.05 = * 





Through alamarBlue assay, the data in figure 4.6:C-D indicated that with Neuro2A there 
was a decrease in the number of live cells between the dipLC-thio-CPP and the dipLC 
incubated cells at high concentrations when incubated over 72 hours, but there was no 
observable difference with SH-SY5Y cells. Like J774.2, this shift in the dose-response curve 
is not toxicity that one would expect from an efficiently functioning cell entry tool. Because 
of this, this study will investigate alternative methods of endosomal escape for the efficient 
delivery of enzymes to their therapeutic targets within the cell.  
 
 
4.2.7 Translocation domains of both diphtheria and botulinum/A increase the 
cytosolic internalisation of enzyme without attached internalisation sequence.  
To increase the translocation of toxin domains into the cytosol of the cells, endosomal 
escape methods were explored. As mentioned in the introduction, there are peptides 
which have been designed and investigated as a means of enhancing cytosolic 
translocation, such as GALA (Li et al. 2004; Haas & Murphy 2004). GALA-thio was acquired 
and was shown to successfully conjugate to dipLC (fig. 4.7:A). Additionally, diphtheriaLcTd 
(dipLcTd)was successfully expressed with a thrombin cleavage sequence between the two 
domains, allowing the cysteines to form a disulphide bridge that is endogenously present 
on the native toxin which in turn can be reduced (fig. 4.7:B-C). Unfortunately, aside from 
the cysteines which form the disulphide bridge, there are no other cysteine residues on 
dipLcTd, therefore thio-peptides are unable to bind (fig. 4.7:D).  
DipLC, dipLcTd and GALA-thio-dipLC were added to J774.2, Neuro2A and SH-SY5Y cell lines 
and incubated for 72 hours, these proteins along with an example of the reduction of 
dipLcTd, are shown as a schematic in figure 4.7:E. There was no noticeable difference in 
the alamarBlue AU % between dipLC and GALA-thio-dipLC in any of the cells tested after 
this timepoint (fig. 4.7:F-H). However, there was a significant difference at higher 
concentrations between dipLC and dipLcTd. Interestingly, the effects of the translocation 
domain was different for each cell type: SH-SY5Y cells were far more sensitive to the 
dipLcTd than Neuro2A cells, with J774.2 cells showing no decrease in % alamarBlue AU 
between the dipLC and dipLcTd samples.  
To further investigate translocation domains, both botulinumLC/A (botLC/A) and 
botulinumLcTd/A (botLcTd/A) were added onto Neuro2A and SH-SY5Y cells to compare the 
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cleavage of SNAP25. Both cell lines showed increased cleavage between botLC/A and 
botLcTd/A (fig. 4.7:I-J). Although there appears to be variation in the response to the 
translocation domains between the cell lines and the toxins, it is evident here that 
translocation domains are able to increase the cytosolic location of the catalytic domains 








Figure 4.718– Investigating cytosolic translocation methods 
A) SDS-PAGE gel showing conjugation between dipLC and GALA-thio. B) SDS-PAGE gel 
showing both dipLC and dipLcTd. C) SDS-PAGE showing the reduction of dipLcTd using TCEP 
to confirm the presence of disulphide bridged domains. D) SDS-PAGE showing attempted 
conjugation between dipLcTd and thio-CRH in the presence of OG 1.2%. E) Schematic of the 
proteins and conjugates to be incubated with cells, and of the reduction reaction of dipLcTd 
when incubated with TCEP. F-H) AlamarBlue assays of J774.2, Neuro2A and SH-SY5Y 
incubated with dipLC, GALA-thio-dipLC and dipLcTd over 72 hours. Significance measured 
by one-way ANOVA for each concentration (n=3, N=3). I-J) Western Blot of Neuro2A and 
SH-SY5Y cells showing SNAP25 cleavage after incubating with botLC and botLcTd after 72 
hours incubation (N=2). Significance for statistical analysis: P>0.05 = NS P<0.05 = * P<0.01 





4.2.8 Thio-Ligand and thio-CPP conjugation via Octyl β-D-glucopyranoside (OG) 
does not enhance cell uptake 
Having determined that pairing catalytic light chains with their native translocation 
domains can enhance cytosolic translocation, it was to be determined whether CPPs and 
other ligands with the pyridyl disulphide group attached would be able to conjugate to the 
LcTd toxins. Because CPPs only marginally increase the internalisation in neuroblastoma, it 
was decided that other ligands which were previously investigated for conjugation in figure 
3.4 should also be investigated for internalisation. The aim of this was to investigate the 
hypothesis that a combination of cell internalisation and translocation is required for 
effective delivery. 
In figure 3.8, it was demonstrated that botLcTd/A was able to conjugate its internal 3 free 
cysteines with the assistance of OG. OG is a light detergent and therefore has the potential 
to be toxic to cells, because of this it was important to first determine the cytotoxic 
threshold that could be used for incubating cells with OG containing samples. Both 
Neuro2A and SH-SY5Y were incubated with a particular % OG which was diluted a further 
1 in 20 into wells (see methods). It was found that both cell types could be incubated with 
0.2% OG, and SH-SY5Y could be incubated with 0.4% (fig. 4.8:A). Next, it was important to 
determine whether it was possible for the entire SNAP25 population within the cells could 
be cleaved by botLcTd/A. This positive control was set up using LF3000 0.5% with the 
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added sample over 72 hours. It was found by western blot that after 72 hours all of the 




Figure 4.819– Thio-Ligand and thio-CPP conjugation via OG is not able to direct 
botulinumLcTd/A into cells. 
A) AlamarBlue graph showing the sensitivity of Neuro2A and SH-SY5Y to OG (n=3, N=2). B) 
Western Blot showing the cleavage of SNAP25 when cells have been incubated for 72 hours 
with either botLcTd/A or botLcTd/A+LF3000. αSyntaxin1 was used as a loading control 
(N=2). C) SDS-PAGE gel showing the conjugation between the thio-peptides and botLcTd/A 
after 1 hour incubation with 1.2% OG (N=3). D) Western blots showing the cleavage of 




Samples of botLcTd/A-thio-peptides were made using 1.2% OG as described in figure 3.8; 
the peptides were incubated with botLcTd/A and OG for 1 hour before running on SDS-
PAGE for two hours to allow effective band separation (fig. 4.8:C). Interestingly, whilst it 
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appeared that all the botLcTd/A had peptide-thio conjugated (although with dermo-thio 
this was difficult to tell) it appeared that the different peptide-thios were able to be 
conjugated in different ways. For instance, thio-CRH mainly conjugated once to the 
botLcTd/A as indicated by the one prominent band, yet VIP-thio was spread equally across 
2 bands. This may be because the larger size of thio-CRH inhibits further conjugation. These 
samples were then diluted to ensure that the OG was less than 0.2% and that the samples 
were at the correct concentration for incubating with cells once diluted 1 in 20 into wells. 
All the samples were then incubated for 72 hours with Neuro2A and SH-SY5Y cells before 
harvesting and analysing for SNAP25 cleavage on a western blot. It was found that there 
was no increase in the amount of the SNAP25 cleaved between conjugated and 
unconjugated botLcTd/A. This result was not entirely unexpected as it is likely that as the 
OG concentration decreased the hydrogen bonds within the botLcTd/A re-formed, 
potentially allowing the protein to fold back over the ligand.  
 
 
4.2.9 Thio-CPP attachment via S25-CRD domain on botulinumLcTd/A slightly 
increases neuroblastoma cell internalisation 
Figure 3.8:F showed that it was possible to attach a S25-CRD to botLcTd/A and that after 1 
hour 50% could be conjugated to thio-CRH; this was repeated with incubation increased 
to determine whether a high proportion of botLcTd/A-S25CRD could be conjugated. Figure 
4.9:A shows that there is no difference in the conjugation of thio-CRH to botLcTd/A-
S25CRD between 1 and 24 hours. Interestingly, when the thio-peptides were conjugated 
to botLcTd/A-S25CRD, it appeared that the efficiency of binding was different for each of 
the peptides. For instance, 50% thio-CRH was conjugated, however substanceP-thio 
appeared as if there was 100% binding and there also appeared to be 2 bands forming with 
the CPP samples. Like figure 4.8:C, this is most influenced by size, however it is difficult to 
fully conclude because of the tiny difference in band sizes even after running the SDS-PAGE 
for over 2 hours (fig. 4.9:B). To determine the function of botLcTd/A-S25CRD in comparison 
to botLcTd/A, Neuro2A cells were incubated with both. Figure 4.9:C shows that the 
internalisation and SNAP25 cleavage of botS25-S25CRD in Neuro2A cells is comparable to 
that of botLcTd/A.  
A Western blot was then used to analyse the SNAP25 cleavage of cells incubated with the 
thio-peptide samples conjugated to botLcTd/A-S25CRD. It was found that unfortunately 
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there was no observable increase in SNAP25 cleavage with the attachment of thio-ligands 
(fig 4.9:D). However, for Neuro2A there was an increase between the non-CPP and CPP 
versions. There was negligible increase in cleavage in SH-SY5Y cells. It is worth bearing in 
mind that the % attachment of CPPs compared to the % attachment of the larger ligands 
may have influenced the internalisation, as ideally a fair comparison would be for the same 
amount of peptide to be conjugated across all the samples. Whilst there was some 
cleavage at the 72 hour timepoint in the thio-CPP samples, it is possible that optimum 
SNAP25 cleavage occurs at a different timepoint. For instance, botLcTd/A could have 
internalised and cleaved SNAP25 by 24 hours, but by 72 hours the cells have proliferated 
and the botLcTd/A may have been degraded; in this case there would be proportionally 
less SNAP25 cleavage at 72 hours. Therefore, at 24 hours the cells incubated with 
botLcTd/A-S25CRD were harvested and run on a western blot (fig. 4.9:E). There was no 








Figure 4.920– Thio-CPPs conjugated to botulinumLcTd-S25CRD can increase SNAP25 
cleavage.  
A) SDS-PAGE showing conjugation between thio-CRH and botLcTd/A-S25CRD over 1 hour 
at RT and 24 hours at 4˚C (N=3). B) SDS-PAGE showing conjugation between a variety of 
thio-ligands and thio-CPPs to botLcTd/A-S25CRD over 1 hour (N=2). C) Western blot 
showing the SNAP25 and after incubating Neuro2A cells with botLcTd/A-S25CRD for 72 
hours (N=2). D) Western blot showing SNAP25 cleavage of Neuro2A and SH-SY5Y cells 
incubated over 72 hours with ligand-conjugated botulinumLcTd-S25CRD samples at 10nM 
(N=3). E) Western Blot showing SNAP25 cleavage of Neuro2A and SH-SY5Y cells incubated 




4.2.10 Design and synthesis of diphtheriaLcTd with cysteines accessible for 
peptide-thio binding.  
Having shown that LcTd domains of botulinum A was better at cleaving SNAP25 in 
neuroblastoma cells than the LC only, and that thio-CPP conjugation improved upon this 
in Neuro2A cells, it was then important to determine whether this was the case with 
diphtheria. As previously mentioned, dipLcTd does not have any free cysteines, therefore 
the conjugation of a cysteine rich domain is necessary. Because in both mCherry-S25CRD 
and botulinumLcTd-S25CRD there was never 100% conjugation it was decided that new 
cysteine containing domains should be explored. There have been other groups which 
have used a slightly different cysteine rich domain (CRD) for attachment, so this was used 
(Lalli & Schiavo 2002; Griffin et al. 1998). Additionally, it was proposed that the cysteine 
containing sequence from dipLC could also be used. A plasmid was constructed externally, 
containing the sequence for dipLcTd along with the 1cys domain from dipLC and also the 
CRD (fig. 4.10:A). When this was expressed there was very little produced. It appeared as 
a smudge above the better expressed dipLcTd (48 kDa) and it was difficult to purify through 
FPLC (fig 4:10:B). Whilst there was an increase in the band through SDS-PAGE when thio-
CRH was added, it can be agreed that the protein produced could not be reliably 
synthesised or used (fig 4.10:C). The CRD was removed through restriction digest to form 
a diphtheriaLcTd-1cys sample; however, like the first sample, whilst there was evidence of 
conjugation, the protein could not be reliably produced (fig 4.10:D-F).  
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Another plasmid was constructed externally containing dipLcTd along with an additional 
LC (fig 4.10:G). This protein was successfully produced and mostly purified through FPLC 
where it was later shown that almost 100% of the protein could conjugate to thio-CRH, 
demonstrating it to be more efficient at conjugation than S25-CRD (fig. 4.10:H-I). This 
protein could therefore be a useful tool to conjugate to the ligands and confirm the data 






Figure 4.1021– Designing a diphtheriaLcTd protein with free cysteines for pyridyldithio 
conjugation 
A) Schematic showing diphtheriaLcTd-MultiCys protein with cysteine domains highlighted. 
B) SDS-PAGE showing the FPLC fractions after production and attempted purification of 
diphtheriaLcTd-MultiCys. C) SDS-PAGE showing the thio-CRH conjugation to two of the 
expressed fractions. D) Schematic showing diphtheriaLcTd-1Cys protein with cysteines for 
binding highlighted. E) SDS-PAGE showing the FPLC fractions after production and 
attempted purification of diphtheriaLcTd-1Cys. F) SDS-PAGE showing the thio-CRH 
conjugation to one of the expressed fractions. G) Schematic showing diphtheriaLcTd-LC 
protein, with the unconjugated cysteine on the second LC indicated for protein conjugation. 
H) SDS-PAGE showing the FPLC fractions after production and attempted purification of 
diphtheriaLcTd-LC. I) SDS-PAGE showing the thio-CRH conjugation to one of the expressed 
fractions. Diphtheria domains PDB ID: 1SGK (McNicholas et al. 2011; Berman et al. 2000). 
 
 
4.2.11 Utilising diphtheriaLcTd-LC for ligand binding and enhanced delivery.  
Having successfully produced dipLcTd-LC and shown it could conjugate to thio-CRH, it was 
necessary to determine how well it was able to conjugate to the other thio-peptides in our 
possession before adding onto cells. Figure 4.11:A shows that all of the thio-peptides were 
able to conjugate to dipLcTd-LC with up to 100% efficiency at 1 hour incubation. This also 
had the advantage over the botLcTd/A-S25CRD conjugation because it appeared that all of 
the protein in the sample had the same amount of thio-peptide conjugated. The LC domain 
which was added to the existing LcTd was a catalytically active domain, therefore it poses 
the possibility that there could be an increase toxicity in between dipLcTd and dipLcTd-LC. 
Figure 4.11:B shows that there was no significant increase in toxicity between these two 
proteins. This was expected because the Td and the added LC are recombinantly fused, as 
the Td is proposed to form a pore to allow the disulphide bridged LC into the cytosol then 
the fused LC would remain attached to the Td within the endosomes.  
All of the ligand conjugated dipLcTd-LC samples were then tested in Neuro2A and SH-SY5Y 
cells at concentrations best suited to the cell line based on figure 4.11:B. Figure 4.11:C and 
D show that, like figure 4.8, there was no apparent increase in the cytosolic translocation 
of the catalytic domain in all apart from those linked with CPPs. It was previously shown 
that SH-SY5Y cells were less sensitive to CPPs than Neuro2A, however, because SH-SY5Y is 
more sensitive to dipLcTd it was hoped that any effect would be amplified. This was not 
121 
 
the case however, as there was a significant difference at the higher concentrations of 
dipLcTdLC-thio-CPPs in Neuro2A cells but this was seen to a far lesser extent in SH-SY5Y 
cells (fig. 4.11:E-F). Together, this data shows that pyridyldithio-peptides are capable of 
binding and modifying proteins and their internalisation capabilities, but that careful 
considerations need to be made regarding the desired targeting motif, the necessity of a 





Figure 4.1122– Utilising diphtheriaLcTd-LC for thio-peptide directed cell entry 
A) SDS-PAGE (run time: 2 hours) showing conjugation between dipLcTd-LC and thio-
peptides after incubating for 1 hour (N=3). B) AlamarBlue assay showing the relative 
toxicity between dipLcTd and dipLcTd-LC in Neuro2A and SH-SY5Y cell lines after 72 hours 
incubation. C-D) Bar graph showing the toxicity of dipLcTd-LC and the thio-peptide 
conjugated samples in SH-SY5Y and Neuro2A cell respectively after 72 hours incubation 
(n=3, N=2). E-F) AlamarBlue assay of titrations of dipLcTd-LC and the thio-CPP conjugated 
samples in SH-SY5Y and Neuro2A cell respectively after 72 hours incubation. Significance 
measured by one-way ANOVA for all sample values of the same concentration (n=3, N=3). 





Within this chapter, it has been established that cell targeting or internalising peptides with 
pyridyl disulphide groups can be used to modify proteins with free cysteines and can alter 
internalisation. However, whilst these modifications do influence internalisation, this does 
not equate to cytosolic presence and catalytic function within cells. It has been shown here 
that native translocation domains can be used to further enhance cytosolic translocation 
and increase therapeutic function. Whilst this has been shown to be the case, it should be 
noted here that the ligands used were not sufficiently optimised, and because of this, 
disulphide mediated internalisation was not as efficient at it might have the potential to 
be. Any future attempts to target toxins to cells using ligands will be optimised before 
utilisation.  
The CPPs were able to increase the presence of the toxins inside the cells through pyridyl 
disulphide binding. Additionally, it was shown that the S25-CRD which was fused to 
botLcTd/A in the last chapter was functional, and that through the recombinant fusion of 
a second dipLC the dipLcTd-LC was able to fully conjugate to the thio-peptides. Research 
into other cysteine rich domains may yet yield a sequence which is able to conjugate 
completely, without the need to fuse an entire 25 kDa domain. Because it was found that 
the CPPs did increase the SNAP25 cleavage when conjugated to botulinumLcTd-S25CRD 
with Neuro2A, it could be that the lack of function seen with OG-assisted conjugation is 
due to the ligand being hidden through folding into the protein when OG concentration 
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decreases. The thio-CPPs used were small peptides, therefore it would be interesting to 
see whether this would still be the case if the thio-CPPs contained a linker between the 
pyridyl disulphide residue and the CPP sequence, therefore the linker would be hidden 
through protein re-folding but potentially not the CPP. Another possibility is that the 
botulinum internal cysteines conjugated to the thio-peptide are necessary for function, 
although as of yet there are no reports of their importance (Pirazzini et al. 2017). However, 
this is dismissed as any disulphide bonds would be reduced intracellularly, allowing the 
enzyme to function. In conclusion, whilst OG can free internal cysteines as shown in the 
last chapter, the modification cannot be taken for granted as being functional. 
As shown in the first few figures of this chapter, LC domains can be attached to CPPs but 
not always effectively internalised. DipLC was able to internalise into the cytosol more 
efficiently than ricinLC, both through thio-CPP conjugation and LF3000. This is not entirely 
understood, as conjugated thio-CPP uptake theoretically should have been equal in both 
dipLC and ricinLC, especially seeing at the EC50 for both LCs is approximately equal. It may 
be that dipLC has a mechanism to increase endosomal escape in a way which ricinLC does 
not, but this has not been explored. An alternative reason could be that ricinLC is able to 
enter into cells is a way that dipLC is not, therefore making CPP attachment redundant. 
There is a report where ricinLC was found to bind to a receptor on polymorphonuclear 
leucocytes, which share precursors with macrophages such as J774.2 (Arfilli et al. 2010). 
This would explain the reasons for ricinLC and dipLC having the same EC50 when dipLC has 
a higher catalytic activity than ricinLC, with one dipLC molecule capable of killing one cell 
(Moynihan & Pappenheimer 1981; Yamaizumi et al. 1978). It was interesting to see that 
after 24 hours of dipLC incubation there was so little cytotoxicity; it has been previously 
documented that diphtheria is not as quick as other toxins, such as ricin, for there to be 
cytotoxicity, with two days appearing to be sufficient (Kageyama et al. 2002; Yamaizumi et 
al. 1978).  
Because it requires over 24 hours for the effects of dipLC to be seen, 3 days incubation for 
the cells with samples appeared to be the optimal timepoint for analysis using metabolic 
activity assays. By doing so, it was possible to see the toxicity of diphtheria and also, 
because of normal cell growth in the control wells, the differences between the dosed 
samples and the control results. However, there are pitfalls of using such assays. Whilst it 
was shown in the beginning of this chapter that both MTT and alamarBlue assay readings, 
used for measuring metabolic activity, were directly proportional to the number of cells 
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counted in the wells, it has not for instance been measured how diphtheria could influence 
metabolic activity in itself. Another flaw in these assays is that that 40% MTT AU does not 
mean that of 60% cells died, it means that some cells died within the three days and 
therefore were unable to produce progeny; therefore, the longer one incubates the cells 
the higher the chance of seeing differences between the incubated samples and the 
control. On the other hand, it has also been shown that lower cell densities could equal 
lower doubling times, this may mean that the surviving cells are proliferating faster to 
compensate. Nonetheless, these assays are the quickest ways of collecting a large amount 
of accurate data; however, careful interpretation of the data is required.  
Within this chapter it was found that in all samples tested there was an increase in the 
catalytic activity within the cells when there was the native translocation domain 
conjugated. Interestingly, although the translocation domains between diphtheria and 
botulinum share a conserved sequence, they behaved completely differently terms of 
intracellular catalytic function (Trujillo et al. 2006). This was evident in the large differences 
in SH-SY5Y and Neuro2A sensitivity to both dipLcTd and botLcTd/A. Reasons for this are 
unclear, but it appears that there may be differing mechanisms within the endosomes of 
these cells which make the translocation domains differently interact with the membrane 
or form pores. This could be because of altered pH within the endosomal pathway, or in 
the case of dipLcTd there may have been differing reactions influencing endosomal 
maturation or numerous other mechanisms which have yet to be investigated (Nagahama 
et al. 2014; Antignani & Youle 2008). Even more interestingly, there was no consistency 
between the two cells, with Neuro2A internalising botLcTd/A more efficiently and likewise 
SH-SY5Y with dipLcTd.  
It was unexpected that J774.2 cells did not show any difference in intracellular catalytic 
activity between dipLC and dipLcTd. This could be because the increased sensitivity to 
toxins shown by Rust and colleagues was not necessarily just because of increased 
internalisation, but because of increased endosomal leakage independent of translocation 
domains (Rust et al. 2015). On the other hand, the reason for this lack of difference 
between the dipLC and dipLcTd could be because the translocation domains are unable to 
function for unknown reasons in these cells. The latter may be more likely owing to 
unregulated endosomal escape potentially resulting in cell death, but this is not always the 
case (Scharf et al. 2012; Erazo-Oliveras et al. 2014). Nonetheless, here there are three 
different cell lines each with different sensitivities to translocation domains of different 
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proteins; this could be a strong indication that the factors which determine endosomal 
escape could be as varied and as cell-specific as those that determine cell internalisation. 
This data suggests that a ‘one size fits all’ approach to endosomal escape is limited, and 
therefore could present problems for increasing the efficiency of the cytosolic 
translocation of drugs because there is another dimension of mechanisms which need to 
be explored. On the flip side, research into such matters could increase specificity of drug 
targeting and function.  
Whilst GALA has been shown in numerous reports to increase endosomal escape, here 
there was no increase in intracellular catalytic activity of the toxins doses (Kakudo et al. 
2004; Futaki et al. 2005). This could be for a number of reasons; for instance that GALA and 
diphtheria was added in a 1:1 ratio, however there may be more GALA peptides needed to 
create bigger pores for diphtheria to get through. Therefore, there is the possibility that a 
higher ratio of GALA to protein would result in increased cytosolic escape, which could 
explain why GALA-coated nanoparticles have had some degree of success (Sasaki et al. 
2008; Nishimura et al. 2014). Alternatively, a smaller protein may be more successful with 
this method. 
The ligands used here were accumulated owing to evidence suggesting that one or more 
of them would be able to bind to receptors and internalise into cells, transporting the 
conjugated toxin. Unfortunately this was not the case for any of the ligands tested. One 
potential reason for this is the orientation of the pyridyldithio attachment; the data in 
figure 4.3:D showing the difference between thio-CPBrevinMM and CPBrevinMM-thio was 
not completed until after ordering most of the peptides. Another reason could be that the 
receptors were not present on any of the cells tested, but this is unlikely as there are 
reports using those ligands to measure effects in the exact cell lines used (Muller et al. 
2006; Lutz et al. 2006).  
A potential reason that CPPs were able to increase delivery and the ligands were not could 
be the difference in the way that CPPs and ligands interact with the cell. For instance, CPPs 
interact with the cell surface, supposedly in a non-specific way, and it is possible that 
because of the flexibility of CPP composition not even the full length of CPP needs to be 
available for this interaction to occur (Bashyal et al. 2016; Zhang et al. 2015). Ligands on 
the other hand specifically bind to receptors, which requires a particular sequence of 
amino acids to be available, and potentially space to interact efficiently. However, whilst 
these cysteines on the botulinum-S25CRD and the dipLcTd-LC are available for 
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pyridyldithio-peptide conjugation, it may be that the size or obstruction of the bacterial 
toxin could obscure the availability of some of the amino acids in the ligand sequence. For 
a specific ligand sequence, this could present problems in receptor-ligand binding, 
however because CPPs are more flexible in their interaction and sequence they are less 
affected. It would be interesting therefore to use these peptides again with botulinum-
S25CRD and the dipLcTd-LC and to insert a short peptide linker in between the pyridyl 
disulphide residue and the ligand sequence to determine whether this improves the 
interaction and internalisation of the thio-conjugates.  
On the other hand, ligand-receptor binding on the surface of the cell does not necessarily 
equal internalisation, as numerous receptors function through downstream pathways 
which are not directed by receptor endocytosis. Another consideration in the reason for 
lack of internalisation of thio-ligands is that there could have been degradation of the 
peptides or that some were not fully functional due to manufacturing issues, this is a 
possibility because previously this laboratory has found success using CRH to target 
botLcTd/A to SH-SY5Y cells (Arsenault et al. 2013). Although the results for the thio-ligand 
conjugation have not been desirable, as shown in the previous chapter and through CPP 
conjugated delivery, the methodology does hold potential. Therefore, through screening 
peptide libraries against desired cells it would theoretically be possible to find suitable 
peptides to modify and direct protein toxins; then, the pyridyl disulphide group and 
potentially a linker can be attached at a location which would not interfere with the cell 
binding.  
There was a large difference across all three cell lines in the amount of FITC-CPP was 
present in the cells and the subsequent uptake of enzyme-thio-CPPs. This was surprising; 
although it has been reported that macrophages such as J774.2 have increased 
macropinocytosis, no difference was expected between Neuro2A and SH-SY5Y (Jones 
2007). This points to the possibility of cell specificity, which is unexpected given the nature 
of CPPs. It could be that receptors exist on Neuro2A which do not on SH-SY5Y, or that some 
of the mechanisms of cell entry discussed in the introduction are more efficient in one cell 
than the other. This is supported by other studies comparing CPPs between cell lines and 
also finding a large variance in both the uptake efficiency and cytotoxicity of CPPs 
(Mussbach et al. 2011). This data highlights a requirement to further investigate the 
bioactive conformation of CPPs and how this influences the cell-uptake based on their 
specific biology and biochemistry.  
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The mCherry-S25CRD conjugated to CPPs was able to greatly increase the amount of 
mCherry-S25CRD into macrophages as shown in figure 4.5; however, it then begs the 
question of how this occurred given the size of mCherry. Looking back to Chapter 1, it was 
reasoned that there were most likely several mechanisms where CPPs internalise 
depending on type and concentration, although only a few of them appear to be 
compatible with the transportation of the conjoined protein. As all concentrations used 
were under 5 µM, enhanced macropinocytosis is likely used at least in part and it would 
have been possible for the conjugated protein to have been also taken up (Fischer et al. 
2004; Chao & Raines 2011). Whilst it has been shown that CPPs can interact with the cell 
membranes and form pores, it is unlikely that this mechanism was used as the pore would 
not be big enough for the translocation of the toxin (Herce & Garcia 2007). On the other 
hand, the ‘inverted-micelle’ mechanism, where electrostatic reactions between the lipid 
bilayer and CPPs cause it to bind to the bilayer and resulting in encapsulation is another 
method where the CPP could have been internalised with the conjugated toxin (Alves et 
al. 2008). 
Figure 4.5 may have shown increase in mCherry-S25CRD internalisation into macrophages 
when conjugated to thio-CPPs, however it also suggested that the problem with CPPs lies 
not in internalisation, but in endosomal escape. This data was supported by other figures 
in this chapter showing that the catalytic activity of the delivered toxins in the cells is not 
what it should be in the case of efficient delivery of such toxic proteins. There have been 
ways proposed to enhance the endosomal escape potential of CPPs, for instance, the 
addition of histidine to CPPs such as TAT increases endosmosis and subsequent endosome 
rupturing via proton buffering (Lo & Wang 2008). Endosomolytic agent would be 
potentially more capable of facilitating the endosomal escape of large toxins than pore-
forming agents such as GALA, but could result increased undesirable cell toxicity (Lönn et 
al. 2016). On the other hand, the data did show that the addition of translocation domains 
was able to increase the amount of catalytic activity. So, maybe a three-pronged approach 
needs to be adopted for efficient drug delivery, with the toxin, the internalisation domain 
and the endosomal escape domain forming an effective multi-functioning protein 
complex.  
In conclusion, through the conjugation of toxic protein domains to peptides via disulphide 
conjugation, it has been found that CPPs are able to deliver into the cells, however their 
mechanisms of endosomal escape are limited. By further exploring this, it was found that 
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translocation domains can enhance the intracellular catalytic activity of the toxic proteins, 
presumably by facilitating endosomal escape. Moreover, through cysteine attachment to 
toxin LcTd domains it was possible for CPPs to further enhance the delivery of the toxins, 
although there appears to be a degree of cell specificity with CPP delivery. Unfortunately, 
the thio-ligand delivery was unsuccessful, but owing to the CPP data and the conjugation 
data from the previous chapter, it appears that the methodology has potential; perhaps if 
ligands were screened or optimised with specific cells and then synthesised with long 
linkers before use there could be efficient delivery of toxin LcTds. One drawback to using 
translocation domains however is that it negates the necessity for a pyridyldithio-
conjugated peptide; one of the main benefits of conjugating via pyridyl disulphide was the 
cleavable linker formed between the targeting domain and the toxin, however 
endogenous LcTd domains have a disulphide bond in between. Because the light chain will 
be cleaved from the translocation domain in the endosomes anyway, recombinant 
attachment of targeting proteins or peptides could be used. Nonetheless, thio-peptides 
could be useful as a library of modifications which could be added to a variety of proteins 
in a quick and stable way as a method of screening. As previously mentioned, this method 
only utilises peptide sequences for pyridyl disulphide attachment; therefore, for protein 
ligands a different strategy would be required. Moreover, there is still demand for a system 
where more than two domains can be conjugated at the same time, preferably in one 
reaction. Therefore, the SNARE stapling method will be investigated to determine whether 















As previously discussed, a big limiting factor with the pyridyl disulphide conjugation 
method used in the previous chapter is that only peptides could be attached with the 
pyridyldithio group. However, by using the stapling proteins optimised in figures 3.9-11 it 
is possible to recombinantly bind either toxin domains or ligand proteins regardless of size. 
By doing so, it is hypothesised that complexes of two or three proteins can be linked 
together through SNARE stapling. As it can be seen from the introduction table 1.2, there 
are numerous different ligands that could be used to target these linked complexes to 
neuroblastoma cell lines and facilitate internalisation. As stated previously, protein ligands 
are good for targeting into cells as proof of concept because they bind to endogenous 
receptors efficiently and are easy to produce through plasmid expression in competent 
bacteria. 
Up until this point, only ricinLC has been successfully conjugated to the SNARE complex 
both through recombinant and pyridyldithio attachment. Because of the data in the 
previous chapter, I will also be using translocation domains in this section to ensure more 
efficient delivery of toxins into the cytosol. It was decided that because of the translocation 
domain being attached to the light chain of both diphtheria and botulinum toxins through 
an endogenous disulphide bonds, that the stapling linkers could be recombinantly fused 
to the toxin translocation domains without interfering with the light chain catalytic 
function. Through the production of ligands and toxin domains with recombinantly fused 
staples (protein-staples), this chapter aims first to identify a potential ligand which can be 
used to target and internalise into neuroblastoma. Then, it will look at the construction of 
the SNARE complexes with chosen ligands and toxin LcTd domains. From this, the 
complexes can be incubated with cells to determine how relatively efficient they are at 
facilitating cytosolic catalytic function of the stapled toxin domains. The main objective of 
this chapter is to create a complex with three domains conjugated, for them to retain their 
functions and behave complementary to each other and to allow the binding and 





5.2.1 Recombinant CNTF and EGF fused botulinumLcTd/A is able to cleave 
SNAP25 in neuroblastoma cell lines 
In order to identify ligands which would be suitable to use with the selected cell types, 
recombinantly fused protein samples made in house were first run on an SDS-PAGE gel to 
check purify and size of the protein. Figure 5.1:A shows that because many of the peptides 
supposedly conjugated to botLcTd/A are 3kDa or less, there is no visible way of 
determining whether they are present. CNTF and EGF are both lager, and there is a 
difference in band migration between these samples and the control botLcTd/A. 
Unfortunately, both adrenomedullin and TNFα are 6kDa or larger and therefore a 
difference would be expected, however it is clear from the SDS-PAGE that they have not 
been successfully fused due to either breakdown or an error in expression. Nonetheless, 
the remaining samples were incubated at 20 nM with SH-SY5Y and Neuro2A cells for 72 
hours before the cells were harvested and lysed to run on a western blot (fig. 5.1:B). The 
membrane showed that both Neuro2A and SH-SY5Y showed significant SNAP25 cleavage 
when exposed to recombinantly fused botLcTd/A-EGF, but botLcTd/A-CNTF only cleaved 
SNAP25 in SH-SY5Y cells. This result therefore gives the means to potentially target cells 
specifically owing to the different cell responses to the ligands. To complement this, LA-N-
5 human neuroblastoma cell line was introduced and also incubated with both botLcTd/A-
EGF and botLcTd/A-CNTF; in contrast to Neuro2A cells, only botLcTd/A-CNTF was able to 
cleave SNAP25 in these cells (fig. 5.1:C).  
From this, to confirm suspicions that the ligands were internalising through the presence 
of endogenous cell surface receptors, the antibodies for both CNTFR and EGFR were 
acquired. The cell lysates of all three neuroblastoma cell lines were blotted with either 
antibodies, before the membranes were re-blotted with SNAP25 as a control. Because 
CNTF also can bind to IL-6, there was a concern that there could be little, if any, CNTFR 
present on SH-SY5Y or LA-N-5 cells; however, it was shown that both cells had CNTFR 
present. Interestingly, there was a small amount of CNTFR present in Neuro2A cells, 
however at this stage the location is undetermined. On the other hand, EGFR was shown 
to be highly present on both SH-SY5Y and Neuro2A cells. Both antibodies appeared to be 
clean with the expected band size and with little non-specific binding (fig 5.1:D). 
Cells were then stained to visualise the presence of the receptors in the cells. Both CNTFR 
and EGFR appeared to be spread throughout SH-SY5Y cells, including presence in the 
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neurites. EGFR was also found throughout the Neuro2A cells, but CNTFR showed little 
presence in these cells. The inverse was true of LA-N-5 cells, where CNTFR presence was 





Figure 5.123– Identification of ligands for potential use in targeting complexes to 
neuroblastoma cells 
A) SDS-PAGE showing the recombinantly fused botLcTd/A-ligand proteins produced. B) 
Western blot showing SH-SY5Y and Neuro2A cells after 72 hours incubated with botLcTd/A-
ligands (N=2). C) Western blot of LA-N-5 neuroblastoma cells after application of either 
botLcTd/A-EGF or botLcTd/A-CNTF (N=2). D) Western blot staining lysates of 
neuroblastoma cell lines with either EGFR or CNTFR with SNAP25 as control. E) Images 
taken using epifluorescent microscope of the SH-SY5Y, Neuro2A and LA-N-5 cells with 
CNTFR or EGFR staining. Hoechst: 20 ms, EGFR: 4000 ms, CNTF: 4000 ms. (N=2). 
 
 
It has been shown here that both EGF and CNTF are potentially good candidates for 
targeting stapled complexes to specific neuroblastoma cell lines. However, it is important 
to consider the potential issues with these endogenous ligands; for example, EGF has been 
shown to activate cell proliferation (Ho et al. 2005). On the other hand, CNTF may increase 
differentiation in the cells causing decreased growth and increased spindle morphology 
(Sleeman et al. 2000). Therefore, both ligands will need to be tested to determine the 
effects they have on these neuroblastoma cells. Nonetheless, both ligand varieties show 
potential as proof of concept targeting domains for their own utilisation in neuroblastoma 




5.2.2 Investigating CNTF and EGF controls with Neuro2A and SH-SY5Y cells  
The desired individual components of the linked complexes were firstly made and applied 
to cells to determine any effect upon proliferation and morphology. As well as syntaxin, 
SNAP25 and brevin, recombinantly fused CNTF-syntaxin, CNTF-Brevin and EGF-Brevin 
(ligand-staples) were also produced (fig. 5.2:A). Figure 5.2:B indicates that there was no 
alteration in the growth of Neuro2A cells for any concentrations tested of any of the 
individual components; however, with SH-SY5Y cells there was increased proliferation with 
the addition of EGF containing proteins. The incubation of CNTF containing proteins did 
not appear to decrease the proliferation of cells. Moreover, images taken of SH-SY5Y cells 
with and without CNTF-brevin showed that there was no observable difference in neurite 
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outgrowth or soma size between the two samples, further indicating that differentiation 





Figure 5.224- Investigating the effects of CNTF and EGF have on SH-SY5Y and Neuro2A cells. 
A) SDS-PAGE showing the proteins to be used in SNARE formation. B) AlamarBlue assay 
with SH-SY5Y and Neuro2A cells where the SNARE components were incubated for 72 hours 
with the cells to determine whether there are any changes in proliferation. Significance 
measured by Student T-test for each concentration against the syntaxin45 20 nM sample 
(n=3, N=3). C) Brightfield images of SH-SY5Y cells either with or without incubating with 
Brevin-CNTF over 72 hours, showing no observable difference in neurite outgrowth or soma 
size. D) Schematic showing the SNARE peptides and the recombinantly fused proteins which 
have been successfully made and the possible combinations for complex linking. D) SDS-
PAGE looking at the formation of both x1 and x2 ligand stapled complexes (N=3). E) 
AlamarBlue assay looking at how the addition of the linked complexes and mixed 
components influences alamarBlue AU % after 72 hours incubation. Significance of OG 
containing samples measured by Student T-test for each concentration against the 0.4% 
OG control sample (n=3, N=3). Significance for statistical analysis: P>0.05 = NS  P<0.05 = * 
P<0.01 = ** P<0.001=***. CNTF PDB ID: 1CNT. EGF PDB ID: 1JL9. BotLcTd/A PDB ID: 3BTA. 




It was then important to determine whether linked complexes could be made from the 
ligand-staple proteins. Figure 5.3:D shows a schematic of the different versions of syntaxin, 
brevin and SNAP25 which were produced and the possible combinations of each of the 
three components that could be attempted. It was first decided to determine how well 
ligand-complexes formed without toxin attachment. After 1 hour incubation, successful 
linking could be seen in all three samples where one ligand-staple formed a complex with 
complementary SNARE proteins (fig. 5.2:E). It was apparent here that only CNTF-brevin 
was able to fully form into the complex, as the other samples showed a proportion of 
unlinked components of all three varieties remaining after 1 hour, especially CNTF-syx. 
Additionally, the linking of more than one ligand was attempted; discouragingly, it 
appeared that there was significantly less complex formation in these samples, even in the 
presence of increased OG % and an increased incubation time.  
Nonetheless, the samples were diluted irrespective of complex formation and applied to 
SH-SY5Y and Neuro2A cells to determine whether the formation of complexes would 
influence cell growth. Because of the dilute nature of some of the ligand-staples produced, 
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samples of approximately 400 nM were the highest concentration which could be reliably 
made. Because of this, and the required 1 in 20 dilution of OG containing samples, 20 nM 
was the highest sample concentration applied to cells. All samples were made through 
incubation with 0.4% OG and 1 hour incubation. Aside from the influence of diluted OG on 
the Neuro2A cells, it appeared that there were no adverse effects on the cell lines when 
complexes or complex components combined were added (fig 5.2:F). Additionally, because 
complexes were being made often with the unconjugated SNARE proteins in excess, it was 
deemed prudent to observe whether these proteins influenced the cells at higher 




5.2.3 CNTF-staples can be linked in a complex with botulinumLcTd/A and used to 
specifically target cell types. 
Despite the less than desirable efficiency in forming the single and double ligand linked 
complexes in the previous section, it is possible that different combinations of different 
linking components may have alternative linking efficiencies. Therefore, botulinumLcTd/A-
SNAP25 (botLcTd/A-S25) was produced and incubated with staple proteins to form 
complexes. It should be understood that this botLcTd/A is catalytically active and does 
cleave the 9 amino acids at the C-terminus of the fused SNAP25 which it is recombinantly 
fused to; however, it has been previously shown that provided the botLcTd/A is bound to 
the N-terminus of the protein there is no effect on SNARE formation (Arsenault et al. 2013; 
Ferrari et al. 2013). Figure 5.3:A shows that 100% of botLcTd/A-S25 was able to successfully 
form complexes. BotLcTd/A-S25 was then incubated with the CNTF-staples in order to 
successfully form linked CNTFbrev-botLcTd/A, linked CNTFsyx-botLcTd/A and linked 
CNTFx2-BotLcTd/A.  
As described in the methods, using SDS-PAGE the concentration for each linked sample is 
measured by running alongside BSA standards. Therefore, through using band intensity 
analysis, the approximate mg/ml and the band size (kDa) can be used to work out the molar 
concentration before preparing samples for incubating with cells. In doing this one can also 
find out the % of the botLcTd/A-S25 which has been used up to make the linked complexes. 
In instances where the SNARE formation was less than 75% the sample was not used.  
Successfully SNARE linked samples were then tested to determine whether the CNTF ligand 
was able to direct the botLcTd/A domain into SH-SY5Y cells in a way comparable to 
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recombinantly fused botLcTd/A-CNTF. There was no significant toxicity or observable 
alteration in cell morphology in any of the cell samples tested when incubated with SH-
SY5Y cells for 3 days (fig 5.3:B-C). Figure 5.3:D investigated the SNAP25 cleavage of complex 
added Neuro2A and SH-SY5Y cells after 72 hours incubation. It was found that, as 
predicted, there was no increase in cleavage in any of the Neuro2A samples when 
botLcTd/A-S25 was linked to CNTF-staple. However, there was a large increase in the 
SNAP25 cleavage in SH-SY5Y when botLcTd/A linked constructs were directed with CNTF. 
There was no distinction between either of the two CNTFx1-botLcTd/A linked samples; 
because of this, the term ‘linked CNTFx1-botLcTd/A’ will refer to linked CNTFbrev-
botLcTd/A henceforth unless otherwise stated.  
Titrations of recombinantly fused botLcTd/A-CNTF up to a maximum of 50 nM showed that 
there was a plateauing in the cleavage of SNAP25 at higher concentrations (fig. 5.3:E-F). 
This could be for a number of reasons; for one, there was evidence of heterogeneity in the 
presence and location of CNTFR in figure 5.1 which could mean that some cells are unable 
to internalise CNTF-botLcTd/A complexes as much as others. It has already been 
established in the previous chapter that all of the SNAP25 within the cells has the potential 
to be cleaved (fig. 4.8); however, if there is a limitation to the amount of botLcTd/A 
entering the cells then there would be a limitation to the cleavage.  
To determine whether this % SNAP25 cleavage could be improved upon, CNTFx1-
botLcTd/A Linked was compared to the CNTFx2 version. Figure 5.3:G shows that there 
appeared to be an increase in SNAP25 cleavage between the two samples. These results 
were then quantified in Figure 5.3:H, showing that there was a significant increase in the 
SNAP25 cleavage at the same concentration between CNTFx1 and CNTFx2 linked 
botLcTd/A. Encouragingly, there was no significant difference between the CNTFx1-
botLcTd/A linked and the recombinantly fused botLcTd/A-CNTF, indicating that the CNTF 
which is linked to the botLcTd/A-S25 remains fully functional. Moreover, because of the 
increase in the SNAP25 cleavage between the CNTFx1 and CNTFx2 directed botLcTd/A 
samples, it strongly indicated that both of the CNTF domains attached in the complex 
remain functional and are complementary to each other. This second linked CNTF domain 










Figure 5.325– CNTFx2-BotLcTd/A-SNARE increases SNAP25 cleavage compared to CNTFx1-
BotLcTd/A-SNARE 
A) SDS-PAGE showing the formation of linked botLcTd/A complexes with CNTF-staples 
(N>3). B) AlamarBlue assay showing the cell growth of samples incubated with botLcTd/A-
SNAREs and CNTF-BotLcTd/A-SNAREs for 72 hours. Significance measured by one-way 
ANOVA across all values (n=3, N=3). C) Images of cells after incubating with samples for 3 
days. D) Western blot showing cleavage of SNAP25 after 3 day incubation with linked 
botLcTd/A and both CNTFx1-botLcTd/A linked varieties (N=2). E-F) Western Blot and 
subsequent quantification of SNAP25 cleavage after 72 hours incubation with botLcTd/A-
CNTF (N=3). G) Western blot showing SNAP25 cleavage after 72 hours incubation with 
CNTFx1-botLcTd/A linked and CNTFx2-botLcTd/A linked. H) Quantification of subfigures E 
and G combined. Significance measured by one-way ANOVA for each concentration (N=3). 




5.2.4 Investigating the optimum time point and effects of accumulation for CNTF-
BotLcTd/A-SNARE SNAP25 cleavage 
To determine whether 72 hours was the optimum timepoint for analysing SNAP25 
cleavage, it was decided stagger the addition of both linked CNTFx1-BotLcTd/A and 
CNTFx2-BotLcTd/A into cell wells over 3 days. It was found that there was no cleavage after 
6 hours incubation and there was little at 24 hours for either complex (fig. 5.4:A-B). 
Therefore, this data supports the use of 72 hours as the optimum timepoint for analysis 
As well as incubating doses for a 72 hour timepoint, it was decided to attempt to increase 
SNAP25 cleavage by adding an additional sample at 24 hours. This cumulative addition of 
samples onto cells did not increase SNAP25 cleavage as there was no significant difference 






Figure 5.426- Investigating the timepoints and accumulation of CNTF linked botLcTd/A 
complexes 
A) Western blot showing the timepoints of cells incubated with CNTFx1-botLcTd/A linked 
and CNTFx2-botLcTd/A linked. B) Quantification of subfigure A. Significance measured by 
Student T-test between samples of the same concentration (N=3). C) Western blot showing 
the effects of SNAP25 cleavage though cumulative addition of CNTFx1-botLcTd/A linked 
and CNTFx2-BotLcTd/A linked at 10 nM at 72 hours and 24 hours. D) Quantification of 
subfigure C. Significance measured by Student T-test between samples added at 72 and 








5.2.5 SH-SY5Y culture is a heterogeneous population. 
In order to investigate the reason for % SNAP25 cleavage plateauing at high concentrations 
of CNTF linked botLcTd/A and recombinantly fused botLcTd/A-CNTF, an antibody was 
obtained which was specific to the cleaved form of SNAP25 from botLcTd/A (αC-SNAP25) 
(fig. 5.5:A). This was then used alongside a mouse total αSNAP25 antibody and both used 
for immunocytochemistry (ICC) (fig. 5.5:B). Both of the secondary antibodies used did not 
show any background in SH-SY5Y cells when used without primary antibodies (fig. 5.5:C).  
SH-SY5Y cells were either incubated with buffer A, 2 nM botLcTd/A or 2 nM linked CNTFx2-
botLcTd/A for 72 hours and were then stained with both αSNAP25 and αC-SNAP25 and 
imaged by confocal microscope. It was shown that the total αSNAP25 presence within cells 
was not homogenous in any of the cell populations, but was present in every cell.                  
αC-SNAP25 staining was not observed in the buffer A incubated cells and there was 
negligible staining in the 2 nM non-ligand attached botLcTd/A incubated cells (fig 5.5:D-E). 
On the other hand, there was significant αC-SNAP25 staining in the 2 nM CNTFx2-
BotLcTd/A stapled sample; whilst there appeared to be SNAP25 cleavage in most of these 
cells, the presence was heterogeneous. This staining of αC-SNAP25 appeared to be 
independent of the amount of SNAP25 in the cells. These images support the hypothesis 
that the SH-SY5Y cells are a heterogeneous population in their internalisation of CNTF 
linked botLcTd/A, and that this is at least in part the reason for the plateauing of partial 
SNAP25 cleavage.  
To further determine the nature of this heterogeneity, images were taken with SH-SY5Y 
cells stained with CNTFR antibody with αSNAP25 as control. In undosed control cells, the 
presence of CNTFR appeared to be throughout the cells, with there being a large amount 
in the neurites and at the cell surface (as indicated); however it should be noted that some 
cells appeared to have a higher presence of CNTFR than others (fig. 5.6:A). There was no 
observable difference between the control cells and those treated with non-ligand linked 
botLcTd/A 2 nM for 72 hours (fig. 5.6:B). When cells had been incubated with linked 
CNTFx2-botLcTd/A 2 nM there was a substantial decrease in the CNTFR quantity 
accompanied with a shift in the location of CNTFR mostly from the cell surface and neurites 










Figure 5.527– SH-SY5Y culture is a heterogeneous sample. 
A-B) Western blot showing the αCleavedSNAP25 (αC-SNAP25) rabbit and total αSNAP25 
mouse antibodies with SH-SY5Y cell lysates, with αSyntaxin1 used as a loading control. C) 
Images showing secondary antibodies Mouse-Alexa488 and Rabbit-Alexa594 with DAPI on 
cells without primary antibodies (epifluorescent microscope: 4000 ms. Obj. x40. Scale bars 
100µm). D-F) Buffer A, 2 nM botLcTd and 2 nM CNTFx2-BotLcTd/A linked complex treated 
SH-SY5Y cells (72 hours), stained with αSNAP25 (mouse) and αC-SNAP25 (Rabbit) and DAPI. 













Figure 5.628– Imaging CNTFR staining in treated cells 
A-E) Images taken using epifluorescent microscope of αCNTFR staining (4000 ms) and 
control αSNAP25 staining (200 ms) in SH-SY5Y cells when incubated for 72 hours with 
various samples at 2 nM, showing relative quantity and presence of CNTFR in cell 
membranes and neurites. Neurites and cell edges indicates with arrows (N=2). F) Images 
taken using epifluorescent microscope of αCNTFR staining (4000 ms) and αC-SNAP25 
staining (200 ms) in SH-SY5Y cells after incubating with CNTFRx2-botLcTd/A linked 2 nM for 
72 hours. Arrows indicate heterogeneity of αC-SNAP25 and the consistency of αCNTFR 
staining. All inset scale bars 50 µm, all obj. x40. 
 
 
To determine whether the shift in the presence and location of CNTFR was dependant on 
botLcTd/A internalisation or CNTF binding, CNTF-brevin 2 nM was incubated with the cells, 
as well as recombinant botLcTd/A-EGF separately. It can be seen in figure 5.6:D that when 
CNTF-brevin 2 nM was applied there was an internalisation of the CNTFR in a way similar 
to that seen in figure 5.6:C. Moreover, when botLcTd/A-EGF 2 nM was incubated there was 
no difference observed in the location of CNTFR when compared to the control or 
botLcTd/A 2 nM samples (fig. 5.6:E). In those cells which were treated with CNTF containing 
samples, the presence of CNTFR appeared to be less heterogeneous than those without 
CNTF (as indicated). From this, there appeared to be no difference in CNTFR presence 
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between those cells which showed high amounts of cleaved SNAP25 and those which 
showed no or little cleaved SNAP25 (fig. 5.6:F). Therefore, it cannot be concluded whether 





5.2.6 EGF linked complexes are unable to internalise in SH-SY5Y or Neuro2A cells.  
As figure 5.1 had previously demonstrated by immunoblotting that recombinantly fused 
botLcTd/A-EGF was able to cleave SNAP25 in both SH-SY5Y and Neuro2A cells, it was 
decided that this warranted further investigation. Fused botLcTd/A-EGF titrations were 
incubated with both SH-SY5Y and Neuro2A cell lines and it was found that there was 
successful SNAP25 cleavage in both which could be observed at 2 - 0.4 nM (fig. 5.7:A). 
Interestingly, there was a higher gradient at the higher concentrations on the graph 
relating botLcTd/A-EGF and % cleaved SNAP25 than when compared to botLcTd/A-CNTF 
(fig. 5.7:B). It could be that this decreased plateauing is due to differences in location and 
expression of EGFR compared to CNTFR. 
Using brevin-EGF, linked complexes were made to bind EGF to botLcTd/A-S25 and CNTF-
syntaxin. It was found that whilst EGF-BotLcTd/A linked was able to form efficiently, there 
was little formation of EGF-CNTF-BotLcTd/A (fig. 5.7:C). This was unfortunate as it would 
have been interesting to see whether a complex with two different linked ligands could 
target the two separate cell lines and how this would have influenced SNAP25 cleavage. 
Nonetheless, EGF-BotLcTd/A linked was applied to both Neuro2A and SH-SY5Y; it was 
found through western blotting that there was little or no cleavage in any of the samples 
(fig 5.7:D). This was an unexpected observation, as it was clear that EGF-BotLcTd/A linked 
was able to successfully form. EGF-brevin is believed to bind to receptors and be functional 
because of its influence on SH-SY5Y growth in figure 5.2. However, a possible reason for 
the lack of stapled-complex effects could have been that EGF is smaller than CNTF and 
therefore when the complex is formed the EGF binding domain is smothered by the formed 
complex. It is a useful demonstration that it is not just complex linking which is a factor in 
SNARE stapling success, as it is possible that even successful stapling can result in 













Figure 5.729– Synthesis of EGF-linked botLcTd/A complexes and investigation of EGFR in 
EGF-dosed cells 
A) Western blot showing the cleavage of SNAP25 in Neuro2A and SH-SY5Y cells when 
incubated with titrations of botLcTd/A-EGF for 72 hours. B) Quantification of SNAP25 
cleavage in A (N=2). C) SDS-PAGE showing the formation of EGF-botLcTd/A linked complex 
and the lack of formation of linked CNTF-EGF-botLcTd/A (N=3). D) Western blot showing 
the cleavage of SNAP25 in Neuro2A and SH-SY5Y cells when incubated with titrations of 
linked EGF-botLcTd/A for 72 hours (N=3). E) Images taken showing the lack of non-specific 
staining of secondary antibodies used without the presence of primary antibodies 
(epifluorescent microscope: 4000 ms. Scale bars 100µm). F-G) Images taken showing SH-
SY5Y cells both with and without recombinantly fused botLcTd/A-EGF addition after 72 
hours, fixed and stained with EGFR (rabbit) (4000 ms) and βIII-tubulin control (mouse)  (200 
ms) (N=2). H-I) Images taken showing Neuro2A cells both with and without recombinant 
botLcTd/A-EGF addition after 72 hours, fixed and stained with EGFR (rabbit) (4000 ms) and 
βIII-tubulin control (mouse) (200 ms) (N=2). Arrows indicating EGF presence in the neurites 






Despite the lack of success with the delivery of botLcTd/A using EGF stapled complexes, it 
was still desirable to determine whether the quantity and location of the EGFR was the 
reason for the difference from CNTF in plateauing at higher concentrations. Figure 5.7:E 
shows that neither of the secondary antibodies used here showed any non-specific binding 
without the presence of primary antibodies in SH-SY5Y cells. SH-SY5Y cells which had been 
either incubated with buffer A or recombinantly fused botLcTd/A-EGF 10 nM were fixed 
and stained with EGFR and βIII-tubulin as a control. It was found that there was no 
observable difference in the location or quantity of EGFR between control and sample 
incubated cells (fig. 5.7:F-G) (as indicated). Potentially, it is this lack of significant receptor 
internalisation and expression inhibition once activated which is the reason for the 
difference between the % SNAP25 cleavage gradient between CNTFR and EGFR. It can be 
seen in figure 5.7:H-I that a similar lack of change in EGFR presence or location is seen in 





5.2.7 SNAP25 cleavage through stapled botLcTd/A delivery directly influences H3-
Noradrenaline exocytosis 
As discussed in the introduction, botulinum neurotoxins can be used for pain relief because 
they inhibit the exocytosis of neurotransmitters, but there is also an argument that it can 
be used for cancer treatment (Bandala et al. 2015; Karsenty et al. 2009) Numerous cancer 
varieties use paracrine and autocrine pathways to enhance growth and increase 
vasculature (Chanthery et al. 2012; Chaban et al. 2013); these signals are made and 
released by cells and therefore to inhibit them could potentially be advantageous.  
SH-SY5Y are commonly used for noradrenaline exocytosis studies and therefore are a good 
cell line in which to determine whether the cleavage of SNAP25 by botLcTd/A is capable of 
inhibiting this exocytosis (Atcheson et al. 1994; Vaughan et al. 1995; Géraldine et al. 2010).  
It has been found previously in literature that botulinum A SNAP25 cleavage is capable of 
inhibiting stimulated release in differentiated cells and nerve terminals, but the 
investigation of the effects of SNAP25 cleavage on undifferentiated neuroblastoma 
remains limited (Arsenault et al. 2013; Raciborska et al. 1998; Huang et al. 1998). It was 
decided to measure the quantity of noradrenaline release through radioactive labelling 
([H3]-NA), with the hypothesis that increased SNAP25 cleavage through CNTFx1 and 
CNTFx2 linked construct botLcTd/A delivery would decrease the stimulated release of [H3]-
NA. It was hoped that there would be a difference in the stimulated release of [H3]-NA 
between the CNTFx1 and CNTFx2 linked constructs.  
In order to determine this hypothesis, the protocol must first my optimised. Quantification 
of radiation was done through a scintillation counter, which measures the radioactive 
decay of samples in counts per minute (CPM). However, for low energy decay not all events 
are recorded because of quenching in the scintillation fluid, therefore the CPM is different 
to the actual value of disintegrations per minute (DPM).  Because tritium is known for 
having significant quenching, titrations of known radioactive concentrations diluted in 
basal buffer was made (fig. 5.8:A). It was shown that the quench had a consistent level of 
around 20% from between 5500000 to 1000 DPM, this is consistent with other reported 
tritium data (fig. 5.8:B) (Thomson 2001).  
At the end of release experiments it was desirable to harvest and lyse the remaining cells 
to determine the overall % of tritium that was released and how much was left behind in 
the cell; it had to be considered whether cell lysates and the number of cells in the lysates 
could influence quench. Therefore, trypsin was first used, then basal buffer with 0.4% 
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triton and 0.2% nuclease benzonase was mixed and left for a further 5 minutes before 
making up to 1ml in basal buffer and placing in the scintillation vial. When samples each 
containing the lysates of 1.2x10  cells were added to titrations of known radioactive 
concentrations it was found that there was a decrease in quench% as the DPM decreased. 
Therefore the amount of CPM found in the lysis buffer needed to be considered before 
working out the % quench to use for calculating the DPM (fig. 5.8:C). Additionally, it was 
found that in lysates containing between 8x10  and 3x10  cells there was no observable 
trend in the degree of quench when 10  DPM [H3]-NA was added (fig. 5.8:D). Because of 
the variance in this data, the % quench for the lysates was measured in each experiment.  
It was also important to consider the drugs and buffers that would be used whilst 
incubating with [H3]-NA and stimulating release. The basal buffers and release buffers are 
shown in section 2.1.2, where the release buffer uses 70 mM KCl, balanced by NaCl, to 
stimulate cell release. It was decided based on similar experiments that 2.775x106 DPM 
[H3]-NA would be incubated in basal buffer with the SH-SY5Y cells for 45 minutes before 
being removed and the wells washed; either basal buffer or release buffer is then added 
to the cells for 5 minutes before collecting to determine basal or stimulated release. The 
buffers with no additional drugs were found to cause the basal release of 5% and the 
stimulated release of 10%, this is comparable to other papers which have used SH-SY5Y 
cells in the same way (Géraldine et al. 2010) (fig. 5.8:E)  
Pargyline is a monoamine oxidase (MAO) inhibitor which prevents the breakdown of 
noradrenaline. Therefore pargyline at a concentration of 20 mM (with ascorbic acid 0.2 
mM) was added to the basal buffer with [H3]-NA during incubation (Atcheson et al. 1994; 
Davletov et al. 1998). It was found that there was no significant difference in either basal 
or release buffer between the cells incubated with or without pargyline (fig. 5.8:E). 
Desipramine, on the other hand, can be used to inhibit the re-uptake of noradrenaline 
(Géraldine et al. 2010). 1 mM desipramine was added to the basal buffer used for washing 
the SH-SY5Y cells after [H3]-NA incubation, however in doing so there was a large increase 
in the proportion of radiation that was being detected in both the basal and release 
samples. On observation, it appeared that the reason for this large detection was because 
the cells were dying and coming away from the plate into the media. This increase in cell 
death was also observed at significantly lower than recommended concentrations (fig. 
5.8:E). It was therefore decided that only pargyline only was to be used in the incubation 




Figure 5.830– Control experiments for establishing a [H3]-Noradrenaline assay 
A) Standard curve using known DPM concentrations of [H3]-Noradrenaline ([H3]-NA) and 
plotting against the measured CPM from the scintillation counter (N=3). B) Graph plotting 
the DPM against the % quench when measuring the CPM (N=3). C) Graph measuring the % 
quench with 1.2x105 cell lysates when mixed with a known DPM of [H3]-NA (N=3). D) 
Scatter plot determining whether % quench in radioactive cell lysate samples is dependent 
on the number of cells lysed (N=3). E) Optimisation of the protocol and determining the 
drugs and concentrations to be used (N=2). F) The % basal and stimulated release of the 
control cells in the 5 experiments which were completed. G) The % uptake of the 2.775x106 
DPM of radiation which was incubated with for 45 minutes. Passage numbers (P) are also 
displayed (Note: SH-SY5Y cells frozen at P21). H) Bar chart showing the number of cells 
counted in each experiment. 
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Upon establishing the assay conditions, wells containing adherent SH-SY5Y cells were 
incubated for three days with different concentrations of CNTF linked botLcTd/A 
complexes before undergoing analysis. Figure 5.8:F shows the basal and stimulated release 
of the control cells in each of the 5 experiments. Even though there were similar values for 
each experiment there was concern that the differences would interfere with detecting 
any subtle changes in radioactive release. Therefore, in each experiment, the basal and 
stimulated release of each condition would be given as a relative percentage of the control 
stimulated release. Approximately 2.5x10  cells were seeded into 24 well plates and the 
number of cells measured before experiments. Neither passage number (P) nor number of 
cells at 72 hours appeared to influence uptake or the amount of NA-[H3] release from cells 
(fig 5.8:G-H). It was ensured that all experiments were done within 10 passages of 
defrosting. 
After protocol optimisation, SH-SY5Y cells were incubated with differing concentrations of 
CNTFx1 and CNTFx2-botLcTd/A linked complexes, before [H3]-NA was added. After 
washing away excess [H3]-NA, it was possible to stimulate exocytosis through KCl-rich 
buffer and compare this to basal release. It was hypothesised that increased SNAP25 
cleavage through CNTFx1 and CNTFx2 linked construct botLcTd/A delivery would decrease 
the stimulated release of [H3]-NA, and that potentially there would be a difference in the 
stimulated release of [H3]-NA between the CNTFx1 and CNTFx2 linked constructs. 
The stimulation buffer was incubated for 1,3 and 5 minutes and compared to 5 minute 
incubation in basal buffer and it was found that there was no stimulated release plateau 
before 5 minutes (fig. 5.9:A). It was undesirable to incubate the buffers for more than 5 
minutes because of potential re-uptake of the [H3]-NA and the eventual escape of [H3]-
NA] in the basal buffer down the concentration gradient. Therefore 5 minutes incubation 
of basal and release buffer with cells before the buffer was removed and analysed 
quantitatively for radioactive [H3]-NA. 
The stimulated and basal release from the control samples were then compared to those 
which had been treated with the CNTF linked botLcTd/A complexes. There was a strong 
correlation between the increase in the concentrations of CNTF-BotLcTd/A linked samples 
added to cells and the decrease in the amount of radiation in samples with stimulated 
release. An issue with linked CNTF-BotLcTd/A complexes there it has not resulted in 100% 
SNAP25 cleavage in any of the concentrations incubated. To determine what would 
happen with enhanced SNAP25 cleavage, botLcTd/A+LF3000 was incubated over 72 hours; 
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it was shown here that there was no significant difference between basal and stimulated 
release in these samples, suggesting a complete blockade of stimulated release (fig. 5.9:B). 
Whilst all the stimulated release points are significantly different from the control 
stimulated release, it should be noted that this is biased because the control stimulated 
release is at 100% with a standard deviation of 0, so almost any difference would have 
resulted in significance. Therefore, the focus here is the level of significance and the 
pattern which ensues when there is increased addition of CNTF-botLcTd/A linked 
complexes. There was no significant difference between the x1 and x2 CNTF linked release; 
however, there was significant difference between the value for CNTFx1-BotLcTd/A 0.4 nM 
and CNTFx2-BotLcTd/A 10 nM.  
One criticism of this experiment was that it was impossible to measure the degree of 
SNAP25 cleavage in the samples which were analysed for release, by doing to it would have 
been possible to directly analyse SNAP25 cleavage against stimulated release. Taking the 
data from figure 5.3, where 10 nM CNTF-BotLcTd/A linked complexes resulted in just under 
50% cleavage, a broad judgement can be made that around 50% of the cleavage results in 
50% decrease in stimulated release. This was surprising as it was hypothesised that 50% 
cleavage would result in more than 50% release owing to numerous SNARE complexes 
needing to form for successful stimulated exocytosis, thereby if a proportion are disrupted 
then it is more likely that the whole process would be disrupted as has been previously 
reported (Huang et al. 1998; Raciborska et al. 1998). Because the SNAP25 cleavage appears 
to be in some cells more than others, as shown in figure 5.5, it is possible that through this 
some cells had very little stimulated release whilst others remained mostly undisrupted, 
which could explain these results. It could therefore be possible that through alternative 
or more efficient targeting moieties, a SNAP25 cleavage of 60-80% could be achieved 
uniformly across the cells and could result in a more significant decrease in stimulated 
release. Nonetheless, it has been suggested here that non-differentiated SH-SY5Y cells are 
able to have neurotransmitter release inhibited in a concentration dependant manner 
through botLcTd/A internalisation and SNAP25 cleavage, which could be of use for non-






Figure 5.931– Comparison of basal release and stimulated release in cells incubated with 
CNTF-linked complexes 
A) Bar chart showing the time points of incubation with release buffer and the resulting % 
release (N=2). B) Graph showing the basal and stimulated release of cells that had been 
incubated for 72 hours with different concentrations of CNTFx1-BotLcTd/A and CNTFx2-
BotLcTd/A linked samples and with LF3000 (N>2 for each bar). Significance measured by 
Student T-test by comparing values to either the control stimulated release or between 
concentrations or conditions as drawn. Significance for statistical analysis: P>0.05 = NS 




5.2.8 The effects of CNTFx1 and x2 linked botulinumLcTd/A can also be seen in 
LA-N-5 cells  
Having established the internalisation of CNTFx1 and CNTFx2 linked botLcTd/A in SH-SY5Y 
cells, it was advantageous to investigate whether these effects could extend to other cells. 
LA-N-5 is another neuroblastoma cell line which exhibits more differentiated behaviours 
such as slow proliferation and robust neurite formation. As shown in figure 5.1, LA-N-5 
cells were able to internalise botLcTd/A-CNTF to cleave SNAP25 but there was no cleavage 
when incubated with botLcTd/A-EGF. Furthermore, it was detected through Western blot 
and imaging that there was CNTFR presence in LA-N-5 comparable with that found on SH-
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SY5Y, but that there was little EGFR detected (fig. 5.1). These properties therefore make 
LA-N-5 useful for further exploring CNTFx1 and CNTFx2 linked complexes. Figure 5.10:A-D 
shows that the cells had a very slow growing and doubling time when compared to the 
other cell lines used. However when grown at 2x10  cells/well in a 96 well plate for 3 days 
they became 60-80% confluent and the alamarBlue assay can be successfully used to 
explore the effects of incubated samples on cell metabolism, and indirectly cell number, 






Figure 5.1032– Controls of LA-N-5 cells and confirmation of their suitability for CNTF 
experiments 
A) Graph showing cell growth of LA-N-5, measuring at 24 hour timepoints through Bio-Rad 
automated cell counter and comparing to the SH-SY5Y data previously shown in figure 4.1 
(n=2, N=3). B) Cell death% of the measured cells over 72 hours through Bio-Rad automated 
cell counter (n=2, N=3). C) Doubling time of the cells as calculated from formula in section 
4.2.1 and comparing to the SH-SY5Y data previously shown in figure 4.1. D) Brightfield 
images of the LA-N-5 cells over 72 hours in culture (Obj. x40). E) AlamarBlue value and the 
% control of the cells after 72 hours of growth at approximately 60-80% confluency (n=3, 
N=3). F) The alamarBlue values and their relationship with manually counted cell number 




It has been previously shown that recombinantly fused BotLcTd/A-CNTF cleaved SNAP25 
at 20 nM, it was then titrated to compare how the cleavage % compared with SH-SY5Y 
cells. Interestingly, it was found that the fused BotLcTd/A-CNTF was capable of cleaving 
SNAP25 at comparable concentrations to SH-SY5Y cells (fig. 5.11:A-B). Potential OG toxicity 
was found to be similar to that of Neuro2A cells with a maximum of 0.2% OG to be used 
(fig. 5.11:C). CNTFx1 and CNTFx2-botLcTd/A linked were then added in the same way as in 
figure 5.3. There was no toxicity or alteration of growth reported in any of the wells 
incubated with samples or linked complex components (fig. 5.11:D-E). The data found 
suggested that the % cleavage difference between CNTFx1 and CNTFx2 linked botLcTd/A 
complexes is similar to that seen in SH-SY5Y cells, as well as there being no significant 
difference between the recombinantly fused botLcTd/A-CNTF and the linked version at any 
of the points (fig. 5.11:G- H). Together, this data demonstrates that the internalisation of 
ligand-targeted toxin complexes as well as the enhanced effects between single and 
double ligand complexes is not unique to SH-SY5Y cells. 
In addition to the quantitative data, it was desirable to stain LA-N-5 cells which had been 
incubated with either buffer A or linked CNTFx2-BotLcTd/A and determine what effects 
these samples had upon the location and presence of CNTFR. In figure 5.11:I it can be seen 
that like SH-SY5Y, CNTFR was strongly present in the cell neurites and throughout the cell 
(as indicated). On the other hand, when incubated with CNTFx2-BotLcTd linked, there was 
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a large decrease in the presence of CNTFR and a retraction away from the neurites and 
into the soma (fig. 5.11:J). This finding is comparable to that of SH-SY5Y. One difference 
however, is that it was noted that the cleaved SNAP25 antibody was far more homogenous 
in its location in linked CNTFx2-BotLcTd/A incubated LA-N-5 cells than in SH-SY5Y cells (fig 
5.11:K). The reason for this may lie in that LA-N-5 cells exhibit far less cancerous behaviours 
than both SH-SY5Y and Neuro2A cells, such as decreased growth small soma with long 
neurites. Therefore, since heterogeneity is a hallmark of cancerous behaviour it is not 









Figure 5.1133– Investigating CNTFx1 and x2 linked botLcTd/A complexes in LA-N-5 cells 
A) Representative Western blot showing SNAP25 cleavage in cells incubated with titrations 
of botLcTd/A-CNTF for 72 hours (N=3). B) Quantification of A using Bio-Rad band analysis. 
C) AlamarBlue assay showing the toxicity of OG concentrations at 1 in 20 dilution in LA-N-
5 cells over 72 hours (N=3). D) Western blot showing SNAP25 and cleavage on incubation 
of LA-N-5 cells with botLcTd/A concentrations for 72 hours (N=2). E) Representative 
Western blot showing cleaved SNAP25 in cell lysates after cell incubation with CNTFx1 and 
CNTFx2 linked botLcTd/A complexes for 72 hours (N=3). F-G) AlamarBlue assays showing 
cells incubated with linked complexes and staple components for 72 hours. Significance 
measured through one-way ANOVA across all samples. H) Quantification of the SNAP25 
cleavage shown in A and E. Significance measured through one-way ANOVA between 
sample values of the same concentration (N=3). I-J) Images of LA-N-5 cells incubated with 
either buffer A or linked CNTFx2-BotLcTd/A 2 nM for 72 hours then stained with CNTFR 
(4000 ms) and SNAP25 (200 ms). K) Image of LA-N-5 cells incubated for 72 hours with linked 
CNTFx2-BotLcTd/A 2 nM and stained with αCNTFR (4000 ms) and αC-SNAP25 (200 ms). 
Images taken from epifluorescent microscope. Arrows indicate neurites and cell edges to 
highlight differences in CNTFR location. Significance for statistical analysis: P>0.05 = NS 




5.2.9 DiphtheriaLcTd-S25 stapled to CNTFx1 and x2 sees an increase in 
cytotoxicity in SH-SY5Y cells 
Having established that botTd/A can be delivered into cells and escape endosomes as 
shown by the cleavage of SNAP25, it is important to determine whether other enzymes 
can be delivered in a similar manner. DiphtheriaLcTd-S25 (DipLcTd-S25) was synthesised 
to determine this (fig. 5.12:A); diphtheria is useful as it kills cells and therefore theoretically 
cells should be more sensitive to the outcomes as once a cell succumbs to the toxicity there 
can be no progeny. DipLcTd-S25 was firstly incubated with brevin and syntaxin to ensure 
that it was able to form a linked complex (fig. 5.12:B). The toxicity of dipLcTd, 
recombinantly fused dipLcTd-S25 and linked dipLcTd complex was then compared in SH-
SY5Y cells; it was shown that the linked and stapled versions were more toxic that the 
dipLcTd itself (fig. 5.12:C). This effect has also been observed independently elsewhere 
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within the Davletov laboratory, with potential reason being that the helices composing 
either the SNAREs or SNAP25 may interact with cell membranes and internalise in a way 
which is not possible by dipLcTd alone. This has been previously shown in figure 5.3:D, 








Figure 5.1234– Forming linked complexes with dipLcTd-S25 
A) Schematic of DipLcTd-S25. B) SDS-PAGE showing the DipLcTd-S25 formation into a linked 
complex (N=3). C) AlamarBlue Assay showing the relative toxicity of dipLcTd compared to 
dipLcTd-S25 and linked dipLcTd after 72 hours incubation. Significance was measured by 
one-way ANOVA for all values at each concentration (n=3, N=3). D) SDS-PAGE showing the 
formation of linked CNTFx1-dipLcTd and CNTFx2-dipLcTd (N=3). E) AlamarBlue assay 
showing the relative toxicity between linked complexes dipLcTd, CNTFx1-DipLcTd and 
CNTFx2-DipLcTd incubated for 72 hours. Significance was measured by one-way ANOVA for 
all values at each concentration (n=3, N=3). F) AlamarBlue assay of linked complexes 
dipLcTd and CNTFx2-DipLcTd added either at 72 hours or 72+24 hours (n=3, N=2). G) 
AlamarBlue assay of linked dipLcTd and CNTFx2-DipLcTd at 72 hours and media changed 
at either 2 hours or 15 hours. Significance for both F and G was measured by Student T-test 
between the values of the same samples at the same concentration, measuring between 
the different incubations (n=3, N=2). H) AlamarBlue assay of linked dipLcTd and CNTFx2-
DipLcTd incubated for 24 hours and immediately analysed. Significance was measured by 
Student T-test between the values at the same concentration (n=3, N=2). Significance for 
statistical analysis: P>0.05 = NS P<0.05 = * P<0.01 = ** P<0.001=***. DipLcTd PDB ID: 1SGK. 




Figure 5.12:D showed that CNTFx1-dipLcTd linked and CNTFx2-dipLcTd linked could be 
successfully formed with brevin-CNTF and syntaxin-CNTF. The toxicity of the CNTF stapled 
complexes was then compared to linked DipLcTd complex without any ligand linked; it was 
found that both versions of the CNTF linked complexes significantly decreased the number 
of cells at lower concentrations, with the linked CNTFx2-dipLcTd being the most toxic (fig. 
5.12:E). Whilst it was extremely encouraging seeing this large increase in cytotoxicity, it 
should be noted that the recombinantly fused version of dipLcTd/A-CNTF was not in our 
possession and therefore could not be compared.  
Because of the substantial change in EC50 brought about through CNTFx2 linking, 
accumulation and timescale experiments were able to reveal more about the nature of the 
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linked complex internalisation and the toxicity of dipLcTd. Linked dipLcTd and CNTFx2-
dipLcTd/A linked were added into SH-SY5Y cells at titrated concentrations for 72 hours, 
with a separate set of wells being dosed again at 24 hours before analysis. Figure 5.12:F 
shows that there was a significant difference between the single and double dosed samples 
with the linked dipLcTd but not with the CNTFx2-dipLcTd/A samples. This is most likely 
because of the passive way which dipLcTd-S25 enters the cells, therefore more protein will 
equal a higher degree of entry. On the other hand, the linked CNTFx2-dipLcTd/A binds and 
is internalised specifically by CNTF receptors; however, it has already been demonstrated 
that after CNTF addition there is internalisation of the receptors (fig. 5.6), which could 
account for the lack of increase in cell death through accumulation of a CNTF containing 
sample.  
In a different experiment, samples were added to cells at 72 hours, before the media was 
changed to remove the complex after either 2 or 15 hours and the cells left to grow until 
analysis. Figure 5.12:G showed that the linked dipLcTd was only toxic at high 
concentrations after 2 hour sample incubation, and that there was a significant increase in 
cell death when the samples were incubated for 15 hours. The CNTFx2-dipLcTd/A linked 
samples also showed an increase in toxicity between the 2 hour and 15 hour sample 
incubated cells. What is particularly interesting about this data is that the linked dipLcTd 
alamarBlue assay values for both 2 hours and 15 hours were different to those shown in 
figure 5.12:F for 72 hours, whereas the 15 hour incubation for CNTFx2-DipLcTd/A linked 
samples were not significantly different from the 72 hour values. This strongly indicates 
that the internalisation of CNTF linked complexes is far quicker than the dipLcTd linked 
complexes without attached targeting domain, with all internalisation occurring before 15 
hours. On the other hand, linked dipLcTd appears to be internalised passively over the 
whole of the 72 hours.  
In figure 4.3 it was proposed that the reason for the lack of PI staining of dipLC incubated 
cells at 24 hours was because of the length of time required for diphtheria to trigger cell 
death. This was investigated by adding linked dipLcTd or CNTFx2-dipLcTd into cells over 24 
hours before immediately analysing. Figure 5.12:H showed that there was a small degree 
of cell death in the higher concentrations of both samples, however this result is 
significantly less than what is seen at 72 hours. This shows that even where it is known that 
dipLcTd has efficiently internalised within 24 hours, as demonstrated in figure 5.12:G, that 
it takes more than 24 hours for effective cell death to occur.  
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5.2.10 Stapling EGF and CNTF together with dipLcTd can internalise into a wider 
variety of neuroblastoma cells than one ligand alone. 
Following the apparent success of using CNTF linked dipLcTd complexes, it was decided to 
attempt using brevin-EGF to link and target complexes to SH-SY5Y cells. Figure 5.13:A 
shows that linked EGF-DipLcTd was successfully formed; moreover, unlike the botLcTd-
S25, dipLcTd-S25 was able to form a complex with both EGF and CNTF. When SH-SY5Y cells 
were incubated with the EGF linked complexes it was found that both EGF and EGF with 
CNTF linked dipLcTd has increased toxicity compared to CNTFx2-dipLcTd (values taken 
from fig. 5.12:E as a comparison) at lower concentrations (fig. 5.13:B). Whilst the EGF and 
EGF-CNTF stapled dipLcTd complex results were similar, it is apparent that at the lowest 
concentrations that linked EGF-CNTF-dipLcTd was not as toxic as linked EGF-dipLcTd. This 
could be for a number of reasons; for one, because CNTF internalisation might not be as 
efficient as EGF, therefore the CNTF binding to CNTFR could distract from EGF-EGFR 
interactions. Another possibility is that there is crowding around the SNARE staple, 
meaning that EGF could interfere with CNTF or vice versa at a protein level.  
Because it was possible to link together brevin-EGF, Syntaxin-CNTF and dipLcTd-S25, it then 
needs to be seen how these complexes behave in alternative neuroblastoma cell lines 
compared to complexes with only one ligand. For instance, Neuro2A cells do not appear to 
internalise CNTF-linked complexes and LA-N-5 cells do not appear to internalise EGF-linked 
complexes; therefore, a good test of double ligand function is to determine whether the 
construct with both CNTF and EGF linked is able to internalise into both cells.  
It was important to firstly investigate was that sensitivity of both LA-N-5 and Neuro2A cells 
to dipLcTd-S25. Unlike SH-SY5Y, there was very little difference in toxicity between dipLcTd 
and dipLcTd-S25 or linked dipLcTd (fig 5.14:A,C). As expected, there was little in the way of 
increased toxicity when CNTFx1 or CNTFx2 linked dipLcTd was incubated with Neuro2A 
cells, however when linked EGF-dipLcTd or EGF-CNTF-dipLcTd was applied there was a 
significant shift in the EC50 of the samples. Likewise, when LA-N-5 cells were incubated with 
linked EGF-dipLcTd there was little alteration in toxicity, but when any of the CNTF 






Figure 5.1335– Formation and utilisation of EGF linked dipLcTd complexes in SH-SY5Y cells 
A) SDS-PAGE showing formation of linked EGF-dipLcTd and EGF-CNTF-dipLcTd (N=3). B) 
AlamarBlue assay of titrations of ligand targeted linked dipLcTd samples for 72 hours (n=3, 
N=3). The linked CNTFx2-dipLcTd readings were those taken from figure 5.12:E. Significance 
was measured by one-way ANOVA for all values excluding dipLcTd linked at each 





Here it was found that in LA-N-5 cells the same decrease in toxicity was observed between 
linked CNTF-dipLcTd and EGF-CNTF-dipLcTd as in SH-SY5Y cells; a likely reason for this could 
be protein interference between both ligand domains. Whilst it is clear that all three 
domains remain functional and can evidently target both cell lines through their individual 
receptors, it is worth being cautious about the addition of other ligand varieties until more 
is understood about how the ligand proteins fit around the SNARE staple and whether 
modifications to the ligand-staples would improve upon the efficiency of double ligand 
complexes. For example, the addition of a long protein linker between the ligand and the 
staple domain of one of the ligand-staples may function to allow the protein domains to 










Figure 5.1436– Comparing the targeting and internalisation of dual-ligand linked dipLcTd 
complexes 
A) AlamarBlue assay of Neuro2A cells with dipLcTd control samples (n=3, N=3). B) 
AlamarBlue assay of ligand linked dipLcTd complexes in Neuro2A cells (n=3, N=3). C) 
AlamarBlue assay of LA-N-5 cells with dipLcTd control samples (n=3, N=3). D)  AlamarBlue 
assay of ligand linked dipLcTd complexes in LA-N-5 cells (n=3, N=3). Significance of A-D 
measured by one-way ANOVA for all sample values of the same concentration). E) 
Representative brightfield images of wells incubated with ligand-linked dipLcTd samples 
(N=2) (Obj. x40). All conditions shown here were after sample incubation for 72 hours. 




Both Neuro2A and LA-N-5 were observed to have similar responses to both dipLcTd alone 
and linked dipLcTd, therefore it was deemed appropriate to use imaging to visualise the 
differences between the ligand linked dipLcTd complexes at the same concentrations. 
Figure 5.14:E shows the morphology and density of both cell lines in control conditions. 
Imaged then show cells which have been incubated for 72 hours linked EGF-dipLcTd. In 
these images there is no visible alteration of LA-N-5 cells, however there is a significant 
decrease in the number of Neuro2A cells seen in these conditions. The inverse is true when 
the cells are incubated with linked CNTF-dipLcTd. This shows that ligand-linked complexes 
can target and internalise into specific cells based on their receptor make-up. When both 
ligands are linked to the dipLcTd complex then both cells show a significant decrease in cell 
density, and morphology in the case of LA-N-5, than when compared to the control. This 
therefore demonstrates that SNARE linking can be utilised to link together domains into a 
tri-functional complex. Together, this shows that SNARE linking could address not just the 
need to mix and match protein combinations together, but also that it is possible for it to 
become a successful conjugation strategy to merge with the current research in dual-






Within this chapter there have been a large variety of protein-staples used to make 
numerous complexes. This versatility in itself is demonstration of the niche which SNARE 
linking occupies as a strategy for building and exploring different combinations of proteins.  
It has also been successfully demonstrated that three different domains can be linked 
together in a co-operative tri-functioning complex which has been shown to improve the 
range of cells that can be specifically targeted for drug delivery.  
There has been a degree of variance in the formation and success of the formed 
complexes. For instance, it is uncertain as to why the double ligand linked complexes in 
figure 5.2 did not form, yet were able to form efficiently in the presence of botLcTd-
SNAP25. Moreover, in figure 5.7 it was demonstrated with brevin-EGF that sometimes 
linking into complexes does happen very efficiently, but there is not the desired function 
when tested. Nonetheless, all of the individual protein-staples were found to be functional 
on their own and all were able to form into complexes of some kind, but it is not currently 
known why some linked complexes form better than others. On the flip side, there is the 
advantage that if one protein-staple does not work then there is the option to use a 
different one. For instance, brevin-CNTF was able to form complexes more efficiently than 
syntaxin-CNTF in most instances, so in single CNTF complexes, brevin-CNTF was more often 
used. This diversity opens up a new avenue of protein complex building to aid in successful 
formation and delivery.  
Within these experiments, correct protein concentration calculations were relied upon to 
ensure the correct ratio of the individual components. This was because the complexes 
were often made in such small amounts that it was not possible to filter or purify, however, 
because of the size differences of all the components, if a large enough stock was made it 
would be possible to filter out the excess. Nonetheless, it was shown in figure 5.2 that most 
of the protein-staples had no influence on cell morphology or proliferation. But there is 
concern, especially with CNTF, that excess ligand could bind and internalise receptors, 
therefore there would be undesirable competitive inhibition of the receptors.  
Whilst both botulinum and diphtheria toxic domains used could have their intracellular 
catalytic effects measured over the 72 hour experiments, it is difficult to determine how 
functional the enzyme itself is across the 3 days as it is possible that through internalisation 
and degradation there is no functional toxin left by day 3. A way of potentially measuring 
this is to remove the sample containing media at particular timepoints during incubation 
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and dose it onto fresh cells, but this would only measure the presence of functional toxin 
remaining in the media. However, without doing this, it can be seen from figure 5.12:G 
that when linked dipLcTd was removed after 15 hours there was significantly less cell death 
than there was when the linked dipLcTd was incubated for the full 72 hours in figure 5.12E-
F. This suggests that there was still functioning dipLcTd in the media between 15 and 72 
hours to facilitate that increase in toxic effect. Additionally, figure 5.4:A shows that at 24 
hours there was very little SNAP25 cleavage, whereas there was significantly more 
botulinum mediated SNAP25 cleavage at 72 hours so therefore there must have been 
active botLcTd/A linked to CNTF either in the media or inside the cells between the two 
timepoints. 
It has been shown here that the recombinant attachment of the translocation domains of 
toxins to stapling proteins does not influence the protein function. In fact, as found in 
figure 5.12, the attachment of SNAP25 to the proteins actually significantly enhanced the 
uptake. It was surprising that there was no decrease in the effectiveness of the protein, 
this is because of the nature of the translocation domain inserting into the endosomes and 
forming pores to allow the light chain domain to escape into the cytosol. One would have 
hypothesised that the recombinant fusing could have interfered with this mechanism but 
there was no interference and there have been other groups which have used this 
technique successfully (Fuentes et al. 2015; Nugent et al. 2017). This quelled initial fears 
raised in figure 3.11 regarding the method of attachment of toxins to stapling proteins as 
light chains need to be cleaved in order to function. Because of the translocation domain 
being attached to the light chain via a disulphide bond there is no need to attach the staples 
via disulphide binding. On the other hand, if there were proteins without translocation 
domains that one would want to link, it is possible that a disulphide bound staple would 
be more effective.  
Another issue to address with SNARE linked complexes is that they require 0.4% OG to 
form and this is toxic to cells if not diluted properly. The toxicity was successfully managed 
through careful diluting and dosing into plates. It should be noted that in this lab samples 
containing 0.4% OG have been injected into rats (including vehicle control) without dilution 
and that no adverse effects have been observed in any of the quantities tested 
(observations from Charlotte Leese and Rebecca Bresnahan of the Davletov lab). Whilst 
there was initial concern that the OG could permeabilise cells and increase toxin entry 
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there was no difference in the function of either botLcTd/A or dipLcTd between OG positive 
and negative samples at the dilutions incubated.  
Given that the main pitfalls of the previous chapter surrounded the lack of an efficient 
targeting sequence, it was especially important here that an effective domain was found 
which could be linked to the complex and successfully facilitate specific internalisation. 
Here, two were found. EGFR and its ligands have been previously established as a receptor 
pathway with potential for targeting numerous cancer varieties cells, however CNTF has 
not yet been fully realised. Whilst most cells express some degree of EGFR, approximately 
30% cancer types have been reported to express up to 200 fold more receptors, 
significantly increasing targeting potential and highlighting the reason for a trend in 
research utilising EGFR for cancer specific drug delivery (Herbst & Shin 2002; Seshacharyulu 
et al. 2013). On the other hand, cancers which respond to CNTF are limited to 
neuroblastoma and other glioma (Kuroda et al. 2001; Weis et al. 1999). The presence of 
CNTF signalling in neuroblastoma however is often a hallmark of more well differentiated 
and less aggressive cancers, which could explain why it was found in the two least 
proliferative cell lines (Rossino et al. 1995; Negro et al. 1997). Nonetheless, both CNTF and 
EGF were able to satisfy the requirements for receptor-mediated specific internalisation 
domains.  
It was especially encouraging that by linking two CNTF ligands to toxin-staples complexes 
there was an increase in measurable catalytic activity, presumably as the result of 
increased internalisation. Both complexes containing either diphtheria or botulinum A 
domains linked with CNTF showed a significant increase in cytosolic enzyme activity 
compared to the complexes without ligand attachment; however, it is worth noting that 
the significance here is slightly biased. This is because assays used to measure diphtheria 
toxin were done in triplicate as well as repeated individually 3 times, meaning that there 
were 9 readings taken; on the other hand, the western blots used to measure SNAP25 
cleavage for the botulinum toxin only produced 3 values from the 3 individual experiments. 
Both ANOVA and Student’s T-test take into account the number of values in a sample size 
when determining significance; therefore, because there were more values taken for the 
diphtheria experiments over the botulinum ones, there is more likely to be significance 
calculated.  
One of the potential reasons for there being a higher amount of SNAP25 cleavage or 
toxicity in double ligand complex incubated cells could be because there is a higher rate of 
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association between the complex and the cell surface receptors. For instance, if both CNTF 
ligands can bind at the same time to CNTFR, it means that if one dissociates the other could 
still remain. On the other hand there are studies that show that CNTF and EGF receptors 
can often dimerise on the cell surface, therefore, dual ligand binding may influence the 
receptor mechanics or alter the rate of internalisation (Neugart et al. 2009; Songtawee et 
al. 2015).  
One of the remarkable features of some of the cells was the level of heterogeneity, not 
just between the different cancer cell lines but also within the cell populations in regard to 
the differences in SNAP25 cleavage between SH-SY5Y cells. Interestingly, LA-N-5 cells did 
not express heterogeneity to this degree, but this could be explained through its other less 
cancerous behaviours such as slow growth and more differentiated morphology. It is not 
uncommon for cancer populations to express heterogeneity; there have been many 
reports alluding to the benefits of such behaviour, including the increased tendency for 
drug resistance and more efficient tumour propagation. It has been observed that within 
numerous tumour microenvironments exists a hierarchy of cells which can have separate 
roles; for instance some cells main attribute is their extensive growth and proliferation, 
whilst another population within the tumour functions to sustain this growth through 
paracrine signalling. This co-operative functioning between cancer cell populations can be 
the driving force behind aggressive tumours (Cleary et al. 2014; Meacham & Morrison 
2013). Because of this, the task of successfully targeting an aggressive cancer cell 
population is a challenging prospect.  
It is therefore advantageous that the SNARE linking method developed in this chapter has 
been shown to be able to target and internalise different receptors on different cells, which 
could be a useful strategy for addressing heterogeneity in cancer. This sort of tri-linked 
protein drug construction is something which has not previously been demonstrated as 
the chemistry can be difficult and the control of differing domain ratios is a challenge. This 
method has been successful in exploring the parameters required for efficient drug 
delivery and identified some of the challenges which have to be overcome. It has also been 
a useful tool for further understanding both the function and potential that botulinum and 
diphtheria toxins have as therapeutic enzymes for cancer. It concludes that this SNARE 
linking is a versatile conjugation platform which has the potential to be utilised with 
numerous proteins, to ‘mix and match’ different components allowing easy drug domain 
optimisation for targeting specific cells and delivering desired therapeutic domains. 
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Chapter 6: General Discussion 
 
The objectives of this project were to investigate pyridyl disulphide conjugation and SNARE 
linking, using these methods to explore drug design by taking apart the therapeutic 
components and re-constructing them in novel ways to best exploit their therapeutic 
potential. Within this, it was also hoped to further understand the nature of particular 
therapeutic toxins, identify cell internalisation peptides or proteins for neuroblastoma 
targeting, and investigate how to enhance cytosolic translocation through endosomal 
escape. This project has touched upon all these key areas with some yielding more success 
than others; however, even where there has not been the desired outcome there have still 
been findings of interest which need to be further contemplated and discussed to 
determine the best course of action for potential future research.  
Two methods of conjugation were investigated: one to modify proteins with peptides and 
the other for protein-protein linking and for triple domain complexes to form. Firstly, 
pyridyldithio conjugation was successful in modifying proteins through the addition of 
small peptides, but had severe limitations in the size of the peptides which could be used. 
There is the possibility that the chemistry exists where proteins could be conjugated to 
pyridyldithio group, but steps would need to be taken to prevent the chemical linker 
containing the pyridyldithio domain from being a limiting factor in stability. The pyridyl 
disulphide conjugation is similar in its efficiency and stability to other methods utilised 
within ‘Click chemistry’, which are numerous chemical reactions that are also used for the 
bioconjugation of peptides in a stereospecific and high yielding reaction in simple reactive 
conditions (H. Li et al. 2013; McKay & Finn 2014). However, one drawback of Click chemical 
reactions over pyridyl disulphide conjugation is that they are mostly non-cleavable linkers 
which cannot be reduced by enzymes once inside cells, which could pose issues with 
therapeutic efficacy. It could be possible that pyridyl disulphide attached peptides or small 
molecules may be a new way to specifically bind to antibodies to develop antibody drug 
conjugates (ADCs). One of the reasons for the extensive use of maleimide in ADCs is the 
lack of available cysteines partnered with an excess of lysines. However, researchers have 
now identified the issues of instability and heterogeneity associated with maleimide-lysine 
conjugation in ADC development and are looking into new ways to modify therapeutic 
antibodies to allow conjugation via cysteines (Jackson et al. 2014; Behrens et al. 2015; 
Deonarain et al. 2015).  
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SNARE linking on the other hand addressed alternative protein linking requirements to 
pyridyl disulphide conjugation, but whilst it was able to work with protein-protein 
conjugation there too were issues which arose. Although protein-staples can be used like 
Lego building blocks as an identification tool for good protein combinations, linking 
together three separate components significantly increases complexity. For instance, one 
issue identified here is that there are occasions where functional SNARE proteins simply 
don’t form in a complex with particular other SNAREs, another is that even if they do form 
there was an example (EGF-botLcTd/A linked) where there was not any complex 
functionality. Additionally, as a consequence of three protein components coming 
together there is more excess unlinked protein. Whilst most of the complexes have 
successfully formed and functioned it could be that excess unlinked protein could result in 
competitive inhibition at particular concentrations. Although here there has been no 
attempt to filter the complexes, Charlotte Leese within the Davletov lab has attempted to 
purify complexes through dialysis membranes, however this resulted in aggregation and 
dilution of the complexes. It may be possible that other methods could be used for filtering 
larger or more concentrated stocks, or that molar ratios of the added components could 
be maintained, making filtering unnecessary.  
One way to prevent there being so much unlinked protein at the end of a reaction has been 
to recombinantly fuse SNARE peptides syntaxin and synaptobrevin together with a desired 
proteins into a protein termed a ‘nanolock’. Thereby, when SNAP25-protein is added the 
supercoiled complex linker forms with all four helices but there being only two separate 
components instead of three. Whilst this is successful with linking together two proteins 
domains, it has not been attempted with three and it would be difficult to do so. 
Nonetheless, if the SNARE stapling method is only to be utilised to link together two 
protein domains it would be desirable to use nanolock to reduce protein waste and the 
need for filtering. On the other hand, it is possible that more than three protein domains 
could be attached to the SNARE complex. In this instance the SNAP25 can be split into two 
helixes and each utilised as separate SNARE-staples. Alternatively, for some protein 
domains it could be possible to attach to both the N and C termini of the staple proteins; 
however, neither of these methods have been attempted. Based on the observations made 
regarding the triple linked complexes in chapter 5 and the hypothesised inter-domain 
interference, it is recommended not to attempt further domain linking until more is known 




Another advantage of note in SNARE linking is that unlike the possibility of pyridyldithio 
being used with proteins, SNAREs can be used with peptides. Complexes consisting of x1 
and x2 SubstanceP-staple domains were successfully formed and also linked with botLcTd-
S25, however this data was not shown here owing to there being no internalisation into 
any of the cell lines tested. Nonetheless, it may be that alternative internalisation peptides 
for particular cells could also be efficiently linked together via SNARE complex and function 
successfully. It was hoped that there would be a suitable peptide sequence identified in 
chapter 4 pyridyl disulphide conjugation investigations that could have been carried over 
into SNARE linking so that a direct comparison could have been made between the two 
methods. Unfortunately, whilst CNTF was successful at targeting SH-SY5Y and LA-N-5 cells, 
it could not have been used attached to pyridyl disulphide because of its size. Human EGF 
is 53 amino acids in length which was longer than anything that was pyridyldithio attached, 
it is possible that it could have been successful, but it would not have been without 
expense or risk. On the other hand, although CPPs did improve toxin uptake through 
pyridyl disulphide conjugation they were not good enough to warrant staple attachment. 
Nonetheless, hypothetically if a peptide library was available and a suitable sequence was 
found it would have been interesting to directly compare the two methods in terms of 
easiness of conjugation and internalisation efficiency.   
Here, both peptide and proteins were investigated for their receptor targeting and cell 
internalisation properties, as well as their ability to direct proteins and complexes. Whilst 
peptide targeting yielded limited success, protein targeting produced far better results; 
this is mostly because of the optimisation steps and the investigation of receptor presence 
which was done at the beginning of chapter 5. In addition to CNTF and EGF, there are other 
proteins which were not tested but could have resulted in a similar level of internalisation; 
interleukins for instance have already proved their success in neuroblastoma as has 
transferrin and EGF (Louis & Shohet 2015; Ho et al. 2005; Nakamura et al. 2012). However, 
it was desirable to uncover a novel neuroblastoma targeting domains. Although CNTFR has 
been previously shown to be present on neuroblastoma cells and CNTF is able to influence 
particular factors within neuroblastoma, it has not been before established the particulars 
of using CNTF to target cancer therapeutic domains (Arsenault et al. 2013; Johnson et al. 
1994). Here is was successful, but this was only in two out of the three cell lines; this is 
most likely because CNTFR has been reported to be most present on the least aggressive 
cancer cells (Garcia et al. 2009; Kuroda et al. 2001). A note of concern is that CNTFR appears 
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to internalise once activated and it is currently unknown the conditions or timepoint where 
it may be recycled to the cell surface.  
Internalisation of proteins is dependent on kinetics and affinity of the ligand to the 
receptor, so once specific receptors on diseased tissue are identified then ligands can be 
modified to improve upon their internalisation. For instance the human CNTF derived 
protein Axokine has been developed as a therapy for amyotrophic lateral sclerosis and 
overeating; whilst there has been no FDA approval, it has been reported that Axokine is up 
to five times more potent than CNTF in both in vivo and in vitro, as well as having increased 
stability (Sleeman et al. 2000; Sleeman et al. 2003; Schuster et al. 2003; Marshal & Barbosa 
2005). It would therefore be interesting to determine whether Axokine conjugation via 
linking to toxins would increase delivery. On the other hand, although CNTF is capable of 
being utilised for toxin targeting to neuroblastoma cells, it is also present on a number of 
other healthy neural tissues, such as the hypothalamus and the optic nerve (Liu et al. 2007; 
Severi et al. 2012). Despite this, relative presence of CNTFR has not been directly measured 
between the healthy tissue and the neuroblastoma, so there still could be potential for 
CNTF targeting.  
Had there been time and resources, it would have been interesting to determine the 
compatibility of both conjugation methods with antibody targeting. For instance, the 
monoclonal antibody dinutuximab which targets glycolipid GD2 expressed on 
neuroblastoma cells and is currently the only antibody therapy approved for 
neuroblastoma. However, dinutuximab is not an antibody-drug conjugate (ADC), it is an 
antibody-dependent cell-mediated cytotoxicity drug (ADCC), which means that it does not 
have a group for drug attachment (Ploessl et al. 2016; Hoy 2016). One of the major 
drawbacks of ADCs is that they are most often based of ADCCs because they are easier to 
develop, however there is an issue surrounding antibody therapies because of intellectual 
property. This makes it difficult for researchers outside the company holding the patent 
for the approved ADCC to research ADCs. Other ways of creating specific receptor binding 
domains are emerging which have the specificity and size of ligands, but the non-activation 
and library selection of antibodies. DARPins (Designed Ankyrin repeat proteins) are derived 
from ankyrin repeat proteins, the most numerous protein family found in the human 
genome (Stumpp et al. 2008; Plückthun 2015). These can be built into libraries and because 
of their variability and size of between 14-21 kDa, they are far more penetrative into tissue 
than antibodies and are therefore being used as an alternative targeting platform 
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(Brauchle et al. 2014; Stahl et al. 2013; Boersma et al. 2011). Therefore, as technology for 
targeting domains evolves so must the conjugation strategies. There is potential that, given 
the circumstances, SNARE linking or pyridyl disulphide conjugation could be utilised with 
the ever changing parameters for cell internalisation. 
As well as investigating novel sequences for neuroblastoma internalisation, both 
conjugation methods were also utilised to reveal the potencies and behaviours of toxins. 
In doing so it was highlighted how long both toxins required before the effect of the 
cytosolic catalytic activity could be measured. It was analysed that both diphtheria and 
botulinum LcTd domains required over 24 hours before effects were seen, this was later 
found to be the case with diphtheria in wider literature however remained unexpected 
with botulinum neurotoxin A (Kageyama et al. 2002; Yamaizumi et al. 1978). It should be 
noted that although botulinum required 24 hours here before cleavage was seen, it has 
been observed by Charlotte Leese within the Davletov lab that when the same botLcTd-
S25 was linked to x2 of the native receptor binding domain for botulinum neurotoxin A 
(Rbd/A) and delivered into differentiated neuroblastoma cells there was approximately 
50% SNAP25 cleavage at 8 hours and 80% cleavage at 24 hours (data unpublished). This 
suggests that botLcTd/A is capable of quickly cleaving SNAP25 within cells, but it does 
depend on the targeting domain which is used to internalise.  
Botulinum neurotoxin was used here because of its link with pain and its potential as an 
anti-cancer agent, however it also made a good enzyme for assaying cytosolic escape due 
to the unique effect of SNAP25 cleavage and the lack of cleaved SNAP25 breakdown by the 
cell (Huang et al. 1998). Diphtheria toxin cytosolic presence on the other hand results in 
cell death, which is not as specific. It is important to clarify the following point:  botLcTd-
s25 cleaves the SNAP25 9 amino acids at the C-terminus (aa.197-206), but there is still 
SNARE formation, this has been previously documented (Huang et al. 1998; Montecucco 
et al. 2005). However, when endogenous SNAP25 is cleaved it is also still able to form 
complexes; it is proposed that the reason for the decrease in exocytosis observed here and 
in other botulinum therapies is because the formed SNARE complex has significantly 
decreased its responsiveness to cytosolic Ca2+ release which stimulates exocytosis 
(Sørensen et al. 2006; Trudeau et al. 1998; Sakaba et al. 2015).  
It was originally intended to use BLF once the delivery of other toxins had been established; 
this would have been useful as a further investigation of how BLF could potentially target 
cells and inhibit growth without killing them, thereby being a useful drug whilst reducing 
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cancer side effects (Rust et al. 2015). However, due to difficulties in synthesis and the lack 
of translocation domain this was not successful. It would also have been interesting to see 
how two different non-toxic enzymes behaved when linked together through SNARE 
stapling, for instance, whether BLF and botLcTd could have been used together to prevent 
growth and signalling.  
Within this project endosomal escape was identified as a major limiting step; whilst this 
was anticipated, there are still relatively few papers which look dedicatedly at endosomal 
escape (Fuchs et al. 2016; Varkouhi et al. 2011). This is maybe because understanding still 
needs to be developed, which presents problems because cytosolic translocation is 
difficult to research independently of cell internalisation. Moreover, it is apparent that 
different cell lines have different internalisation pathways and mechanisms. The data here 
suggest that endosomal escape could also hold a degree of cell specificity; however, this is 
hard to conclude because in the system here the factors influencing internalisation and the 
eventual endosomal escape could not be reliably separated.  It could be important to 
further understand factors which influence endosomal escape as specific translocation 
domains may be more preferential depending on the cell line or toxin used.  Whilst this 
was suggested with dipLcTd in its difference in EC50 between Neuro2A and SH-SY5Y cells, 
it was less apparent with botLcTd, but there could be numerous other examples of cells 
and translocation domains showing preference. It should be noted that patents do exist 
which specify the invention of combining clostridial neurotoxins and diphtheria catalytic 
and translocation domains in order to enhance delivery into neuronal cells (Sutton & Shone 
2004; Shone et al. 2003). These modified protein constructs could reveal more about the 
nature of translocation domain preference in cells, and whether translocation domain 
function is transferrable between toxins.  
For future experimentation, it would be useful to conclude whether a Td-staple linked to 
a toxinLC-staple would still be able to enhance cytosolic translocation in the same way that 
the translocation domain would if it was directly attached. Based on current data, it is 
difficult to speculate; the translocation domain could still interact with the endosomal 
membrane and form pores. However, on the other hand, the translocation domain stability 
without the attached light chain is unknown, and there is data which suggests that the 
diphtheria translocation domain functions as a chaperone as well as a pore (Chassaing et 
al. 2011; Hammond et al. 2002). It has not been determined whether this chaperone 
activity would still exist with a long linker in between the two domains.  
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One of the drawback of the method of assaying the drug complexes is that it is very one-
dimensional. Whilst there is evidence of specific targeting and stability, real cancer exists 
in 3 dimensions with environmental factors (e.g. circulation, inflammation etc.) which are 
not mimicked in these experiments. Therefore, these results are unlikely to be 
representative of the results found in an in vivo environment. Whilst this is impossible to 
fully do in vitro, an improvement could have been made by using special microplates which 
encourage the 3D growth of cells, this would aid in testing the penetrative nature of the 
complexes in tissue (Ravi et al. 2015; Edmondson et al. 2014). It should be noted that 
colleagues (Rebecca Bresnahan – Davletov Lab) have successfully injected botLcTd/A 
containing samples linked to RbdA (200 ng in 30 µL) into rat hind-paw and cleaved SNAP25 
was found in surrounding tissue as well as in spinal cord at day 7. This strongly suggests 
that these linked complexes are capable of being used in vivo for specific delivery, with 
their action being dependant on the attached delivery domain.  
As well as the development of the conjugation techniques over the course of this project 
it has been interesting seeing how the understanding of efficient internalisation of protein 
toxins has been enhanced throughout through investigation into endosomal escape, 
internalisation domains and how these can all be exploited by the linking platform and cell 
type. For instance, the dipLC internalisation of chapter 4 in SH cells has worked 
methodically up to the efficient internalisation of linked CNTFx2-dipLcTd in SH cells at the 
end of chapter 5. In conclusion, this project has shown how taking a conjugation focused 
approach to investigating efficient internalisation has enabled a large variety of findings 
from a different perspective. Additionally, it has identified how these methods of 
conjugation address currently unmet needs within drug research as well as the limitations 
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Appendix 1: Amino acid sequences.  
 
All sequences are taken from the point of GST cleavage from thrombin. 
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Diphtheria Light Chain  Thrombin cleavage site   Diphtheria Translocation 



















BoNT/A Lc (1-449)  Thrombin cleavage site  Optimized BoNT/A Td (449-872) 
 



















BoNT/A Lc (1-449)  Thrombin cleavage site   Optimized BoNT/A Td (449-872)   
Mouse SNAP25 (1-206)  
 
SNAP25B- Cysteine rich domain (S25-CRD) 
GSPGISGGGGGILDSMEAEKNLTDLGKFCGLCVCPCNKLNSS 
 





































Appendix 2 - Design of a new cell-penetrating peptide: CP-BrevinMM. 
A) Synaptobrevin 2 sequence, full-length rat vesicle-associated membrane protein 2. Short 
peptides (Brevins 37-84, 44-84, 51-84 and 59-84) used as a negative control. Brevin, lysine-
enriched peptide from juxtamembrane region of synaptobrevin 2 as a cell-penetrating 
peptide. B) The ability of these peptides to act as CPPs was tested in RAW 264.7. Cells were 
treated with 1 µM of FITC-labelled peptides for 1 h and the amount of fluorescence inside 
the cells was determined after cell lysis by measurement of fluorescence intensity 
(excitation 490 nm / emission 525 nm).  Cells were treated with for 1h with FITC-peptides 
and the uptake of 1 µM Brevin 59-84 and Brevin was analysed by confocal microscopy (C). 
The amount of Brevin inside cells (D) and the percentage of cells containing the peptide (E) 
were estimated by FACS. – All data here was done by Violeta Ruipérez. 
